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RESUMEN 
Una característica común en las patologías relacionadas con el envejecimiento es 
la progresiva acumulación de macromoléculas dañadas que provocan daño celular y 
finalmente la muerte. La autofagia es un mecanismo fundamental en la homeostasis 
celular que regula la eliminación de moléculas dañadas y realiza una función protectora 
y de supervivencia celular. Estudios recientes indicaron una disminución de autofagia 
en el cartílago y condrocitos envejecidos y artrósicos. Por otro lado, existen claras 
evidencias de que la disfunción mitocondrial juega un papel fundamental en la 
aceleración del proceso de envejecimiento. En este sentido, diferentes líneas de 
evidencia han demostrado una desregulación mitocondrial en el cartílago artrósico. 
Basándonos en estas premisas, los objetivos propuestos en esta Tesis Doctoral han sido: 
(1) Estudiar los efectos de un defecto de autofagia sobre la función mitocondrial 
mediante aproximaciones farmacológicas y genéticas y (2) Identificar dianas 
terapéuticas asociadas a una disminución de autofagia en la patología del sistema 
musculoesquelético. Para llevar a cabo estos estudios empleamos aproximaciones 
farmacológicas y genéticas para inhibir la autofagia y estudiar su efecto sobre la función 
mitocondrial en condrocitos humanos. Además, hemos analizado el proteoma de los 
condrocitos humanos asociados a una disminución de autofagia para la identificación de 
potenciales dianas terapéuticas. Finalmente, validamos la diana identificada empleando 
la tecnología de edición genética CRIPSPR/Cas9 en condrocitos humanos y un modelo 
de delección genética en ratón. En conclusión, nuestros datos destacan el papel de la 
autofagia como un mecanismo de protección crítico frente al daño articular, por lo tanto, 
intervenciones farmacológicas encaminadas a activar la autofagia podrían tener 
actividad condroprotectora frente a los procesos degenerativos del sistema 
muscoloesquelético. 
 
  
  
 
RESUMO 
Unha característica común nas enfermidades relacionadas co envellecemento é a 
progresiva acumulación de macromoléculas danadas que provoca danos celulares e 
finalmente a morte. A autofaxía é un mecanismo fundamental na homeostase celular 
que regula a eliminación das moléculas danadas e realiza unha función protectora e 
supervivencia celular. Estudios recentes indicaron unha diminución da autofaxía no 
cartílaxe e condrocitos envellecidos e artrose. Por outro lado, existen claras evidencias 
de que a disfunción mitocondrial xoga un papel fundamental na aceleración do proceso 
de envellecemento. Neste sentido, diferentes liñas de evidencia demostraron unha 
disregulación mitocondrial no cartílaxe artrósico. Tendo en conta isto, os obxectivos 
propostos nesta Tese doutoral foron: (1) Estudar os efectos dun defecto de autofaxía 
sobre a función mitocondrial mediante aproximacións farmacolóxicas e xenéticas e (2) 
Identificar as dianas terapéuticas asociadas cunha disminución da autofaxía na patoloxía 
do sistema musculoesquelético. Para levar a cabo estes estudos empregamos 
aproximacións farmacolóxicas e xenéticas para inhibir a autofaxía e estudiar o seu 
efecto sobre a función mitocondrial nos condrocitos humanos. Ademais, analizamos o 
proteoma dos condrocitos humanos asociados cunha diminución de autofaxía para a 
identificación de dianas terapéuticas potenciais. Finalmente, validamos a diana 
identificada empregando a tecnoloxía de edición xenética CRIPSPR / Cas9 en 
condrocitos humanos e un modelo de delección xenética en rato. En conclusión, os 
nosos datos destacan o papel da autofaxía como un mecanismo de protección crítico 
fronte ao dano articular, polo tanto, as intervencións farmacolóxicas encamiñadas a 
activar a autofaxía poderán ter actividade condroprotectora fronte ós procesos 
dexenerativos do sistema musculoesquelético.  
  
 
ABSTRACT 
A common feature in pathologies related to aging is the progressive 
accumulation of damaged macromolecules that cause cellular injury and finally death. 
Autophagy is a fundamental mechanism in cellular homeostasis that regulates the 
elimination of damaged molecules and performs a protective function and cell survival. 
Recent studies have indicated a decrease in autophagy in the cartilage and aged and 
osteoarthritic chondrocytes. On the other hand, there is clear evidence that 
mitochondrial dysfunction plays a key role in the acceleration of the aging process. In 
this sense, different lines of evidence have shown mitochondrial dysfunction in 
osteoarthritis cartilage. Based on these premises, the objectives proposed in this 
Doctoral Thesis have been: (1) To study the effects of a defect of autophagy on 
mitochondrial function through pharmacological and genetic approaches and (2) 
Identify therapeutic targets associated with a decrease in autophagy in the pathology of 
the musculoskeletal system. To carry out these studies we use pharmacological and 
genetic approaches to inhibit autophagy and study this effect on mitochondrial function 
in human chondrocytes. In addition, we analysed the proteome of human chondrocytes 
associated with a decrease in autophagy for the identification of potential therapeutic 
targets. Finally, we validate the target identified using the genetic editing technology 
CRIPSPR/Cas9 in human chondrocytes and a model of genetic deletion in mouse. In 
conclusion, our data highlights the role of autophagy as a critical protective mechanism 
against joint damage; therefore, pharmacological interventions aimed at activating 
autophagy may have condroprotective activity against the degenerative processes of the 
musculoskeletal system. 
 
  
  
 
Table of contents 
CHAPTER 1: INTRODUCTION .............................................................................................. 1 
1.1 Joint ............................................................................................................................ 1 
1.1.1 Definition .............................................................................................................. 1 
1.1.2 Types of body joints .............................................................................................. 1 
1.1.3 The diarthrosis or Synovial Joints ......................................................................... 2 
1.1.4 The amphioarthrosis or semi-mobile joints: The spine ......................................... 3 
1.2 Articular cartilage. ...................................................................................................... 6 
1.2.1 Composition .......................................................................................................... 6 
1.2.2 Structure and function of articular cartilage .......................................................... 9 
1.3 Osteoarthritis ............................................................................................................ 12 
1.3.1 Clinical features ................................................................................................... 12 
1.3.2 Articular Cartilage in OA .................................................................................... 14 
1.4 OA Risk Factors ........................................................................................................ 17 
1.5 Prevalence and treatments ........................................................................................ 19 
1.6 Molecular mechanisms of aging related disease of musculoskeletal system: The 
autophagy ......................................................................................................................... 21 
1.6.1 Autophagy ........................................................................................................... 21 
1.6.2 The Autophagy pathway ..................................................................................... 22 
1.6.3 Autophagy as a key mechanism in aging-related Disease ................................... 26 
1.6.4 Autophagy and OA. ............................................................................................. 27 
1.6.5 Role of Autophagy in Mitochondrial Function ................................................... 29 
1.6.6 Autophagy and Aging ......................................................................................... 32 
 
CHAPTER 2: SIGNIFICANCE, HYPOTHESIS AND OBJETIVES.................................. 38 
Significance to the musculoskeletal system ....................................................................... 39 
Key Points ........................................................................................................................ 39 
Objectives ......................................................................................................................... 40 
Objective 1: To study the effects of defective autophagy to mitochondria function using . 40 
Objetive 2: To identify potential targets of defective autophagy associated with the 
pathology of muskuloletal system ..................................................................................... 40 
 
 
  
 
CHAPTER 3: MATERIAL AND METHODS ....................................................................... 41 
3 Cell culture ......................................................................................................................... 42 
3.1 Primary chondrocyte isolation and culture................................................................ 42 
3.1.1 Culture of cell lines in monolayer ....................................................................... 42 
3.2 General conditions of the cell culture experiments .................................................... 43 
3.2.1 Stimuli used in the experiments .......................................................................... 43 
3.3 Mitochondrial function studies .................................................................................. 45 
3.3.1 Determination of mitochondrial membrane potential (MMP) ............................ 45 
3.3.2 Quantification of reactive Oxygen Species Production ....................................... 46 
3.4 Cell Death Studies ..................................................................................................... 47 
3.4.1 Determination of Cell Death by Apoptosis ......................................................... 47 
3.5 Autophagy function studies ....................................................................................... 48 
3.5.1 Immunofluorescence ........................................................................................... 48 
3.6 Proteomic studies ...................................................................................................... 49 
3.6.1 Processing of protein samples for isobaric tags for relative and absolute 
quantification (iTRAQ) labeling ......................................................................................... 49 
3.6.2 LC/MS/MS Analysis ........................................................................................... 50 
3.6.3 Peptide Identification .......................................................................................... 51 
3.6.4 Western blotting .................................................................................................. 53 
3.7 Genome editing studies in chondrocytes .................................................................... 54 
3.7.1 Autophagy inhibition by silencing autophagy-related (ATG-5) with small 
interfering RNA................................................................................................................... 54 
3.7.2 Genetic deletion of Zmpste 24 by clustered regularly interspaced short 
palindromic repeats (CRISPR-Cas9) technology ................................................................ 54 
3.7.3 Gene expression analysis: RT-PCR and real-time PCR. ..................................... 56 
3.8 Consequences of Lamin A/C Accumulation in the Musculoskeletal System............... 58 
3.8.1 Accelerated aging model: Zmpste24 Deficient Mice .......................................... 58 
3.8.2 Animal Care ........................................................................................................ 59 
3.8.3 Mice Genotyping ................................................................................................. 60 
3.9 Histological studies. ................................................................................................... 62 
3.9.1 Tissue samples..................................................................................................... 62 
3.9.2 Immunohistochemistry for paraffin embedded samples. .................................... 62 
3.9.3 Safranin O / Fast Green Staining. ........................................................................ 63 
3.9.4 Hematoxylin-Eosin staining. ............................................................................... 63 
3.9.5 Histologic analysis of joint cartilage in Zmpste24 mice ..................................... 63 
  
 
3.10 Statistical analysis ..................................................................................................... 65 
 
CHAPTER 4: RESULTS .......................................................................................................... 66 
CHAPTER 4.1 : TO STUDY THE EFFECTS OF DEFECTIVE AUTOPHAGY TO 
MITOCHONDRIAL FUNCTION USING PHARMACOLOGICAL AND GENETIC 
APPROACHES ................................................................................................................ 67 
4.1.1 Specific background ............................................................................................ 68 
4.1.2 Material and methods .......................................................................................... 70 
4.1.3 Results ................................................................................................................. 71 
CHAPTER 4.2: TO IDENTIFY POTENTIAL TARGETS OF DEFECTIVE 
AUTOPHAGY ASSOCIATED WITH THE PATHOLOGY OF THE  
MUSCULOSKELETAL SYSTEM ......................................................................................... 82 
4.2.1 Specific Background ........................................................................................... 82 
4.2.2 Specific Material and methods ............................................................................ 84 
4.2.3 Results ................................................................................................................. 86 
 
CHAPTER 5: DISCUSSION.................................................................................................. 103 
5.1 To study the effects of defective autophagy to mitochondrial function using 
pharmacological and genetic approaches ....................................................................... 104 
5.2 To identify potencial targets of defective autophagy associated with the pathology of 
the musculoskeletal system ............................................................................................. 107 
 
6 CHAPTER 6: CONCLUSIONS ..................................................................................... 109 
1. To study the effects of defective autophagy to mitochondrial function using 
pharmacological and genetic approaches: ............................................................................ 110 
2. To identify potencial targets of defective autophagy associated with the pathology of 
the musculoskeletal system ............................................................................................. 110 
 
CHAPTER 7: REFERENCES ............................................................................................... 112 
CHAPTER 8: SUPPLEMENTAL DATA ............................................................................. 124 
Appendix 1: Resumen en lengua castellana .................................................................... 125 
Appendix 2:  Total proteins identified in defect autophagy in chondrocytes. .................. 132 
Appendix 3: Tables to evaluate the state of mouse. ......................................................... 160 
 
Chapter 9: Publication ............................................................................................................ 164 
  
 
 
Figure and table Index 
Figure 1.1: Knee anatomy .......................................................................................................... 3 
Figure 1.2: Graphical representation of a motion segment of spine, sagittal view................ 4 
Figure 1.3: Gross anatomy of a disc. ......................................................................................... 5 
Figure 1.4: Structure and composition of ECM of articular cartilage. .................................. 8 
Figure 1.5: Structure of the articular cartilage. ..................................................................... 10 
Figure 1.6: Clinical characteristics of a healthy knee vs. OA knee. ...................................... 13 
Figure 1.7: Scheme of pathway to catabolic and anabolic process (39). .............................. 15 
Figure 1.8: Scheme of pathway to catabolic and anabolic process. ...................................... 16 
Figure 1.9: incidence of disease with age. ................................................................................ 20 
Figure 1.10: scheme of autophagy pathway. ........................................................................... 24 
Figura 1.11: Autophagy regulation by mTOR. ...................................................................... 26 
Figure 1.12: Structure and function of mitochondria. ........................................................... 29 
Figure 1.13: Maturation pathway of prelamin A. .................................................................. 36 
Figure 3.1: Schematic Plasmid of pCMV-Cas9-GFP cronstruction. .................................... 55 
Figure 3.2: PCR program for Zmpste24 mice genotyping. ................................................... 61 
Figure 3.3: Representative example of Zmpste24 mice genotyping. ..................................... 61 
Figure 4.1: Inhibition of mitochondrial respiratory chain induces mitochondrial 
dysfunction  in human chondrocytes. ...................................................................................... 72 
Figure 4.2: Inhibition of mitochondrial respiratory chain induces cell death by apoptosis 
in human chondrocytes. ............................................................................................................ 73 
Figure 4.3: Autophagy is defective in human chondrocytes subjected to mitochondrial 
dysfunction. ................................................................................................................................ 74 
Figure 4.4: Autophagy activation protects from mitochondrial dysfunction in human 
chondrocytes. ............................................................................................................................. 76 
Figure 4.5: Oligomycin-mediated mitochondrial dysfunction is dependent on Akt/mTOR 
pathway activation in human chondrocytes. .......................................................................... 78 
Figure 4.6: Defective autophagy induced by ATG5 siRNA increases mitochondrial 
dysfunction in human chondrocytes. ....................................................................................... 79 
Figure 4.7: Flow chart for autophagy protective effect against mitochondrial dysfunction 
on human chondrocytes. ........................................................................................................... 80 
Figure 4.8: Defective autophagy induced by ATG5 siRNA in human chondrocytes. ......... 86 
Figure 4.9: Defective autophagy increases Lamin A/C accumulation in human 
chondrocytes. ............................................................................................................................. 89 
Figure 4.10: Increased Lamin A/C expression in aging cartilage. ........................................ 90 
Figure: 4.11: Lamin A/C expression is increased in OA cartilage. ....................................... 92 
  
 
Figure 4.12: Upregulation of Lamin A/C expression reduced autophagy in human 
chondrocytes. ............................................................................................................................. 94 
Figure 4.13: Increased mitochondrial dysfunction in accelerated ageing chondrocytes. ... 95 
Figure 4.14: Phenotypic changes of Zmpste24 deficient mice. .............................................. 97 
Figure 4.15: Aging-associated histopathologic changes in Zmpste24 deficient mice joint 
tissues. ......................................................................................................................................... 99 
Figure 4.16: Accelerated aging induces intervertebral disc degeneration (IVD) 
in Zmpste24 mice. .................................................................................................................... 101 
Figure 4.17: Loss of cellularity in Intervertebral disc in accelerated aging mice. ............. 102 
 
Table 1.1: Structure and composition of articular cartilage layers. ..................................... 11 
Table 1.2: OARSI classification score to OA. ......................................................................... 14 
Table 3.1: Stimuli used in the experiments ............................................................................. 44 
Table 3.2: Primary Antibodies used in WB studies. .............................................................. 53 
Table 3.3: General conditions of mice accommodation. ........................................................ 59 
 
  
  
 
Abbreviations  
OA Osteoarthritis 
LCL Lateral collateral ligament 
LCP Posterior cruciate ligament 
LCM Medial collateral ligament 
LCA Anterior cruciate ligament 
LBP Low back pain 
IVD Intervertebral disc 
DD Degenerative disc 
NP Nucleus pulposus 
AF Annulus fibrosus 
VBs Vertebral bodies 
CEPs Cartilaginous end plates 
ECM Extracellular matrix 
PG Proteoglycan 
GAG Glycosaminoglycan  
HA Hyaluronic acid 
COMP Cartilage oligomeric matrix protein 
mRNA Messenger RNA 
SV40 Virus T antigen 49 
Col2A1 II Collagen 
OARSI Osteoarthritis Research Society International 
KL Kellgren and Lawrence 
JSN Joint space narrowing 
MMP Matrix Metalloproteinase  
ADAMTS Disintegrin and Metalloproteinase with Thrombospondin motifs 
Il-1β Interleukin 1 beta 
  
 
TNF-α Tumor necrosis factor alpha 
PGE2 Prostaglandin E2 
COX-2 Cyclooxygenase 2 
ATP Adenosine triphosphate 
ROS Reactive oxygen species 
CMA Chaperone-mediated autophagy 
ULK-1 Serine/threonine-protein kinase ULK1 
LC3/Map1LC3b Microtubule-associated proteins 1A/1B light chain 3B 
mTOR Mammalian Target of Rapamycin 
mTORC1 Mammalian Target of Rapamycin complex 1 
mTORC2 Mammalian Target of Rapamycin complex 2 
Akt RAC-alpha serine/threonine-protein kinase 
PI3K Protein I3 kinase 
SGK1 Serum and glucocorticoid-regulated kinase 1 
PKC Protein kinase C 
AMPK AMP-activated protein kinase 
PARP Poli ADP ribosa polimerasa 
AGE Advanced glycation end products 
SSP Senescence secretory phenotype 
CAAX C-cysteine, A-aliphatic, X-any residue 
ZMPSTE24 Zinc Metallopeptidase STE24 
FTI Farnesyltransferase inhibitors 
SIRT1 Sirtuin 1 
FOXO3 Forkhead box O3 
HGPS Hutchinson-Gilford Progeria syndrome 
LD Neonatal restrictive lethal dermopathy 
MRC Mitochondrial Respiratory chain 
  
 
Il-6 Interleukine 6 
Il-8 Interleukine 8 
NSAID Nonsteroidal anti-inflammatory drug 
ΔΨm Mitochondrial membrane potential 
CRISPR Clustered regularly interspaced short palindromic repeats 
FCS Fetal calf serum 
EDTA Ethylenediaminetetraacetic acid 
JC-1 5',6,6'-Tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide 
PBS phosphate buffered saline 
DCFH-DA 2,7-dichlorodihydrofluorescein diacetate 
PS phosphatidylserine 
PI Propidium iodure 
NGS Normal goat serum 
MALDI Matrix Assisted laser desorption/ionization 
TOF Time of Flight 
iTRAQ Isobaric tag for relative and absolute quantification 
SDS Sodium Dodecyl Sulfate 
RP-LC Reversed phase liquid chromatography 
WB Western-Blot 
HRP Horserradisch peroxidase 
CFU Colony Forming Unit 
RT-PCR Reverse transcriptase Polimerase chain reaction 
qPCR Quantitative real time Polimerase chain reaction 
DMEM Dulbecco's modified Eagle's medium 
cDNA Complementary DNA 
LMNA Lamin A/C 
ACTB Actin B 
  
 
CHUAC University Hospital of A Coruña 
HT Heterocygous 
KO Knock Out 
ANOVA ANalysis Of VAriance 
  
  
 
  
  
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
  
  Chapter 1: introduction 
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1.1 Joint 
1.1.1 Definition 
The human skeleton consists of a large number of bones to make the movement 
possible. They are assembled together by the joints. Therefore, The joint is a specialized 
structure, a point of union of two or more bones, which allows stability and movement 
(1). Depending on the degree of mobility that allows the articulation, and the way of 
contact between the bones, the joints are classified as diarthrosis, sinarthrosis or 
amphiarthrosis. 
 
1.1.2 Types of body joints 
Synarthrosis joints or Fibrosis (fixed) permit little or no are the ones that do not 
allow practically movement, because they are united by more or less dense tissue. There 
are different types depending on the morphology, and even the type of elements that 
come into contact, which may be two cartilages (sinchondrosis) or have a fibrous nature 
(sinfibrosis) as occurs with the bones of the skull or the joint between the tooth and 
Dental alveoli, or even synostosis as occurs in the bone welds that appear after the 
disappearance of growth cartilage. 
The amphiarthrosis or semi-mobile joints may be slightly articulated the joints in 
which the bones are joined by cartilaginous tissue or a fibrocartilaginous mass, while 
peripherally the articular ligaments are differentiated. Such is the case of the joints of 
the vertebral bodies, which only allow small movements. In spite of this, when the 
movements of the set of articulations of the spine are added, it can describe extensive 
movements of flexion, extension or rotation. 
Diarthrosis joints or synovial (mobile) joints are the most frequent that provide 
a greater range of movement. A synovial joint consists of smooth articular surfaces of 
cartilaginous nature, which cover the ends of the bones, and are the articular cartilage. 
The joint is surrounded by the articular capsule, of a fibrous nature. The internal capsule 
is covered by a delicate synovial membrane, which secretes small amounts of 
lubricating liquid or synovium. In some joints, a pad of cartilaginous tissue constituting 
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a meniscus or articular joint is arranged to regularize the contact surfaces between the 
bones. 
 Finally, the joint capsule may be reinforced by a series of articular ligaments (2, 
3). Within them, the greater to less mobility are distinguished: the enanthroses that 
allow movement in three planes (humeral-scapular articulation); The condyle 
(temporomandibular joint) and reciprocating or saddle (trapezium-metacarpal joint) 
both with two axes of movement: the trochlear joints (interphalangeal joints) and the 
trochloid (atloidoaxoid joints) that only allow mobility on single axis.  To conclude,  the 
artery (intercarpal joints), in which, due to its flat shape, it only allows small sliding 
movements. (4, 5) 
1.1.3 The diarthrosis or Synovial Joints 
The joint is a specialized point of union of two or more bones, which allows 
stability and movement. There are different types of joints, synovial joints being the 
most frequent in the body. Synovial joints make pain-free movement possible and are 
composed of multiple structures: an articular capsule, continuous with periosteum that 
surrounds joint cavity; a synovial membrane – thin membrane that covers the joint 
cavity, responsible for the secretion of synovial fluid to maintain joint lubrication and 
provide nutrition to the articular cartilage; and hyaline articular cartilage which covers 
the end of bones in a joint. Other tissues such ligaments, muscles and tendons may be 
also present and provide additional support to synovial joints (2, 3).  
The knee is one of the largest and most complex synovial joints in the body. The 
knee consists of 2 joints: the femorotibial joint and the patellofemoral joint. The bony 
architecture of the femur, tibia, and patella contribute to the stability of the knee joint, 
along with static and dynamic restraints of the ligaments, capsule, and musculature 
crossing the joint. 
Tendons connect the knee bones to the leg muscles to provide stability to the 
knee in the knee movement.  The anterior cruciate ligament prevents the femur from 
sliding retrograde on the tibia (or the tibia sliding forward on the femur). The posterior 
cruciate ligament prevents the femur from sliding forward on the tibia (or the tibia from 
sliding backward on the femur). The medial and lateral collateral ligaments prevent the 
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femur from sliding side to side. The structure of synobial joints are presented in Figure 
1.1 
 
Figure 1.1: Knee anatomy. Schematic representation of the major structure of normal synobial joint 
(available online in http://comportho.com/2016/07/page/2/) 
 
1.1.4 The amphioarthrosis or semi-mobile joints: The spine 
Low back pain (LBP) is an important cause of disability worldwide and the 
second most common cause of physician visits. There are many causes of back pain, 
including disc herniation and intervertebral disc (IVD) degeneration are the most 
common diagnoses and targets for intervention. 
Intervertebral discs (IVDs) are pads of fibrocartilage which lie between the 
vertebrae of the spine (Figure 1.2). They allow the vertebral column to turn and, and 
distribute compressive loading on the adjacent vertebral bodies. The mechanical 
properties of discs are important because human lumbar IVDs are often physically 
disrupted, which may give rise to degenerative changes and to chronic back pain (6). 
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Figure 1.2: Graphical representation of a motion segment of spine, sagittal view. ALL and PLL refer 
to the anterior and posterior longitudinal ligaments, respectively (6). 
 
The IVD has three main components, a soft, deformable, nucleus pulposus (NP), 
which is surrounded by the fibrous concentric layers of the anulus fibrosus (AF), and 
bonded above and below to adjacent vertebral bodies (VBs) by the thin layers of the 
cartilaginous end plates (CEPs). 
The nucleus pulposus (NP) is gelatinous that accounts for 40–50% of the volume 
of the adult disc and 25–50% of the transverse cross-sectional area, composed 
predominantly of type II collagen and proteoglycans, with high water content that 
contributes to its hydrostatic pressurization and resistance to compressive forces, and 
this pressure generates tension in the surrounding AF. Proteoglycan accounts for 35–
65% of the dry weight of the NP, and is important for binding water into the tissue. The 
collagen type II fibrils, which account for 5–20% of dry weight, provide a loose, 3-
dimensional fiber network, which holds the nucleus. The rest of the dry weight of the 
NP is non-collagenous proteins and elastin. The NP water content decreases with age, 
from approximately 90–70% from the ages of 1– 80 years old, imitating a similar 
reduction in proteoglycans. In the degenerative process, loss of proteoglycans and water 
content are observed, which results in redistribution of load onto the fibrochondrocyte-
like cells in the annulus fibrosus (AF).  
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The AF consists of concentric of 15–25 concentric layers, the lamellae, rich in 
collagen and elastin, which are approximately 0.05–0.5 mm thick, of increasing 
thickness from outer to inner. (7) Approximately 48% of the lamellar layers are 
circumferentially incomplete and the percentage of incomplete layers increases with 
age. Each layer consists of coarse and strong collagen type I fiber bundles, as in tendon, 
with their orientation alternating between ± 25–45° in relation to the transverse plane 
(Figure. 1.3). The complex organization of collagen fibers in the AF permits it to 
develop tensile, like a “hoop”, stress due to the pressure in the nucleus. 
In the healthy IVD, the AF contains 65–70% water. Dry weight is approximately 
20% proteoglycan, 50–70% collagen, and 2% elastin.  
The CEPs are thin layers of hyaline cartilage that bind the disc inferiorly and 
superiorly to the adjacent bony endplates (BEPs). They are approximately 0.6 mm thick, 
while they are generally thinner towards the center where they are in contact with the 
NP. Thickness decreases with age. Dimensions in the transverse plane reflect those of 
the adjacent vertebral bodies, and so increase from an anteriorposterior length of 16–19 
mm and lateral width of 17–29 mm in the cervical spine, rising to an anterior-posterior 
length of 30–36 mm and lateral width of 43– 54 mm in the lumbar spine. (6) 
 
Figure 1.3: Gross anatomy of a disc. (a) Cross section of a disc in the coronal plane, (b) diagram of a 
transversely sliced IVD and (c) diagram showing the alternating fiber alignment in successive 
lamellae.(6).  
 
Spine degeneration is a natural part of the aging process that is most common in 
the neck (cervical) and lower back (lumbar). Disc degeneration (DD) is a multifactorial 
process characterized by cellular and biochemical changes in disc tissue that result in 
structural failure. While DD is a part of normal aging, a significant number of people 
with indications of DD on MRI are actually asymptomatic, with no history of pain or 
disability. Numerous alterations are observed in DD, each of which provides 
understandings into the disease process.  
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1.2 Articular cartilage. 
1.2.1 Composition 
Hyaline cartilage is a specialized connective tissue, avascular, aneural and 
alymphatic, consisting of two elements, one cellular and the other extracellular (8). The 
extracellular matrix (ECM) is nourished through the diffusion of the fluid from the joint 
cavity, where nutrients cross the synovial barrier from the synovial fluid and diffuse 
through the matrix of articular cartilage to reach the cells. The ECM consists mainly of 
water, collagen (mainly collagen type II) and proteoglycans that correspond to 97-98% 
of the total weight, while chondrocytes represent only 1-2% of the total.(9) 
 
1.2.1.1 The extracellular matrix 
Extracellular Matrix (ECM) represents 95% of the dry weight of articular 
cartilage. As already mentioned, the ECM is constituted by a liquid fraction and by a 
series of macromolecules that provide the cartilage its special biomechanical 
characteristics. The water content of the matrix is not evenly distributed along the 
cartilage layers, its concentration is higher in the surface area gradually decreasing to 
the deep zone, it is around 80% near the cartilage surface, decreasing to around 65% in 
the Deep zone (8). The major component of ECM is the collagen (60 to 70% of the dry 
weight) and the major type is II collagen (95%) that interacts with other types of 
collagen such as type IX and XI (also VI, XII and XIV).   
Type IX and XI collagens stabilize the collagen fibrils assembled from type II 
collagen, while type VI collagen, mainly present in territorial matrix, anchor 
chondrocytes to the matrix (10). Further collagen types, including types III, XII and 
XIV, are also found but in smaller amounts(11). Type X collagen only appears in the 
calcified cartilage zone of articular cartilage or in the hypertrophic zone of the growth 
plate (12). Collagens are composed of a triple helix of three identical polypeptide chains 
(α- chains) which provide the shear and tensile strength to maintain the integrity of 
articular cartilage. Overall, the collagen forms a highly organized fibrillary network that 
immobilizes proteoglycan aggregates and serves as a tensile element (8).  
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The ECM is also rich in proteoglycans (PGs), which are macromolecules 
synthetized by chondrocytes and constitute the second largest group of the ECM 
components, accounting to 10- 15% of the tissue wet weight (13).   
They consist of glycosaminoglycans (GAG), long unbranched polysaccharide 
made of repeating disaccharide units, covalently attached to a central core protein. The 
glycosaminoglycan chains are composed of negatively charged carboxyl or sulfated 
groups, which attract positively charged ions and have the ability to retain large 
amounts of water in the matrix. This leads to different ion concentrations between 
articular cartilage and surrounding tissues. As a consequence of this osmotic imbalance, 
water is drawn into the tissue causing swelling and expansion of the matrix network, 
crucial for the biomechanical properties of cartilage (10). Among the most outstanding 
GAGs in the ECM, there are chondroitin sulfate 4 and 6, keratan sulfate and dermatan 
sulfate and hyaluronic acid (HA).  
The aggrecan being the largest and most abundant PG (90% of the total cartilage 
matrix proteoglycan mass). Aggrecan, that occupies most of the interfibrillar space of 
the matrix cartilage, has more than one hundred chondroitin sulfate and keratan sulfate 
chains that are associated with HA to constitute multimeric aggregates via link protein, 
which stabilizes this interaction.  Aggrecan make available a really high fixed charged 
density, creating an elevated osmotic environment necessary to retain the water needed 
for nutrient and solute transport (14, 15). The matrix also contains non-collagenous 
proteins, such as fibronectin and Cartilage Oligomeric Matrix Protein (COMP), whose 
function is to form part of the maintenance of cartilage structure and repair mechanisms. 
(9, 16, 17). 
Although these proteins are less studied, they have a role in tissue assembly and 
in maintaining the properties and functions of the tissue (10, 15). Structure and 
composition of ECM of articular cartilage are presented in figure 1.4. 
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Figure 1.4: Structure and composition of ECM of articular cartilage. Three classes of proteins exist 
in the articular cartilage: collagen, proteoglycans and other non-collagenous proteins. The interaction 
between highly negatively charged cartilage proteoglycans and type II collagen fibrils is responsible for 
the compressive and tensile strength of the tissue. (18) 
 
1.2.1.2 Chondrocytes 
Chondrocytes are the only cellular elements present in adult hyaline cartilage. 
Chondrocytes represent only 2-5% of the total tissue volume (19) and are considered as 
highly specialized cells an play a key role in the biosynthesis and maintenance of ECM 
components, ensuring periodic replacement of the constituent elements of the matrix to 
conserve the normal conditions in adult cartilage, the balance between anabolic and 
catabolic processes (20, 21). Chondrocytes can vary in size, shape and number per unit 
of tissue from the surface to the deep layers in the cartilage. They are able to respond to 
biochemical, structural or physical stimuli by synthesizing different enzymes, growth 
factors, cytokines and components of the ECM. Chondrocytes live in an avascular 
environment, with low levels of nutrients and oxygen. As a consequence, chondrocyte 
metabolism operates at low oxygen tension, ranging from 10% at the surface to 1% in 
deep zone, mainly supplied by the synovial fluid due to a lack of blood vessels (19). 
Low oxygen tension, the more physiological environment for chondrocytes, is the best 
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environment, where they can synthetize higher amounts of PGs and collagen, and 
reduce the mRNA expression and protein release of catabolic enzymes(22). In order to 
adapt to these low oxygen concentrations, healthy chondrocytes obtain energy from 
glucose, mainly through the glycolytic pathway(23). With ageing, chondrocytes tend to 
decrease, as well as their anabolic activity, because their ability to replace the collagen 
is altered and only the synthesis of proteoglycans appear to be maintained, albeit to a 
very limited way (21). 
The lack of chondrocytes of human origin suitable for in vitro experiments has 
limited the progress of studies related with pathologies related to cartilage. Developing 
cell lines that express the phenotype and characteristics of human chondrocytes  has 
been a key are of attention (24).The TC28-a2 line was obtained by retrovirus-mediated 
transfection. Primary costal chondrocytes from a healthy donor were transfected with 
virus T antigen 49 (SV40). It is a virus that codes for a multifunctional regulatory 
protein that is used for the immortalization of cells. Infection of cells with SV40 causes 
continuous growth, preventing them for entering into apoptosis, which results in a 
proliferation state (25). The expression of type II collagen (Col2A1) is a widely marker 
of differentiated chondrocytes and a major component of ECM. T/C28-a2.chondrocytes 
express transcripts for matrix proteins, collagens and aggrecanes which are all deposited 
in the extracellular matrix (ECM). In addition, this cell line conserves the chondrocyte 
morphology and to maintain the continuous proliferation in monolayer, making it very 
useful for the study of chondrocyte biology (25, 26). 
 
1.2.2 Structure and function of articular cartilage 
Cartilage is a heterogeneous tissue, made up of a single layer of cells that varies 
from the surface to the deepest layer in terms of composition, organization and 
metabolic activity. Thus, four structural and functional zones can be distinguished: 
superficial zone, intermediate or transition zone, deep zone and an area of calcified 
cartilage. These zones are not perfectly delimited, but instead there are  gradual changes 
in its composition and structure of both collagen, a major component of ECM, and 
chondrocytes. (27) 
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Figure 1.5: Structure of the articular cartilage. In the articular cartilage four zones can be 
distinguished: superficial zone, intermediate zone, deep zone and a zone of calcified cartilage. Between 
the deep layer and the layer of calcified cartilage is a calcification front, tidemark. The picture represents 
of healthy and OA cartilage illustrating the zonal architecture and distribution of chondrocytes (28) . 
 
There are differences in the structure and composition of collagen and 
chondrocytes according to the depth within the hyaline cartilage. In the case of collagen, 
we can observe that the structure varies from fine fibres in parallel to the surface to 
being perpendicular to the surface in the deep zone and to its disappearance in the zone 
of calcified cartilage. On the other hand, the chondrocytes are arranged parallel to the 
surface and are smaller in surface areas. The deeper is the zone the more disorganized 
the chondrocytes, often arranged in clusters perpendicular to the surface or in a scattered 
way. Viability and morphological properties also vary with deep. A summary of the 
main structural and composition differences of articular cartilage layers is shown in 
Table 1.1 
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Table 1.1: Structure and composition of articular cartilage layers.  
  Superficial zone Transition zone Deep zone Calcified cartilage 
 
Collagen 
 
Fine & parallel 
fibers to the 
surface 
Oblique course 
through the 
matrix 
Same 
orientation as 
columns of 
chondrocytes 
 
 
 
Chondrocyte 
Small and 
flattened parallel 
to the joint 
surface 
Large and 
spherical. 
Elliptical & 
forming 
columns of 2-6 
cells which are 
perpendicular 
to the surface 
Scattered, fewer 
and viable 
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1.3 Osteoarthritis 
Osteoarthritis (OA) is the most common joint disease, being ageing one of the 
determining factors in the development of this pathology. Almost 80% of those over 75 
years old have radiological or clinical abnormalities of OA. It is a degenerative 
pathology of the joints characterized by the alteration of the cartilage. Its pathogenesis is 
complex, since many genetic, metabolic and local factors play a role in decreasing 
cartilage and increasing in subchondral bone and synovial inflammation (9, 29). 
In 1987 OA was defined as “heterogenous group of conditions leading to joint 
symptoms and signs associated with defective integrity of articular cartilage in addition 
to associated changes in the underlying bone and at the joint margins” (30). Since, a 
variety of definitions emerged but there is a consensus that OA is a heterogeneous 
disease considered as a whole joint disease. 
Nowadays, the Osteoarthritis Research Society International (OARSI) defines 
OA as a “disorder involving movable joints characterized by cell stress and 
extracellular matrix degradation initiated by micro and macro-injury that activates 
maladaptive repair responses including pro-inflammatory pathways of innate immunity. 
The disease manifests first as a molecular derangement (abnormal joint tissue 
metabolism) followed by anatomic, and/or physiologic derangements (characterized by 
cartilage degradation, bone remodeling, osteophyte formation, joint inflammation and 
loss of normal joint function), that can culminate in illness” (31, 32). 
 
1.3.1 Clinical features 
The clinical manifestations are very variable depending on the affected joint and 
the moment of the evolution. The fundamental symptom is chronic pain presented by 
the patient due to inflammation of periarticular structures, increased intraosseous 
pressure, periosteal disturbance, synovitis or muscle contracture. In fact, the first events 
observed in OA occur in cartilage, at the joint surfaces areas, but structures around 
articular cartilage are also affected, including synovium, ligaments, muscles, meniscus, 
intra-articular fat, and subchondral bone (33, 34). Thus, phenotypic changes in cells of 
superficial layer, fibrillation with progressive loss of articular cartilage, cartilage 
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calcification, subchondral bone remodeling, sclerosis, osteophyte formation, and mild to 
moderate inflammation in synovial lining are some characteristic features in OA (35, 
36). Some of the more relevant features are presented in Figure 1.6. 
 
Figure 1.6: Clinical characteristics of a healthy knee vs. OA knee. We can observe the state of the 
Normal knee in comparison with the OA knee is shown. Degradation of articular cartilage, presence of 
osteophytes, synovial inflammation and abnormal exposure of bone are among the main pathological 
characteristics (37). 
 
The appearance and improvement of advantage medical imaging of the 
musculoskeletal system using X-ray techniques have significantly enhanced both the 
diagnosis and the study of arthroscopic pathology. Thus, through the images obtained 
by this technology, Kellgren and Lawrence, established the scale of radiological OA 
clinical graduation according to the condition of the joint that bears his name whose 
values range from 0 to 4 according to the observed radiological signs. (38) A patient is 
usually considered as an arthritic when his KL degree is equal to or greater than 2. 
More recently the Osteoarthritis Research Society International (OARSI) 
considered as criteria related to osteoarthritis the following critical aspects: 
-  Presence of marginal osteophytes in the femoral and tibia condyles of the medial 
and lateral compartments. 
-  Reduction of joint space in the medial and lateral area. 
Depending on the degree of involvement, the scale ranges from 0 to 3. 
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In addition to the radiological manifestations, during OA, other symptoms occur 
such as joint pain and stiffness, resulting in a symptomatic definition of osteoarthritis. 
When both signs are taken into account, it must be bear in mind that there is not always 
a correlation between them, since there may be radiological signs but not pain. 
Depending on the degree of joint space narrowing (JSN) and osteophyte classification, 
the scores of the scale range from 0 to 3 (Table 1.2) 
Table 1.2: OARSI classification score to OA. 
Radiologic Scale OARSI in OA knee 
Score  JSN classification (% reduction) Osteophytes classification 
0 Normal  normal 
1 Medium (1-33%) Grade I 
2 Moderate (34-66%) Grade II 
3 Severe (67-100%) Grade III 
 
 
1.3.2 Articular Cartilage in OA 
Adult healthy cartilage is characterized by maintaining a homeostatic balance 
between anabolic (ECM synthesis) and catabolic (ECM degradation) processes. 
However, in the development of OA it is characterized by increased catabolic processes 
of articular cartilage due to the degradation of ECM, the appearance of clusters of 
chondrocytes, increased cartilage calcification  increased area of the tidemark and onset 
of the subchondral bone (16). As the process continues, the increased catabolic activity, 
mediated by an up-regulation of cartilage-degrading proteinases and inflammatory 
mediators, occurs in conjunction with a decrease in matrix metalloproteinase enzyme 
inhibitors and ECM synthesis. 
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Figure 1.7: Scheme of pathway to catabolic and anabolic process (39).   
 
In OA cartilage, proteases are considered the most important elements involved 
the degradation of cartilage and ECM. The products of the proteolytic activity by this 
enzymes can trigger a catabolic response leading to a process of cell death with 
apoptosis characteristics (40). Matrix metalloproteinases (MMPs) and 'aggrecanase' a 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) are well 
established to play key roles in OA. MMPs are responsible for degrading ECM, 
eliminating molecules such as collagen (MMP-1 and MMP13), proteoglycans, gelatin 
or fibronectin (MMP-3 and MMP-10). 
 On the other hand, proinflammatory cytokines such as IL-1β interleukin and 
tumor necrosis factor alpha (TNF-α) also influence cartilage degradation, which induce 
the formation of other interleukins such as IL-6 and IL-8, which stimulates the 
formation of MMPs and increment the level of nitric oxide. In addition, they are able to 
stimulate other molecules such as prostaglandin E2 (PGE2) and the enzyme 
cyclooxygenase 2 (COX-2) (41, 42). 
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Figure 1.8: Scheme of pathway to catabolic and anabolic process. This pathway is mediated 
by Matrix metalloproteinases (MMPs) and 'aggrecanase' a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTSs). (43) 
 
Furthermore, it is important to mention that once the collagen network is degraded, it 
cannot be restored to its initial state (44). Therefore the therapeutic challenge is and will be to 
avoid damage or promote the repair of the physiological and functional properties of the initial 
hyaline cartilage at early stages (45). It is important to note that the articular cartilage 
chondrocytes have traditionally been classified as highly glycolytic cells. However, until 
relatively recently it was believed that mitochondria did not mediate the pathogenesis of the 
disease. Recent studies in this regard have shown a mitochondrial dysfunction in OA, associated 
with excessive production of reactive oxygen species (ROS), accompanied by alterations in 
ATP production, calcium levels and redox status, which may explain in part some of the 
processes that lead to cartilage degradation during OA(20, 46). 
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1.4 OA Risk Factors 
OA has been considered as a disease associated to ageing and to the mechanical 
stress of joints, without taking into account other risk factors. This concept changed and 
OA is now considered a disease where many interconnected with mediators such as 
metabolic, hormonal and humoral, and recycling pathways have been shown to 
contribute to the initiation and progression of the disease (47). Nowadays, OA is 
considered a multifactorial disease, whose causes are not yet completely understood. 
The development and progression of the disease can be a result of the interaction 
between various systemic and local factors that include age, sex, ethnicity, genetics, 
nutrition, osteoporosis, smoking, obesity and metabolic disease, sarcopenia, and local 
mechanical risk factors (48). 
Aging is a main risk factor for OA, and the phenotype of aging-associated 
changes in both cartilage cells and extracellular matrix (ECM) has been characterized in 
detail. Cell density in cartilage decreases with aging, remaining cells express certain 
features of cellular senescence, produce reduced amounts of ECM and increased levels 
of matrix degrading enzymes and inflammatory mediators, Recent progress in 
understanding mechanisms related to cartilage cell aging includes the demonstration 
that chondrocytes are less responsive to anabolic stimuli and deficient in defenses 
against oxidative stress.  
Osteoarthritis is not a consequence of aging, but it does increase its prevalence is 
dramatically increased due to the mechanical changes suffered over time by the 
periarticular musculature joint, as well as the decreased stability to withstand increased 
load to withstand increased load.  
Aging modifies the structure and function of articular cartilage and other joint 
tissues such as subchondral bone, muscle, soft tissues, synovial membrane, and synovial 
fluid. (49, 50)  
Consequently, based on differential risk factors, OA can now be classified 
according to a variety of OA phenotypes including, age-related metabolic,  
inflammatory, hormonal, pain-related, genetic and injury-related phenotypes (51, 52). 
At this moment, there are no efficient treatments to stop OA progression. This failure 
might be a consequence of evaluate OA as a unique disease without consider the 
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different OA phenotypes (49, 50). It is likely that these different phenotypes may need 
different therapeutic approaches. 
In fact, understanding the underlying mechanisms of disease progression can 
help to differentiate OA phenotypes, and thus provide the right treatment to the right 
patient. This knowledge could enable the development of more effective and tailored 
therapies (34, 49, 53) 
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1.5 Prevalence and treatments 
About one tenth of the world's population over 60 years old is estimated to have 
symptomatic problems that can be attributed to OA. As other musculoskeletal disorders, 
it causes significant pain, disability and decreased quality of life. The prevalence of the 
OA increases with age (Figure 1.9) and is highly related to obesity. Therefore, due to 
the adoption of new, more sedentary lifestyles, it is expected that by 2030 the affected 
population over 60 will be 30%. 
Population studies, usually based on radiographs, have demonstrated a transition 
from normality to the development of pathology in the joint. Generally, most patients 
with chronic knee pain between the ages of 35 and 50 are likely to develop OA in the 
next decade. The most commonly recognized risk factors for knee OA (obesity, 
mechanical injury, occupational or excessive leisure physical activity, and osteoarthritis 
of the hand) have a greater effect on incidence and progression (54, 55). 
Although the prevalence and incidence of osteoarthritis varies among the 
different studies, if there is an agreement about the proportion of adults affected, as 
documented  in epidemiologic studies on the prevalence of knee, hip and hand as shown 
in the figure 1.9 (56). 
Osteoarthritis also involves an economic cost related to diagnosis, follow-up and 
treatment. It is the second pathology that generates more expenses, below the 
cardiomyopathies. According to a study carried out by ArtRoCad study, the treatment of 
hip and knee, supposes a direct and indirect cost of almost 5000 million a year. 
The  burden of OA is expected to the increase with ageing of the population, the 
absence of therapeutics and the increase of the lifespan in the population (57). 
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Figure 1.9: incidence of disease with age. Note that the impact of knee OA in the elderly is Higher 
compared to the other joints (56). 
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1.6 Molecular mechanisms of aging related disease of musculoskeletal 
system: The autophagy 
To maintain homeostasis, cells need to constantly adapt to environmental cues, 
by balancing between biosynthetic and degradative processes. In eukaryotic cells, two 
main degradative processes can occur: proteasomal degradation, responsible for the 
breakdown of short-lived proteins; and autophagy, responsible for the degradation of 
long-live proteins, protein aggregates, and entire organelles (58). 
1.6.1 Autophagy 
In recent years, we have witnessed an explosion of research on a cell biology 
pathway called autophagy, or from the Greek roots “self-eating” process. It is an 
evolutionarily conserved intracellular process that occurs in all eukaryotic cells, with a 
number of similar basic components shared between yeast and mammals (59). 
Autophagy occurs constitutively and exerts two main functions: quality control, 
through the removal and degradation of damaged intracellular components, and 
maintenance of the cellular energetic balance, or cellular homeostasis, through the 
release of nutrients from macromolecules. However, additional functions have been 
suggested, including cellular remodeling and tissue differentiation, cellular survival and 
response to stress, cell death, senescence, and anti-aging functions. Indeed, autophagy is 
now considered essential in many physiological and pathological conditions (60, 61). 
Three forms of autophagy have been identified: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA). All of them promote 
proteolytic degradation of cytosolic components at the lysosome. However, they display 
different mechanisms for the delivery of the cytoplasmic material to the lysosomes. 
Moreover, micro and macroautophagy have the capacity to engulf large structures, such 
as entire organelles, through selective and nonselective mechanisms. On the other hand, 
CMA can only degrade soluble proteins in a selective manner (59, 60). Macroautophagy 
is the most intensively characterized type of autophagy and, due to increased interest in 
macroautophagy in articular cartilage; this thesis will focus solely on macroautophagy, 
hereafter referred to as “autophagy”. 
Autophagy is a degradation lysosomal process essential for survival, 
differentiation, development and cellular homeostasis. It is a degradation mechanism 
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that plays a fundamental role in the regulation of energy and nutrients, as well as in the 
elimination of organelles and/or macromolecules that are toxic to the cell (62). It can be 
activated by different factors that induce stress in the cell, such as nutrient deprivation, 
hypoxia or an increase in ROS production (63). However, in certain pathological 
conditions, autophagy may act as a type of cell death mediated by the formation of 
lysosomal vacuoles in the cytoplasm. This type of cell death is known as type II cell 
death, to differentiate it from type I cell death or apoptosis, which is characterized by 
chromatin condensation and DNA fragmentation and subsequent disintegration 
independently of vacuole formation (64). 
The most important characteristic of autophagy is the formation of 
autophagosomes with double membrane by the sequestration of vesicles or organelles in 
the cytoplasm after the activation of the autogenic machinery or Atg genes.  
 
1.6.2 The Autophagy pathway 
The Atg genes are involved in the regulation of autophagy by control of the 
process of induction and nucleation of autophagy vesicles or autophagosomes, in 
addition to its expansion and fusion with lysosomes, permitting the degradation by 
lysosomal enzymes and the degraded material can be recycled and used by the own cell. 
  The process starts with a double membrane structure, called the phagophore or 
isolation membrane. The phagophore elongates and engulfs intracellular cargo, resulting 
in the formation of a double membrane structure named the autophagosome. 
Consequently, the outer membrane of the autophagosome fuses with the lysosome to 
form the autolysosome. In here, the degradation of the autophagosomal contents and of 
the inner membrane of the autophagosome happens, by lysosomal acid proteases (65). 
Proton pumps, such as ATPases, present in the lysosomal membranes, are responsible 
for the acidification of the autophagolysosome content. This acidification is required for 
the activation of lysosomal enzymes responsible for content degradation (66). Then, 
amino acids and other products generated from the degradation are transported back to 
the cytoplasm through membrane permeases, where they can be re-used for biosynthesis 
or energy production (67). 
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The Atg genes were discovered in yeasts and are highly conserved in the 
eukaryotes (68). More than 30 Atg proteins have been identified in the last decade, and 
it was discovered that autophagy is highly regulated at multiple steps (69),  Atg1, Atg6, 
Atg8 (ULK, Beclin 1, LC3 in humans, respectively) and Atg5 are considered the four 
most important regulators in the autophagy process. ULK1 acts as an intermediary in 
autophagosome formation; Beclin 1 is part of a complex consisting of PI3K type III and 
Vps34 that allows the sequestering and nucleation of the vesicles (70). Finally, the 
formation and expansion of the autophagosome depends on two systems: LC3 and Atg 
12-Atg 5. During autophagy, LC3-I is converted into LC3-II through a lipidation 
process, so it is associated with LC3 -II with vesicles of autophagy with double 
membrane or autophagosomes (71). A general scheme of the pathway is shown in 
Figure 1.10. 
In the elongation/enclosure step, the final step of autophagosome formation, two 
ubiquitin-like conjugation systems are required, Atg12 and microtubule-associated 
protein 1 (MAP1) light chain 3 (LC3):  
- In the first one requires the conjugation of Atg12-Atg5, which is 
produced by two ligases, Atg7 and Atg10. Conjugated Atg12-Atg5 then 
associates with Atg16L dimers to form a multimeric Atg12- Atg5-
Atg16L complex, which associates with the phagophore membrane (71, 
72). This complex is present on the outer side of the isolation membrane 
and is essential for its proper elongation and dissociates from the 
membrane immediately before or after autophagosome formation (68). 
- The second time requires the cleavage of the C-terminus of the 
unprocessed form of LC3 (pro-LC3) by Atg4 to produce the soluble form 
LC3-I, or cytosolic LC3. LC3-I subsequently conjugates with 
phosphatidylethanolamine (PE), with the participation of Atg7 and Atg3. 
The resulting lipidated form of LC3, LC3-II, associates with newly 
forming autophagosome membranes and is present in both the inner and 
outer membranes of the autophagosome. This conversion of LC3-I to 
LC3-II is a key regulatory step in autophagosome formation (71). LC3-II 
allows the expansion and closure of the autophagy vacuole which means 
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it is required for autophagosome formation and is commonly used as a 
marker for autophagosomes (73). 
- LC3-II in the outer membrane of the autophagosome is removed by Atg4 
that cleaves the PE, returning it to the cytosol for reuse. LC3-II in the 
inner membrane is digested with the cargo. (74). These two conjugation 
systems seem to be interconnected. The Atg12-Atg5-Atg16L complex 
plays an essential role in Atg8/LC3-PE conjugation, and has an 
E3(ubiquitin ligase)-like activity for LC3 lipidation, contributing to the 
expansion of the autophagosomal membrane and to the correct 
localization of LC3 lipidation (75-77) . 
 
 
 
Figure 1.10: scheme of autophagy pathway. The most important steps of the cascade are shown: 
initiation, nucleation, expansion and fusion of the autolysosome with the lysosome (78) 
 
The amount of LC3-II is related to the formation of autophagosomes and consequently 
to the activation of the autophagy process (37, 79).  
In addition, it is important to highlight the role of the rapamycin target in 
mammalian cells or mTOR, as the most important regulator of the autophagy process 
(80). The mTOR complex is a protein kinase that regulates important functions in the 
cell, such as transcription control, cell cytoskeleton organization, regulation of growth, 
proliferation and cell survival. The complex mTOR is composed of two components: 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (40, 61). In fact, 
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mTORC1, it is responsible for the stimulation of anabolic processes such as protein and 
lipid synthesis, promotes growth, ribosome biogenesis, gene transcription, and 
metabolism, and also the control of regulation of autophagy (81, 82).  
Effectively, mTORC1 is highly sensitive to cellular nutrient content. In high 
nutrient and energy conditions, mTORC1 is activated downstream of growth factor 
receptor signaling, involving activation of Akt and PI3Kinases, and promotes cell 
growth through induction of ribosomal protein expression and increased protein 
translation.  In starvation and energy conditions mTORC1 is inactivated, resulting in 
diminished cell growth and allowing the restauration of energy and nutrient levels by 
autophagy activation.(83) 
 On the other hand, mTORC2 is involved in the regulation of the cytoskeleton 
(84).  mTORC2 signaling controls members of the AGC kinase family including Akt, 
serum/glucocorticoid-induced protein kinase1 (SGK1) and protein kinase C (PKC), thus 
playing an important role in actin cytoskeletal organization, and cell survival and 
metabolism. Although it seems that mTORC2 is insensitive to nutrients, it responds to 
growth factors, although the exact mechanism is still unknown. (83) 
  Both, the deficiency of nutrients by starvation or the use of pharmacological 
compounds such by Rapamycin or Torin 1 inhibits mTOR, activating the formation of 
autophagosomes and consequently the activation of the autophagy process. 
 Rapamycin is a macrolide antibiotic with immunosuppression activity that 
induces autophagy by blocking mTORC1. In this way, it regulates the participation of 
PI3-kinase/AKT and the activation of the protein Kinase AMP (AMPK) (62, 83). On 
the other hand, Torin 1 is a molecule considered highly specific of mTOR, since it 
inhibits both complexes (85). 
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Figura 1.11: Autophagy regulation by mTOR. MTOR is the major regulatory complex of autophagy 
composed of two components mTORC1 and mTORC2. Blocking this complex with mTOR inhibitors  
such as rapamycin permits the autophagosome formation and consequently the activation of the 
autophagy process, to degrade the dysfunctional organelles or mutant protein and to reuse as energy (62). 
 
1.6.3 Autophagy as a key mechanism in aging-related Disease 
Autophagy is a mechanism of lysosomal degradation essential for survival, 
differentiation, development and cellular homeostasis. Autophagy fulfills an adaptive 
neurodegeneration, heart disease and aging (21). Basal autophagy is key to maintaining 
function of protection against various pathologies, such as infections, cancer, cellular 
homeostasis and is rapidly activated when increased demand for intracellular nutrients 
or energy. In addition, it is also activated to protect the cell against oxidative stress, 
infections or accumulation of protein aggregates or dysfunctional organelles, such as 
mitochondria (80). Autophagy defects are directly related to abnormalities in 
musculoskeletal development, neurodegeneration, cardiomyopathies, and even death 
(86, 87) . A better understanding of autophagy mechanisms may lead in the discovery of 
new therapeutic approaches to prevent joint damage. 
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1.6.4 Autophagy and OA. 
The articular cartilage is an avascular, aneural, alymphatic, and viscoelastic 
connective tissue that obtains its nutrition and oxygen supply by diffusion from synovial 
fluid and subchondral bone. (88) 
The articular cartilage is characterized by a low rate of cell renewal, so an 
activation of autophagy could be essential to maintain cell integrity, function and cell 
survival.(89) Although the mechanism implicated in the development of OA remains 
undetermined, it is known that there is an interruption of the homeostatic state and an 
increase in chondrocytes. 
Autophagy is an essential component of chondroptosis and, in excess; it can also 
lead to autophagic cell death in chondrocytes. Nevertheless, autophagy can play a dual 
role in chondrocyte fate, as compelling studies have congregated on the cytoprotective 
role of autophagy in OA development. More exactly, it seems that the chondrocyte 
death process evolves during OA progression and depending on the cartilage layer 
considered.  Induction of autophagy by Rapamycin reduced IL-1β-induced intracellular 
ROS production, possibly by removing damaged mitochondria, thereby protecting 
chondrocytes from IL-1β-induced OA-like changes (90). 
In this sense, it has been demonstrated that the expression of autophagy 
mediators (ULK1, Beclin1 and LC3) is increased in human normal cartilage, promoting 
the maintenance of cartilage homeostasis. This increase was observed predominantly in 
the superficial zone. However, the expression of these mediators decreased in human 
aging and OA cartilage and this decrease was correlated with an increase in cell death 
by apoptosis.  
This increase was observed predominantly in the superficial zone. However, the 
expression of these mediators decreased in human aging and OA cartilage and this 
decrease was correlated with an increase in cell death by apoptosis (37, 91). During the 
initial degenerative phase, autophagy is increased in OA chondrocytes and cartilage, 
with increased expression of LC3 and Beclin1 messenger RNA in OA chondrocytes, 
might be as a compensatory response to cellular stress, with damage occurring when 
prolonged stress exceeds the capacity of this mechanism (92). In cartilage with mild 
OA, ULK1, Beclin1, and LC3 protein expression are decreased in the cartilage 
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superficial zone, though these three proteins are strongly expressed in the OA cell 
clusters as well as in the middle and deep zones (37, 93). In mouse OA knee joints, 
expression of ULK1, Beclin1, and LC3 are decreased together with glycosaminoglycan 
loss, whereas poly (ADP-ribose) polymerase (PARP) p85 expression is increased with 
gradual cartilage degradation. This reduction in autophagy regulators is accompanied by 
increased apoptosis (92).  
In this sense, spontaneous aging model in mice indicated that basal autophagy 
levels are diminished with age, which might contributes to the accumulation of 
damaged macromolecules or dysfunctional organelles (94). These pathological features 
are key in the development of many diseases aging-related diseases, such as OA (95, 
96). By contrast, other studies showed an increase in LC3-II and Beclin1 expression in 
OA chondrocytes, suggesting an up-regulation of autophagy in OA chondrocytes 
compared to normal chondrocytes (90). Another study described that OA tissues display 
numerous autophagic LC3 puncta while no elevation in punctate LC3 was observed in 
healthy cartilage (97). The authors justified these opposite observations with the 
different location of harvested OA cartilage that potentially corresponds to different OA 
stages. The authors proposed that during OA progression, autophagy can act as an 
adaptive response to protect cells. However, once severe OA is established, a decrease 
in autophagy was detected, indicating that failure of autophagy could contribute to OA 
progression (90). Genetic studies support the importance of autophagy in physiological 
and pathological events. In most experimental models, suppression of this mechanism 
leads to cell death, indicating that autophagy promotes cell survival and protection (86). 
Additionally, the cartilage-specific deletion of mTOR upregulates autophagy and 
protects mice from developing OA (37, 91). In this sense, many studies identified 
correlations between the mTOR signaling pathway and autophagy. Upregulated mTOR 
expression in OA is correlated with increased chondrocyte apoptosis and reduced 
expression of key autophagy genes, including ATG3, ATG5, ATG12, ULK1, 
MAP1LC3B and Beclin-1. Interestingly, Rapamycin treatment, which promotes 
autophagy by mTOR inhibition, increased levels of autophagy markers and 
autophagosome formation in healthy chondrocytes, in response to mechanical damage 
and in an experimental OA model in mice. (37, 91) 
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1.6.5 Role of Autophagy in Mitochondrial Function 
The mitochondria is present in the most eukaryotic cells like  the fundamental 
organelles, for the generation of cellular energy in the form of ATP by the process of 
oxidative phosphorylation (98). In addition, it plays an important role in many cellular 
events, ionic homeostasis and various anabolic and catabolic processes. 
The mitochondria contains the mitochondrial respiratory chain (MRC)or the 
electron transport chain (ETC), consisting of 5 multimeric protein complexes: CoQ1 
NADH dehydrogenase (complex I), succinate dehydrogenase (Complex II), ubiquinone 
cytochrome C reductase (Complex III), cytochrome C oxidase (IV complex), and ATP 
synthase (V complex) (99). ETC also requires two small electron carriers, ubiquinone 
(coenzyme Q10) and cytochrome c (100). The movement of electrons between the four 
first complexes of the chain produces a proton gradient through the inner mitochondrial 
membrane that is used by the V complex to generate ATP.  While this process is 
efficient, a reduced number of electrons can partially reduce oxygen giving rise to the 
formation of superoxide free radical, which can cause oxidative damage in the 
mitochondria and contribute to decline in its function (101). In this regard, over the past 
decade, numerous studies have shown that alterations in mitochondrial proteins are 
implicated in the development of some human diseases, such as Alzheimer's, 
Parkinson's, Type 2 diabetes, cardiovascular diseases and aging-related pathologies 
(102), such as the topic of my thesis, OA. 
 
Figure 1.12: Structure and function of mitochondria. A, image of the morphology of a mitochondria, 
where the mitochondrial crests formed by the invagination of the double membrane are represented. B, 
Mitochondrial respiratory chain located on the double membrane of the mitochondria, where 
mitochondrial respiratory chain complexes are represented. We can see the flow of e
-
 and H
+
, for 
obtaining energy from the mitochondria. Image obtained from Blanco et al, 2011 (20). 
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The role of mitochondria is being studied in detail, and recent studies have 
emphasized its important potential in understanding many aging-related pathologies, 
including OA. In this sense, several studies have described the occurrence of a failure in 
mitochondrial function in OA pathology associated with excessive production of 
reactive oxygen species (ROS) (20, 103). In addition, OA chondrocytes have been 
shown to decrease the activity of complexes I, II and III compared to normal 
chondrocytes, consequently causing a reduction in mitochondrial membrane potential, a 
decrease in ATP synthesis, and finally Cell death (99, 104). A defect in the 
transmembrane potential of mitochondria leads to a cascade of signals linked to 
programmed cell death or apoptosis. On the other hand, increased citrate synthase 
activity in OA chondrocytes suggests that mitochondrial mass is increased as a possible 
compensatory mechanism for electron deficiency, as well as low ATP levels and altered 
membrane potential. The ETC is one of the most important sites for the regulation of 
ROS production. The Inhibition of activity in complex III with Antimicin A has been 
shown to increase ROS production (16, 105). 
In addition, in vitro studies that use human articular chondrocytes have indicated 
that the use of specific ETC inhibitors suppress the synthesis of both proteoglycans and 
collagen, fundamental components of the cartilage structure (106) and increase the 
production of inflammatory mediators (99). In this sense, inhibition of complex I using 
Rotenone reduces the content of proteoglycans in the superficial and intermediate zone 
of the cartilage and an increase in the liberty of glycosaminoglycans from the cartilage 
to the supernatant. On the other hand, the inhibition of complexes III or V in 
chondrocytes induced the production of proinflammatory mediators, such as IL-1, IL-6 
and IL-18 cytokines or prostaglandin E2 (PGE2). All of these findings suggest that 
mitochondria may be an interesting organelle to study in our model of defective 
autophagy related to cartilage degradation (107). 
Previous studies have shown that mitochondria represent one of the most 
important pathways of chondrocyte degradation. Patients with different genetic 
polymorphisms in mitochondrial DNA (mtDNA) have higher probability of suffering 
from osteoarthritis, as well as their regulation of metalloproteases and OA biomarkers 
(108).  
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The T haplogroup a slower progression OA, unlike as compared to the carriers 
of haplogroup H.  When the thickness of the cartilage was analyzed, there was also a 
smaller decrease in the haplogroup T than in H, similarly as occurred in other non-H 
haplogroups, whose cartilage degradation was slower (109). 
The relationship between mitochondria and autophagy is dual. First, 
mitochondria may be the selective target of autophagy or Mitophagy (110)., an 
important process for the removal of damaged mitochondria that are potentially 
hazardous to ROS production. Second, mitochondria actively contribute to autophagy in 
response to multiple mechanisms, since mitochondrial membranes are the first organelle 
to mediate autophagy vesicles formation (111, 112). In addition, defects in autophagy 
are associated with different human diseases such as cancer and neurodegenerative 
diseases, which are also related to mitochondrial dysfunction. 
At the cellular level, a failure in autophagy leads to an increase in the reactive 
oxygen species (ROS) and abnormal gene expression that can trigger cell death (38). 
Increased levels of ROS can cause oxidative damage in mitochondrial DNA (mtDNA), 
lipid peroxidation and activation of pathways that can accelerate cartilage degradation. 
In addition, high levels of ROS can lead to the elimination of collagen and hyaluronic 
acid (113). ROS are intimately associated with accelerated aging and with the 
development of degenerative pathologies. In addition, ROS increase is stimulated by the 
deposition of proteins that stimulate the production of ROS and the accumulation of 
defective mitochondria 
Therefore, understanding the relationship between mitochondria and autophagy 
is critical to understanding the cellular and molecular mechanisms of aging-related 
diseases (114). 
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1.6.6 Autophagy and Aging 
Aging is a natural and inevitable process by which living organisms approach 
the twilight of their existence. Human aging is a complex physiological process, 
characterized by the declining ability of the different organs and tissues to respond to 
stress, increasing homeostatic imbalance and risk of disease,(115) which is 
accompanied by the gradual decline and adaptation of different body systems to the un 
avoid able passage of time. It is characterized by a progressive loss of structure, 
function, co-ordination and physiological integrity, leading to impaired homeostasis in 
all systems. 
One of the hallmarks of aging is cellular senescence. Normal cells possess a 
finite lifespan. Cells are continually exposed to a variety of harmful exogenous and 
endogenous factors that may induce stress and cause reversible or irreversible damage 
leading to complete recovery or cell death, respectively.(116) 
Clearly, age is one of the most important risk factors for OA, followed by other 
factors such as metabolic diseases, joint trauma, joint instability or genetic factors. As 
we age, our tissues undergo age-related changes. OA is a multifactorial disease in which 
cartilage degradation is a central feature. The ageing includes changes in metabolic 
activity, mitotic activity, sensitivity of chondrocytes to growth factors, responsiveness 
to anabolic stimuli. Age-related changes in articular cartilage contribute to the 
development and progression of OA. 
 In aging, articular cartilage chondrocytes show not only failure in proliferative 
and synthetic capacity but also have increased secretion of pro-inflammatory mediators, 
matrix degrading enzymes and oxidative stress, all of which can contribute to the 
development and progression of OA (117).  
Osteoarthritis (OA) is closely associated with aging, but its mechanism is not 
well understood. Many factors, including senescence, low chondrocyte metabolic rate, 
mitochondrial dysfunction, oxidative stress, and abnormal accumulation of advanced 
glycation end products (AGEs) may all play a key role in the pathogenesis of age-
related OA (103, 118). 
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As mentioned earlier, “chondrosenescence”, is an age-dependent deterioration of 
chondrocyte function, characterized by expression of senescence-associated markers, 
erosion of chondrocyte telomere length and mitochondrial dysfunction due to oxidative 
damage causing the age related loss of chondrocyte function (119). In this new 
framework chondrosenescence is intimately linked with inflammation and the disturbed 
interplay between autophagy and inflammasomes. This refined definition contextualizes 
the pro-inflammatory phenotype of chondrosenescent cells during the aging process and 
in age-related joint diseases, implicating mitochondrial dysfunction, oxidative stress and 
activation of inflammasomes.  
Extracellular matrix changes with aging also contribute to the propensity to 
develop OA and include the accumulation of proteins modified by non-enzymatic 
glycation. Thus, the survival of the chondrocytes is important for maintaining a suitable 
cartilage matrix. Damage to chondrocyte function and survival would lead to the 
breakdown of the articular cartilage. The release of soluble and insoluble factors 
secreted by senescent chondrocytes further contributes to the inflammatory 
microenvironment that is believed to drive the catabolic degradation of extracellular 
matrix (ECM) macromolecules in articular cartilage (119). 
The OA chondrocytes show a senescence secretory phenotype (SSP) consisting 
on the overproduction of cytokines (interleukins 1 and 6), growth factors and matrix 
metalloproteinases (MMP) (115). MMPs are important regulators of the degradation of 
ECM during OA development. Among the MMPs, MMP-3 and MMP-13 are important 
for degrading components of ECM, including collagens, proteoglycans, and other 
extracellular matrix macromolecules in cartilage. The serum level of MMP-3 was found 
to be elevated with aging in patients with OA, and this protease is capable of cleaving 
proteoglycans. In addition, MMP- 3 can indirectly activate pro-MMP-9, a gelatinase. 
Recent studies elucidated that elevated MMP-13 was noted at the deep zones of arthritic 
cartilage, and this protease appears to be the major MMP responsible for matrix 
degradation.(120) Reactive Oxygen Species (ROS) play a major role in the induction of 
the SSP. In chondrocytes, an increase in ROS production leads to hyper-peroxidation, 
protein carbonylation and DNA damage which alter chondrocyte function. ROS 
overproduction also induces changes in metabolic pathways such as PI3K-Akt and ERK 
(115).   
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Alterations in protective mechanisms such as decreased antioxidant defense and 
reduced autophagy, also occur with aging, disturbing the anabolic-catabolic equilibrium 
and reducing the remodeling and repair ability of cartilage (121, 122).  
Autophagy plays a crucial role in the homeostatic regulation of energy and 
nutrients, by removing macromolecules and damaged organelles, allowing cell survival 
under limited nutrient conditions. A failure in homeostasis can lead to 
neurodegenerative diseases, cardiomyopathy, abnormal musculoskeletal development 
and premature death (62, 80).  
Autophagy is closely associated with the retardation of aging and therapy for 
age-related diseases due to its cellular housekeeping role by removing dysfunctional 
cellular organelles and proteins. However, autophagy declines with aging and during 
OA. Furthermore, the reduction of autophagy is often accompanied with increases in 
apoptosis and cartilage degeneration. It has been proposed that autophagy maintains its 
declination tendency after its peak at the early stage of OA and further causes the 
aggravation of OA. 
As discussed earlier, articular cartilage is characterized by a low rate of renewal, 
, which fails to regenerate and remodel the cartilage adequately (123), autophagy seems 
to play an essential role in cell survival, since a reduction in the expression of 
autophagy in cartilage of mice and elderly humans is observed is accompanied by an 
increase in apoptosis of chondrocytes (62, 124). 
In cartilage, aging-related loss of autophagy leads to chondrocyte death and OA, 
while stimulation of autophagy exerts protective effects on cartilage deterioration. 
Aging also interferes with epigenetic mechanisms such as activity of histone acetylases 
that control the pattern of DNA methylation, and induces up- or down-regulation of 
microRNAs expression. A deeper knowledge of the mechanisms involved in 
chondrocyte aging could identify potential targets for the treatment of OA, a prevalent 
and therapeutic-orphan disease (115). 
More recently, autophagy has been studied as a mechanism that can regulate 
age-related changes in articular cartilage. Aging human chondrocytes and old mice 
exhibit a reduction in constitutive autophagy some mechanisms occurring during the 
aging process can explain the impaired autophagy observed, including defects in 
autophagy induction and inefficient lysosomal clearance. For instance, the altered 
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hormonal regulation of autophagy observed in aged tissues can be a possible 
explanation. In fact, in old organisms the ability of glucagon to upregulate autophagy 
appears compromised (89). Moreover, the interactions of the signaling network 
involving longevity factors, determinate pathways involving pro-longevity factors such 
as Sirtuin 1 (SIRT1) and transcription factor forkhead-box O3 (FOXO3), and pro-
senescence factors like mTOR, NF-kB and p53 are also autophagy regulators and thus 
can be involved in aging (125).  
On the other hand and as we said before, the activation of autophagy by 
inhibition of mTORC1 presumably maintains cellular function during ageing by 
allowing enhanced degradation of aged cellular components, thus protecting from 
toxicity, and consequently slowing aging. Additionally, other processes regulated by 
mTORC1 can also contribute  to the pro-longevity effects of mTOR inhibition, 
including reduction of protein synthesis, regulation of mitochondrial function, reduction 
in inflammation, increased stress resistance and preserved stem-cell function (126). 
A large body of evidence suggests that the activation of autophagy by 
rapamycin, extend the lifespan of mice and protects them against degenerative 
pathologies. However, increased autophagy does not always have a beneficial effect, in 
fact may also contribute to the opposite effect, as seen in progeroid premature aging 
mice. Interestingly, rapamycin reduces the senescence in cells derived from patients 
with Hutchinson-Gilford, which is characterized by the accumulation of progerin, a 
defective variant of lamina A, which is detected in low amounts during normal aging. 
Activation of autophagy by rapamycin promotes the removal of diseased cells, and 
therefore limits normal progerin accumulation with age (127). Proper regulation of 
autophagy is likely to be a determinant of healthy aging, and further studies are needed 
to determine the exact role of autophagy in OA and how it is regulated (128). 
  
1.6.6.1 The role of autophagy in age related targets: Lamin A/C 
The nuclear lamins are proteins of the intermediate filaments that form part of 
the network of proteins that underlies the nuclear envelope. They participate in the 
regulation of the structure and form of the nucleus, and they provide the organization of 
heterochromatin, transcription factors and nuclear complexes. There are two types of 
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sheets, type A (isoforms A and C) and type B (sheet B1 and B2). All sheets other than 
sheet C are subjected to a post-translational maturation process at their C-terminal 
CAAX (C-cysteine, A-aliphatic, X-any residue). The CAAX modification involves a 
series of events including CAAX cysteine farnesylation, endoproteolytic elimination of 
terminal residues (aax) and finally carboxymethylation of farnesylated cysteine (129). 
Subsequent to modification of the C-terminal end of prelamin A, the 15 amino 
acids of the "glue" of prelamin A are cleaved endoproteolysis giving rise to mature A-
lamina. The enzyme mediating this cleavage step is the Zn
2+ 
membrane metalloprotease 
(Zmpste24). The Zmpste24 plays a double role in the maturation process of prelamin A, 
on the one hand it participates in the elimination of the endoproteolytic of the terminal 
end -AAX, but on the other hand, it is the only one to participating in the 
carboxymethylation of farnesylated cysteine. 
 
 
Figure 1.13: Maturation pathway of prelamin A. In the absence of Zmpste 24, the excision of -AAX 
does not occur which produces an accumulation of farnesylated prelamin in the nuclear membrane of the 
cell. It is not performed in the endoproteolytic cleavage process, resulting in anomalous maturation of 
lamin  A, resulting in progerin accumulating in cells (130). 
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However, this whole process can be blocked by farnesyltransferase inhibitors 
(FTI). The absence of farnesylation, prevents the endoproteolytic prelamin processing 
so there is no accumulation of farnesylated prelamin. 
The reason for the removal of the tail of prelamin A is not entirely clear, but its 
non-cleavage is associated with disorders ranging in severity from mild to deadly 
neonatal progeroid syndrome. These diseases, in order of increasing severity, include 
metabolic disorder, mandibuloacral type B dysplasia, Hutchinson-Gilford Progeria 
syndrome (HGPS) and neonatal restrictive lethal dermopathy (LD). These diseases are 
either caused by mutations in the genes encoding any lamin A isoforms, or in the 
enzyme Zmpste 24. 
The HGSP is the most known and studied disease, related to premature aging 
resulting from an active mutation at the cryptic splicing site in the lamina A gene. This 
error eliminates the coding zone for Zmpste24, so it does not occur the cleavage in the 
prelamin A, resulting in a mutant form of lamin A, called progerin. Progerin produces 
toxic effects in the cell, which leads to damage in chromatic and cellular senescence, 
causing acceleration in aging. HGSP, as well as other progeroid disorders or 
laminophaties, highlight spot the importance of correct maturation of prelamin A by 
Zmpste24 (129, 131).  
Lamin A/C was previously found dysregulated in OA cartilage, but the 
mechanism that regulates this alteration is still unknown (132).   
Aging is the most important risk factor correlated with OA (133) and  is 
intimately associated to decreased basal autophagy activity (134). The role of lamin A/C 
in the context of defective autophagy might shed light in the molecular mechanism of 
cartilage aging and joint disease. 
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Significance to the musculoskeletal system 
OA is a major musculoskeletal cause of disability in the elderly, but current 
therapeutic approaches, including moderate exercise, lifestyle modification and pain 
medications, do not prevent initiation and progression of the disease. OA affects nearly 
to 27 million people in the United States, accounting for 25% of visits to primary care 
physicians, and half of all NSAID prescriptions. It is estimated that 80% of the 
population have radiographic evidence of OA by 65 years of age. Given the 
epidemiological evidence, the identification and validation of novel and effective targets 
for OA is expected to have a dramatic impact on OA prevention and treatment.  
Recent progress has led to the characterization of some pathogenic pathways, but 
little is known about mechanisms of aging and OA. The results showed in this doctoral 
thesis will contribute to a better understanding of the role of autophagy in aging and 
how defective autophagy contributes to OA. 
 
Key Points 
1. Aging-related pathologies, including osteoarthritis (OA), are the major causes of 
disability and contribute substantially to the global burden of disease. 
2. OA, the most common disease related to aging, is characterized by the destruction 
of articular cartilage, the degradation of the extracellular matrix and a reduction of 
cellularity.  
3. Autophagy is a key mechanism of cell homeostasis and exerts a protective and 
promoting function. 
4. Mitochondrial function is central in aging and is associated to the development of 
OA.  
5. Autophagy defects are found in aging and OA. As a result, damaged 
macromolecules accumulate and lead to cell death accelerating the breakdown of 
tissue. The molecular mechanisms of action regulating this degenerative process are 
still unknown. 
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Hypothesis 
“A reduction in autophagy related to the aging process contributes to the 
accumulation of damages organelles and proteins, which would lead to a failure in the 
mechanisms of cartilage homeostasis, contributing to the development of OA”.  
 
Objectives 
The general goal of this thesis is to elucidate the role of autophagy in the 
mitochondrial function, and to identify molecular regulators of autophagy. Our study 
leads to the discovery of new therapeutic strategies for aging-related musculoskeletal 
disorders such as OA. To address this problem, we propose the following specific 
objetives:  
Objective 1: To study the effects of defective autophagy to mitochondria function 
using pharmacological and genetic approaches: 
1.1. Modeling mitochondrial dysfunction in human chondrocytes. 
1.2. To study the effect of mitochondrial dysfunction on autophagy pathway in 
human chondrocytes. 
1.3. To evaluate the effect of pharmacological activation of autophagy in human 
chondrocytes with mitochondrial dysfunction. 
Objetive 2: To identify potential targets of defective autophagy associated with the 
pathology of muskuloletal system 
1.1. Differential proteomic screening of defective autophagy in human 
chondrocytes.Identification and validation of regulators of defective autophagy 
related to aging and OA in human chondrocytes. 
1.3. To analyse the consequences of laming A/C accumulation in the 
musculoskeletal system by using an in vitro and in vivo model of accelerated 
aging. 
  
  
41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 CHAPTER 3: MATERIAL AND METHODS 
  
  Chapter 3: Material and Methods 
42 
 
3 Cell culture 
3.1 Primary chondrocyte isolation and culture. 
Normal human articular cartilage was harvested at the time of autopsy from the 
femoral condyles and the tibial plateaus of donors who had no history of joint disease 
and had macroscopically normal cartilage surfaces. OA human cartilage was obtained 
from patients undergoing knee replacement. Briefly, cartilage slices were incubated for 
15 minutes at 37°C with trypsin (0.5 mg/ml; Sigma-Aldrich, St. Louis, MO, USA). 
After the trypsin was removed, the cartilage slices were incubated overnight at 37°C 
with 2 mg/ml of clostridial collagenase (Sigma-Aldrich) in DMEM with 5% Fetal Calf 
Serum (FCS), with shaking.  
The isolated chondrocytes were recovered and plated in DMEM supplemented 
with 10% FCS, L-glutamine, and 1% antibiotics (Penicillin-Streptomycin, Sigma-
Aldrich) and were allowed to attach to the culture flasks. The cells were incubated at 
37°C in a humidified gas mixture containing 5% CO2 balanced with air. The 
chondrocytes were used in the experiments in the first passage at confluence.  
The Ethics Committee of Galicia, Spain, approved this study.  
 
3.1.1 Culture of cell lines in monolayer 
The immortal juvenile human chondrocytes, T/C28a2, used in this study were 
developed and donated by Mary Goldring as we described in the Introduction section 
(24). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life 
Technologies) supplemented with 10% (FCS; Life Technologies) 10% FCS, L-
glutamine, and 1% antibiotics (Penicillin-Streptomycin, Sigma-Aldrich) and maintained 
at 37°C in the presence of 5% CO2. Cells were cultured in monolayer and grown to 
confluence. 
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3.2 General conditions of the cell culture experiments 
To perform the experiments, T/C-28a2 cells or primary human chondrocytes 
were plated in different formats depending on the study to be performed: 6-well plates 
(1.5x10
5
 or 5x10
5
 cells /well) for transfection studies or protein isolation, respectively; 
12-well plates (2.5 x10
5
 cells/well) for determination of mitochondrial membrane 
potential (Δψm), Reactive Oxygen Species (ROS) production, or quantification of cell 
death by apoptosis; 8-well chamber slides (1x10
5
 cells/well) for microscopy 
experiments (Hoescht and LC3 quantification) and 96 well plates for clone isolation in 
CRISPR / Cas9 genetic editing technique.  
Experiments were performed when the cells have acquired proper confluence. 
The chondrocytes were plated in 10% FCS and then media was changed to DMEM 2% 
FCS, under basal conditions or in the presence of different stimuli. For transfection 
experiments, human chondrocytes were plated in 6-well dishes in DMEM containing 
10% FCS without antibiotics prior to transfection.  
 
3.2.1 Stimuli used in the experiments 
All the stimuli used in the development of this project were prepared as 
solutions according to the manufacturer's recommendations. The solvent used for 
resuspension, the recommended storage concentration and the final concentration are 
summarized in Table 3.1. 
 Oligomycin (Oligo, 10μg/ml, Sigma-Aldrich), a mitochondrial respiratory chain 
complex V inhibitor was employed to induced mitochondrial dysfunction in human 
chondrocytes at the indicated times. Rapamycin (Rapa, 10μM, Calbiochem), a 
mTORC1 inhibitor, or Torin1 (50nM, Tocris Biosciences), a mTORC1 and mTORC2 
inhibitor, were employed to induced autophagy in human chondrocytes at the indicated 
times. Antimycin A (40μg/ml), Valinomycin (μM), H2O2 (100μM), or Tumor Necrosis 
Factor α (TNFα; 10ng/ml) and Actinomycin D (1μg/ml), all from Sigma-Aldrich, were 
used as positive controls for mitochondrial dysfunction, mitochondrial membrane 
depolarization, ROS production, and cell death by apoptosis, respectively.  
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Table 3.1: Stimuli used in the experiments 
Name Solvent Concentration Function 
Oligomycin DMSO 10µg/ml MRC Complex V Inhibitor 
Antimycin A DMSO 40µg/ml MRC Complex III Inhibitor 
Rapamycin DMSO 10µM mTORC1 Inhibitor 
Torin1 DMSO 50µg/ml mTORC1/C2 Inhibitor 
Valinomycin DMSO 1µM Mitochondrial Dysfunction 
TNFα Water 10ng/ml Proinflammatory cytokine 
Actinomycin D DMSO 1µg/ml Transcription Inhibitor 
Hydrogen Peroxide  Water 100µM ROS production 
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3.3 Mitochondrial function studies 
3.3.1 Determination of mitochondrial membrane potential (MMP) 
To determinate the mitochondrial membrane potential, the fluorophore JC-1 
(5',6,6'-Tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide) and cationic cyanine 
dye DiIC1 (1, 1 ', 3,3,3', 3'-hexamethylindodicarbo-cyanine iodide) were employed. 
Briefly, the chondrocytes were cultured in 12-well plates at 2.5 × 10 5 cells/well 
and treated with experimental conditions. After the incubation time, the cells were 
washed with PBS, trypsinized and centrifuged at 1800 rpm for 10 min at 4 ° C. Then, 
the cellular precipitates were resuspended in 0.5 ml of PBS and centrifuged again. 
Subsequently, after decanting the supernatant, the precipitate was resuspended in 300 μl 
of a mixture of fluorophore (10 μg/ml) and DMEM medium with 2% FCS. The samples 
were then incubated in 1.5 ml open tubes for 20 min at 37 ° C in a humidified oven with 
5% CO2, covered with silver paper to protect them from light. After the incubation time, 
the cells were washed with PBS to finally be resuspended in 350 μl of PBS and 
analyzed on a flow cytometry (FACScan, Cell-Quest program, BD). 
JC-1 is a cationic carbocyanine which has the property of emitting two types of 
fluorescence depending on membrane potential changes. If the membrane potential is 
not altered, the fluorophore will emit red fluorescence, as it has the ability to aggregate 
it and reach the mitochondrial intermembrane space. In contrast, if the membrane 
potential is decreased, the fluorophore cannot access the mitochondrial intermembrane 
space and therefore will remain in monomeric form by emitting green fluorescence.  
As a positive control, Valinomycin (1µM, Sigma), which is characterized as a 
potent membrane depolarizer, was used. Analysis of data was performed using a flow 
cytometer (FACScan, Cell-Quest program, BD). The cytometer was calibrated to detect 
the fluorescence of the monomeric form through the detector FL1 (green fluorescence at 
390nm) and the fluorescence signal of the aggregated form through the detector FL2 
(red fluorescence at 340nm). In each experiment, 10,000 events were analysed. The 
values obtained were plotted as a function of the relationship between red fluorescence 
(unchanged potential) and green fluorescence (potential decreased) for JC-1 
experiments. 
DilC1 accumulates primarily in mitochondria with active membrane potential. 
However, DilC1 staining intensity decreases when the mitochondrial membrane 
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potential is disrupted. Photomultiplier settings were adjusted to detect DilC1 
fluorescence signal on the FL4 detector. Mean fluorescence intensity values for FL4 
were obtained in all experiments. In each experiment, 10,000 events were analyzed. 
Results are expressed as the ratio of DilC1 fluorescence intensity values. DilC1, which 
accumulates in the mitochondria when the membrane potential is active, so the 
fluorescence intensity decreases when the membrane potential is low, when cells are 
treated with reagents that disrupt mitochondrial membrane potential. 
 The cytometer was calibrated to detect the DilC1 signal in FL4. In each 
experiment 10,000 events were analysed, the results were expressed as a function of the 
fluorescence intensity of DilC1. 
 
3.3.2 Quantification of reactive Oxygen Species Production 
The dye 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA; Sigma-Aldrich) 
was used to evaluate the intracellular production of Reactive Oxygen Species 
Production (ROS). Briefly, chondrocytes were treated as indicated, and the cells were 
washed and incubated for 30 minutes with DCFH-DA (10 μM) in 1 ml of DMEM. 
DCFDA is deacetylated by cellular esterases to a non-fluorescent compound, which is 
later oxidized by ROS into 2’,7’–dichlorofluorescein (DCF). DCF is a highly 
fluorescent compound which can be detected by fluorescence spectroscopy with 
maximum excitation and emission spectra of 495 nm and 529 nm, respectively. After 
washing, the cells were resuspended in phosphate buffered saline (PBS), and visualized 
by flow cytometry (FACScan, Cell-Quest program, BD Biosciences) in the FL1 
channel, with fluorescence levels indicating the percentage of positive cells for 
intracellular ROS production.  
For MitoSOX Red–based flow cytometric detection of mitochondrial 
superoxide, cells were treated as indicated and then incubated for 30 minutes with 
MitoSOX Red superoxide indicator in Hanks’ balanced salt solution with Ca+2/Mg+2 
(HBSS, all from Life Technologies). After washing, the cells were resuspended in PBS 
and visualized by flow cytometry in the FL2 channel, with fluorescence levels 
indicating the percentage of positive cells for mitochondrial superoxide. In each 
experiment, 10,000 events were analysed. 
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Cell Death Studies 
3.3.3 Determination of Cell Death by Apoptosis 
To determine early and late apoptosis, chondrocytes were labeled with Annexin 
V and Propidium Iodide, respectively (ImmunoStep). Human chondrocytes were 
cultured as described above. Before reaching confluence, the cells were plated in 12-
well plates at 2.5x10
5
 cells per well and cultured in DMEM with 10% FCS for 24 hours. 
Then, medium was replaced with DMEM with 2% FCS, and the chondrocytes were 
preincubated for 4 hour with Rapamycin (10μM) or Torin1 (50nM) and then stimulated 
Olygomycin (10μM) for 18 hours. After the incubation time, cells were trypsinized, 
washed with PBS and centrifuged at 1500 rpm. After decanting the supernatant, the 
precipitate was resuspended in PBS and centrifuged again at 3000 rpm/5 min and then 
incubated with Annexin-V and PI.  
Annexin-V, is a fluorophore active in normal live cells, while 
phosphatidylserine (PS), a fluorophore that attaches to the cytoplasmic surface of the 
cell membrane. However, in apoptotic cells, PS is translocated from the inner to the 
outer leaflet of the plasma membrane, thus exposing PS to the external cellular 
environment. The human anticoagulant, Annexin V, is a 35–36 kDa Ca2+-dependent 
phospholipid- binding protein that has a high affinity for PS. Annexin V can identify 
apoptotic cells by binding to PS exposed on the outer leaflet (135).  
On the other hand, PI is impermeant to live cells and apoptotic cells, but stains 
only dead cells with red fluorescence, binding tightly to the nucleic acids in the cell.  
Then, the cells were analyzed on a FACSCalibur instrument (Becton 
Dickinson). For each condition, 10,000 events were collected. Results are expressed as 
the percentage of Annexin V–positive cells or the percentage of PI–positive cells. 
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3.4 Autophagy function studies 
3.4.1 Immunofluorescence 
Human chondrocytes were cultured on 8-well slides (Corning Costar) and 
treated with different stimuli as indicated. Then, the cells were fixed with 4% 
paraformaldehyde–PBS for 10 minutes at room temperature, and permeabilized with 
0.3% Triton X-100 in PBS at room temperature for 15 minutes. Then, the cells were 
blocked in 5% normal goat serum (NGS) in PBS for 30 minutes and incubated for 1 
hour at room temperature with rabbit polyclonal light chain 3 (LC3) antibody (1:500 
dilution, catalog no. PM036; MBL International) in 1% NGS/PBS. A fluorescent dye–
conjugated secondary antibody (Alexa Fluor 488–conjugated rabbit IgG, 1:200 dilution, 
catalog no. A-11034; Life Technologies) was added and incubated for 30 minutes at 
room temperature. The nuclei was analyzed by incubating the cells for 10 minutes with 
Hoechst 33342 (1 μg/ml; Life Technologies). Finally, the slides were mounted with 
ProLong Gold Antifade Reagent (Life Technologies) and observed with fluorescence 
microscopy (Olympus). All images were imported into ImageJ Software (National 
Institute of Health) for quantitative image analysis. 
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3.5 Proteomic studies 
3.5.1 Processing of protein samples for isobaric tags for relative and absolute 
quantification (iTRAQ) labeling  
Proteomics based on mass spectrometry has emerged a powerful method to 
search for potential protein targets. As typical proteomic experiment, consist of 
extraction of proteins, their separation and identification by mass spectrometry.  
This technique permits the analysis of 4 to 8 biological samples at the same time. 
The four reagents used in the iTRAQ 4-plex version are named 114, 115, 116 and 117. 
The eight reagents include these four and four additional reagents called 113, 118, 119 
and 120. Each reagent is composed of a peptidic reactive group and an isobaric label 
consisting of a reporter group and an equilibrium group. For this, the labeling of the 
peptides is generated after digestion at the N-terminal end. The reactive group is derived 
from N-hydroxysuccinamide and reacts with the amino group of lysine residues and the 
N-terminal end of all peptides (136). 
Human chondrocytes were transfected to induce defective autophagy (siCtrl and 
siAtg5) and processed for iTRAQ analysis as previously described (Calamia et al., 
2014). Briefly, protein from OA human chondrocytes was lysed using 6M urea/2% 
sodium dodecyl sulfate (SDS) buffer and then cleaned up by acetone precipitation. 
Protein pellets were dried in air and then resuspended in 25 ml Dissolution Buffer. 
 Then iTRAQ labeling was performed according to the supplier’s instructions 
(ABSciex, Foster City, CA, USA).  The samples were labeled as follows: 114;116 for 
siCTRL and 115;117 for siAtg5. Then, the iTRAQ-labeled peptides were mixed and 
desalted using reversed phase columns (Pierce C18 Spin Columns, Thermo Fisher 
Scientific, Rockford, IL, USA) prior to liquid chromatography coupled to mass 
spectrometry (LC-MS) analysis (137). 
In the first phase, to each sample tube containing 50-100 μg of protein, we add 
20 μl Dissolution Buffer and vortex the samples for 1 hour and then sonicate for 3 min. 
Next, add 1μl Denaturant kit, 2μl Reducent Reagent tube, mix well and incubate at 60 
°C for one hour. After incubation time, add 1μl of Cysteine Blocking Reagent and 
incubate for 10 min. at room temperature. Afterward, we will begin the digestion with 
trypsin, for this we had to reconstitute a trypsin vial in the following proportion 10μl of 
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water + 4μl of trypsin (1μg / μl), and added to each sample 10μl (5μg): 20 enzyme: 
substrate) and incubate at 37 ° C overnight. Finally, the labeling of the proteins digested 
with iTRAQ Reagents takes place. We will add 70 μl of ethanol to each vial of iTRAQ 
which will then be transferred to one of the samples and incubate for 1 hour to label 
each vial with the different labels of 114, 115, 116 and 117. After the incubation time, 
we had centrifuged at 13000 rpm and checked the sample by the MS/MS to see that 
each sample contains the peaks corresponding to each label. We mixed the 4 vials and 
lyophilized the samples all night in the SpeebBack. To eliminate possible residues that 
may interfere with the technique, we washed it by column cleaning with Pierce® C18 
Spin Columns. Once the samples are cleaned, freeze-dried and stored at -20ºC. 
 
3.5.2 LC/MS/MS Analysis 
The Sample tags are excised during tandem mass spectrometry (MS/MS). Each 
reporter tag produces different MS/MS signatures that can be detected as peaks of the 
m/z ratio. The relative intensity of the reporter group labels provides information about 
the relative abundance of the proteins in each sample. The equilibrium group maintains 
the total mass of the isobaric label constant. (138, 139). 
The peptide mixture was firstly separated by high performance reversed-phase 
liquid chromatography (RP-LC) at basic pH (pH=10). The separation of the samples 
was carried out in HP 1200 system (Agilent Technologies, Santa Clara, CA, USA) 
using a reverse phase C18  Reverse-phase column (Zorbax extend C18, 100 3 2.1 mm 
id, 3.5 mm). The flow rate used is 0.2 ml/minute. Each fraction has been collected based 
on the UV intensity peaks (214 nm).Several fractions were pooled post-collection 
(FC203B fraction collector, Gilson, Middleton, WI, USA) based on the peak intensity 
of the UV trace, yielding a total of 60 samples per LC run.  
Each fraction was dried in a vacuum concentrator and stored at -20ºC for the 
next step of analysis. The dried peptide fractions were dissolved in 0.1% trifluoroacetic 
acid (TFA) and 2% acetonitrile; 5 mL of this sample were injected onto a capillary trap 
column (0.5 3 2 mm, Michrom Bioresources, Auburn, CA, USA) at a flow rate of 
15ml/minute. Peptides were desalted for 10 minutes and loaded onto a C18 column 
(Integrafit C18, ProteopepTMII, 75 mmid, 10.2 cm, 5 mm, 300A˚;New Objective, 
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Woburn, MA, USA) at a constant flow rate of 350 nl/minute to perform the separation. 
Then peptides were separated using linearly increasing concentration of acetonitrile in 
buffer B. The RP analytical column eluent was spotted onto a matrix-assisted laser 
desorption/ionization (MALDI TOF) sample plate using the Sun Collect MALDI 
Spotter/Micro Collector (SunChrom Wissenschaftliche Geräte GmbH, Germany) and 
analyzed by a 4800 mass spectrometer (AB Sciex). After the screening of all LC-
MALDI sample positions in MS positive reflector mode, the fragmentation of 
automatically selected precursors was performed to generate fragment ions that 
provided sequence information for the peptide and reporter ions. The LC-MS analysis 
and the MS and MS/MS parameters have been extensively detailed previously for 
articular cartilage chondrocytesm (137, 140, 141). 
 
3.5.3 Peptide Identification 
Protein identification is usually performed by the peptide mass fingerprint. The 
peptide mass fingerprint identification of the protein corresponds to a mass spectrum 
(MS) corresponding to the peptides resulting from the enzymatic digestion of the 
protein. Many times the MS spectrum is not sufficient to identify the protein, whereby 
fragmentation of the peptides is proceeded to be obtained from fragments of a tandem 
mass spectrum of the protein (MS/MS). The spectra obtained by MS or MS/MS are 
transferred to a computer program with a database in which we can compare the spectra 
and identify the protein.(142) 
Protein identification and quantification of proteins has been carried out using 
the program ProteinPilotTM software v.4.0 (ABSciex). Each MS/MS spectrum was 
searched in the Uniprot/Swissprot database for Homo sapiens. Search parameters within 
ProteinPilot were set with trypsin cleavage specificity; methyl methanethiosulfate 
(MMTS) modified cysteine as fixed modifications; biological modification ‘‘ID focus’’ 
settings, and a protein minimum confidence score of 95%. Thus, the identity of the 
protein from the analyzed peptide was confirmed, and the ratios of the peak areas of 
iTRAQ reporter ions were used to compare the relative abundance of the protein 
identified in the sample. The data were normalized based on error and background 
correction using Pro Group
TM
 algorithm (ABSciex). Only proteins identified with at 
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least 95% confidence, were considered for further analysis. Data were normalized for 
loading error by bias and the background correction was calculated using the Pro 
GroupTM algorithm (ABSciex). To determine the cutoff value for significant fold 
changes, coefficient of variation and cumulative frequency were calculated for the 
common proteins employing the R statistical package58. Using this tool, it was 
considered as statistically significant those changes with a p-value less than or equal to 
0.05 and a ratio of 1.4. The data obtained in the ProteinPilot were exported to Microsoft 
Excel for further analysis (143). 
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3.5.4 Western blotting 
Western blotting was performed with a chemiluminescence detection system. 
Protein from normal human chondrocytes was lysed using 6M urea/2% sodium dodecyl 
sulfate (SDS) buffer. Cell lysates were sonicated at 4°C, and protein concentrations 
were determined using a Pierce bicinchoninic protein assay kit kit (Pierce 
Biotechnology, Rockford, IL, USA). Then, protein extracts (20μg) were incubated with 
4×laemmli Sample buffer solution (Bio-Rad, Hercules, CA, USA) and β-
mercaptoethanol (Sigma-Aldrich), a reducing agent. The proteins were separated on 4–
20% SDS–polyacrylamide gels and transferred to PVDF membranes (Bio-Rad, 
Hercules, CA, USA), blocked with 5% dry skimmed milk or 5% bovine serum albumin 
in Tris buffered saline–Tween (TBST), and blotted for 1 hour with rabbit polyclonal 
antibody specific for LC3 (1:1,000 dilution, catalog no. PM036; MBL International), 
with p-Akt (Ser473), with p–ribosomal protein S6 (1:2,000 dilution, catalog Nº. 4060 
and 4858, respectively; Cell Signaling Technology), or with mouse antibody tubulin 
(1:2,000 dilution, catalog no. T9026; Sigma). The membranes were then incubated for 1 
hour with horseradish peroxidase (HRP)–conjugated donkey anti-rabbit IgG or sheep 
antimouse IgG (1:5,000 dilution, catalog nos. NA934 and NA931, respectively; GE 
Healthcare). Afterward, the membranes were washed 3 times with TBST and developed 
using enhanced chemiluminescence substrate (Pierce Biotechnology, CA, USA). A 
summary of primary antibodies used in this study is detailed in Table 3.2  
Table 3.2: Primary Antibodies used in WB studies. 
Protein Source Clonality MW 
(KDa) 
 Dilution Supplier/Ref. Number 
LC3 Rabbit Polyclonal 16-18 1: 1000 MBL 
International/PM036 
Atg5 Rabbit Polyclonal 55 1:1000 Cell Signaling/8540 
p-rpS6 
(Ser 235/236) 
Rabbit Polyclonal 32 1:2000 Cell Signaling/4858 
p-Akt (Ser473) Rabbit Polyclonal 60 1:2000 Cell Signaling/4060 
Lamin A/C Goat Polyclonal 70 1:50 Santa cruz /6214  
α-Tubulin Mouse Monoclonal 50 1:2000 Sigma-Aldrich®/ T9026 
GAPDH Mouse Monoclonal 30 1:10000 Invitrogen 
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3.6 Genome editing studies in chondrocytes 
3.6.1 Autophagy inhibition by silencing autophagy-related (ATG-5) with small 
interfering RNA 
Primary normal human chondrocytes were transiently transfected with siRNA 
for ATG-5 (siATG-5, ID s18160; Ambion), an essential autophagy gene (90) using 
Lipofectamine 2000 (Life Technologies) as described previously (86, 144). Silencer 
negative control #1 siRNA (Ambion), containing a RNA scramble sequence was used 
as control.  
The sense-strand sequence of the siRNA was 5-
GCUAUAUCAGGAUGAGAUATT-3.  
The transfected chondrocytes were then used for determination of mitochondrial 
membrane potential, ROS production analysis, Western blot analysis, proteomic 
screening by iTRAQ analysis and immunofluorescence.   
 
3.6.2 Genetic deletion of Zmpste 24 by clustered regularly interspaced short 
palindromic repeats (CRISPR-Cas9) technology 
Genome editing has recently emerged as a robust and efficient method to 
manipulate the genome with accuracy and precision. These technologies have apened 
opprotunities to study the functional consequences of genes and mutations relevant to 
disease.  
The CRISPR/Cas technology comprises two components, a small guiding strand 
and the Cas9 nuclease, which recognizes and binds to the specific DNA site. The 
plasmid containing guiding RNA, PCMV-Cas9-GFP (Figure 3.1), was obtained from 
Sigma-Aldrich (Plasmid (V6-gRNA/CMV-Cas9 GFP; NM-005857; Zmpste24 Gene 
ID10269, HS0000322098). The target site is a 20 bp complementary to gRNA that 
targets to Zinc Metalloproteinase STE24 (Zmpste24) genomic sequence that was 
included into the plasmid. The sequence to target was 5’-
GGCATCGCTGGACGCTTTGTGG- 3’. 
The plasmid was replicated replication by heat shock transformation in DHLOβ 
competent bacteria were used, the plasmid was included within the bacterial genome by 
thermal shock. The amount of plasmid used was 20ng/µl. These bacteria were incubated 
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in super LB medium for 1 hour at 37 ° C. After that time, the bacteria were seeded in 
culture medium in superLB-Kanamycin selective medium (20 μg/μl) overnight at 37 ° 
C. A colony-forming unit (CFU) was picked and grown in LB medium for 24h at 37ºC 
and then, the DNA was isolated by the Maxi-prep technique following the 
manufacturer's instructions for the Qiagen Maxiprep kit. 
TC28a2 human chondrocytes were cultivated in DMEM-F12 containing 10% 
FBS and 1% antibiotics in a humidified 5% CO2 at 37ºC. TC28a2 chondrocytes were 
cultivated to 60-80% confluence in 10 cm plates and transfected with the target vector 
(5µg) using Lipofectamine™ 2000 (Life Technologies, NY, USA) according to 
manufacturer´s instructions.  
The positively transfected chondrocytes were selected by sorting. Isolated clones 
of Zmpste24-transfected chondrocytes were incubated in 96 well plates in increasing 
order for expansion. To confirm the mutation, we screen each clone by isolating 
genomic DNA and genotyping by using the following primers:  
Forward: 5’-GCTCTGAAGGGACGAGTGTC-3’;  
Reverse: 5’-GTCCAGGAAAAGAGCAGCAC-3’.   
PCR products were separated in 1% agarose gel, and the absence of Zmpste24 
was confirmed by sequencing. A total of 3 mutated Zmpste24
-/-
 clones were selected for 
functional analysis. 
 
Figure 3.1: Schematic Plasmid of pCMV-Cas9-GFP cronstruction. 
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3.6.3 Gene expression analysis: RT-PCR and real-time PCR. 
The analysis of mRNA expression consists of different steps: extraction of 
mRNA, polymerase chain reaction in reverse transcription (RT-PCR) and quantitative 
real-time polymerase chain reaction (qPCR). 
RNA from our clones was extracted using the trizol technique. The trizol 
technique uses a complete reagent ready for the isolation of high quality RNA, being 
able to simultaneously extract RNA, DNA and protein from tissue samples or cell 
culture. The trizol reagent is a monophasic solution from phenol and guanidine 
isothiocyanate, which allows the RNA, DNA and proteins to be isolated in different 
phases. Due to the chemical properties of the reagent, trizol maintains RNA integrity 
through RNase inhibitors, while destroying cells and dissolving cellular components 
during homogenization of samples. After the homogenization of the sample, chloroform 
is added allowing the separation of the sample in different phases: aqueous where it is 
located in RNA, and organic phase and interface containing DNA and protein. The 
RNA from the aqueous phase is precipitated with isopropanol and subsequently washed 
to remove the impurities with 70% ethanol. The precipitate is resuspended in free 
RNase water. The quantification of the mRNA concentration obtained after the 
extraction was evaluated using spectrophotometric techniques (Nanodrop ND-1000) at 
260nm and its purity was evaluated as a function of the absorbance ratio at 260nm and 
280nm. 
The extracted RNA permits the obtaining of introns-free DNA strand by the RT-
PCR technique. Therefore, upon expression of this RT-PCR product, a messenger RNA 
(mRNA) consisting exclusively of exons might be generated. In conjunction with real-
time PCR (qPCR), we can detect the amount of specific mRNA from small amounts of 
RNA cells. 
Complementary DNA amplification (cDNA) was performed using the 
ThermoScrit ™ RT™ PCR System kit, where 1μg of RNA sample was transcribed. The 
cDNA synthesis consists of two phases, a first denaturing RNA where the RNA and 
primer are incubated for 5 min at 65 ° C; And a second step of cDNA synthesis 
consisting of three 10 min steps at 25 ° C, 50 min at 50 ° C and final step at 85 ° C for 5 
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min. Finally, the reaction is maintained at 4 ° C. Subsequently the DNA will be stored at 
-20 ° C after a 1:10 dilution in nuclease-free water until further use. 
To complete the study of gene expression, the qPCR technique was carried out. 
In this way, we analyzed the expression and quantification of genes involved 
(Hs00797944_s1-MAP1LC3B; Cat Number 4331182, Life Technologies) and aging 
(Hs00153462_m1-LMNA; Cat Number: 4331182, Life Technologies). Actin B (ACTB) 
was used as the reference gene. The design of the different primers was carried out by 
the Primer 3 application. 
The real-time amplification and quantification assay was performed on the 
Applied Biosystems 7300 Real-Time PCR System. Each sample was evaluated in 
triplicate in 96-well optical plates using 4.5 μl (10 ug) of cDNA from RT-PCR, 5 μl of 
Master Mix for Syber Green or TaqMan probes and 0.5 μl of primer 10 μM (Forward + 
Reverse). The conditions used were: incubation for 2 min at 50 ° C; 10 min at 95 ° C; 
Amplification of 40 cycles of 15 seconds at 95 ° C and 1 minute at 60 ° C; Followed by 
a dissociation cycle of 95 ° C for 15 seconds, 60 ° C for 20 seconds, 95 ° C for 15 
seconds and 60 ° C for 15 seconds. Finally the samples are cooled to 4 ° C. 
The fluorescence signal intensity emitted is proportional to the amount of 
amplified product, and therefore as a function of the amount of expression of the cDNA 
levels. The expression and quantification of the different genes was normalized based 
on our ACTB reference gene. 
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3.7 Consequences of Lamin A/C Accumulation in the Musculoskeletal System 
3.7.1 Accelerated aging model: Zmpste24 Deficient Mice 
To carry out this study, we used Zmpste24 deficient (KO) mice, since they 
produce a mutation in the processing of lamina A, which is interesting for the study of 
premature aging in the musculoskeletal system. The Zmpste24 KO mice were kindly 
provided by Dr. Carlos López-Otín (Universidad de Oviedo, Spain) and Animal 
experiments were conducted in accordance with the guidelines of the Committee on 
Animal Experimentation of Instituto de Investigación Biomédica de A Coruña 
(INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, 
Spain.  
The Zmpste24 KO mice exhibit phenotypic changes that accelerate the aging 
process in most tissues. These mice have different phenotypic characteristics with 
respect to the wild type or Zmpste24 heterozygous (HT). At birth, the Zmpste24 KO, 
whose genotype is Zmpste24
-/-
, present the same phenotype like the rest of their siblings 
in the first weeks of ageing. As tim goes by, we can distinguish both genotypic classes 
by size and weight. Zmpste24
 
HT mice exhibit normal appearance at least until the first 
12 months of life, but their Zmpste24 KO siblings at 4 months of age have a weaker, 
lost hair and weight aspect. This is because after weaning (21-30 days old) KO mice 
begin to gain weight in a slower way. They also present atrophy of the musculoskeletal 
system, presenting muscle weakness, and at approximately 6-8 weeks of age, develop 
kyphosis in the spine, as well as malnutrition. Over time, they begin to exhibit less 
mobility, and their hind legs are more arched at the time of walking, with greater tremor 
and unable to keep the bow upward as the wild and/or heterozygous phenotype. These 
mice have a lower half-life, presenting a lifespan of approximately 20 weeks, so due to 
animal welfare regulations we chose a point of slaughter at 18 weeks of age. 
Zmpste24 KO mice are not fertile, so Zmpste24
  
HT were employed to form the 
colony. Zmpste24 HT mice do not have any alteration until approximately 15 months of 
age. To start the colony, two Zmpste24
  
HT female mice and two Zmpste24
  
HT male 
mice of three months of age were crossed to obtain the optimum number of KO and HT 
mice required for the study. 
Once the mice are genotyped they are kept in colony until the time of sacrifice, 
approximately 18 weeks after their birth. From the sacrificed mice, both hind limbs will 
be collected from the femoral head, in addition to spine. 
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As mentioned, KO mice show obvious phenotypic alterations from 10-12 weeks, such 
as slower growth without weight gain and height, and although the causes of premature 
death are unknown, is likely due to cardiac changes (ref). For this reason, this animal 
model was classified as severe and therefore undergo periodic monitoring in which their 
overall appearance is evaluated and the mouse weight was evaluated weekly to note any 
observed abnormalities. 
The body weight was monitored weekly for metabolic phenotype studies. 
3.7.2 Animal Care 
Because these mice are genetically engineered and more sensitive to 
environmental conditions than HT mice, we were very rigurous about their care and 
attention. The conditions of lodging, zootechnical and cares of the animals were carried 
out respecting the animal well-being, being and are collected in the Table 3.3. 
Table 3.3: General conditions of mice accommodation. 
Accommodation Groups of max. 5 mice per cage 
Bed of the cages Sterilized absorbent material made from wood 
Feeding Feed for rodents of standard experimentation 
Water Tap water 
Ventilation: 15 air renewal per hour 
Temperature and 
Humidity 
20 ° C and 24 ° C (± 1 ° C) and humidity of 55% (± 10%) 
Light Controlled artificial in cycles of 12 hours of light of 8 to 20 hours 
Noise Controlled 
Health Animal health and welfare strategy of the facility 
Enrichment Paper and cardboard inside the cage 
 
 
To evaluate the general state of the mouse, we used a template with criteria of 
severity (Apendix 2-Table 1) that includes those clinical signs that are visibly 
perceived about its symptomatology with a score of 0 to 4. 
Mice is programmed for slaughter at 18 weeks of age according to current regulations, 
one month before their life expectancy, to decrease the suffering and alterations caused 
by the mutation in the mice. On the other hand, if, during the follow-up, any of the mice 
has a score greater than or equal to 10 (Appendix 2-Table 2), they will be sacrificed to 
avoid suffering the animal.  
  Chapter 3: Material and Methods 
60 
 
This study has been approved by the ethical animal experimentation committee of 
the XXIAC, following Royal Decree 53/2013, which establishes the basic norms 
applicable for the protection of animals used in experimentation and other scientific 
purposes, including teaching. (145) 
 
3.7.3 Mice Genotyping 
For mice genotyping, we performed a DNA extraction from the tail tissue (small 
size) by using the QIAamp DNA Mini Kit (Quiagen). First, tissue was incubated with 
180 μl of ATL buffer and 20μl of proteinase K at 56 °C with shaking until the tissue 
became completely lysed. Then, we added 200μl AL Buffe and mixed for 15 seconds 
and then incubated at 70°C for 10min. Next, we added 200μl of ethanol (96-100%) and 
place the sample in the QIAamp Mini spin column (2 ml collection tube) and centrifuge 
at 8000 rmp for 1min. Then, we transferred the column to a clean tube and add 500μl of 
AW1 Buffer and centrifuge again at 8000 rpm for 1 min. Afterwards, 500 μl of 
AW2Buffer was added and centriguged at 14000 rpm for 3min. Finally, we transfered 
our column to a clean tube of 1.5ml and carefully added 100μl of elution Buffer and 
then, the column was incubated for 5 min at room temperature and centrifuged. The 
eluted solution contained the DNA of each sample to evaluate the genotype by PCR. 
3.7.3.1 PCR conditions for genotyping  
The genotyping was performed by PCR by using the following primers and  
conditions shown in Figure 3.2. 
 
Zmpste24_Forward: GCTGGCCTTGTTGCTGGAAT 
Zmpste24_Reverse KO: CTTCCGGAGCGGATCTCAAA 
Zmpste24_Reverse WT: GCTTCCTCCCTGAGCCAACC 
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Figure 3.2: PCR program for Zmpste24 mice genotyping. The PCR program conditions was: one 
cycle of DNA denaturation, then a 35 cycles of DNA amplification, then one cycle of final elongation and 
finally a preservation of DNA at 4ºC. 
 
 
 
 
Figure 3.3: Representative example of Zmpste24 mice genotyping. A single band at 520pb correspond 
to Wild-type animals, a simple band at 303 pb correspond to Knock-out mice, so animals with two bands 
at 520 and 303 pb are Heterozygous mice. 
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3.8 Histological studies. 
3.8.1 Tissue samples 
Human Cartilage sections from healthy, aged cartilage and OA cartilage grade 
II-III and OA cartilage grade III-IV donors from University Hospital of A Coruña and 
The scrrips Research Institute in La Jolla, CA-USA, were employed for 
inmunohistochemical studies. 
Mice were euthanized at 18 weeks of age, and the liver knee joints and spine 
were collected for analysis. Male and female mice were included in the study 
(Zmpste24 HT: 20 mice and Zmpste24 KO: 13 mice). 
 
3.8.2 Immunohistochemistry for paraffin embedded samples. 
Sections from paraffin-embedded joints were first deparaffinized in the xylene 
and rehydrated in graded ethanol and water. For antigen unmasking, sections in 10 mM 
sodium citrate buffer (pH 6.0) were heated in a microwave oven and kept at 80–85°C 
for 1.5 minutes. Slides were cooled for 20 minutes at room temperature after antigen 
unmasking. After washing with phosphate buffered saline (PBS), sections were blocked 
with 5% serum for 30 minutes at room temperature. Then, sections were incubated with 
antibodies for Lamin A/C (BM6000P, Acris Antibodies); pre-treatment EDTA; Dilution 
1:50 overnight at 4°C. After washing with PBS, sections were incubated with 
biotinylated goat anti-mouse secondary antibody for 30 minutes at room temperature, 
and then incubated using Vectastain ABC-AP alkaline phosphatase (Vector 
Laboratories, Burlingame, CA) for 30 minutes. Slides were washed, and sections were 
incubated with 3,3´-diaminobenzidine (DAB) substrate for 3-10 minutes. 
3.8.2.1 Quantification of Lamin A/C-positive cells 
In human cartilage from healthy, aging and OA donors, the total number of 
Lamin A/C-positive cells was counted in three independent areas of each section (135).  
Results are expressed as the percentage of Lamin A/C-positive cells.  
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3.8.3 Safranin O / Fast Green Staining. 
Mice tissue (joint and spine) were fixed in formalin for 24 hours, decalcified 
solution (Decalc™, HistoLab, 00601) for 6 hours, and then embedded in paraffin. Serial 
sagittal sections (4μm) were cut, stained with Safranin O-fast green. Safranin O is a 
cationic dyes that stain proteoglycans. Safranin O binds the carboxyl groups and sulfate 
groups (both negatively charged) which abound in the extracellular matrix of the 
articular cartilage 
 
3.8.4 Hematoxylin-Eosin staining. 
Hematoxylin is used in histology to stain the anionic (acid) components of the 
tissues, to which it gives a blue-purple coloration. It stains intensely the nuclei of the 
cells, since these contain nucleic acids rich in acid radicals. In contrast, eosin is an 
acidic compound whose property is based on its negative polarity, allowing it to bind to 
positively charged cellular constituents. It therefore colors cytoplasmic components and 
organelles, collagen and muscle fibers. 
In the first time, the sample is stained with Harris hematoxylin (PANREAC 
2539491612) for 5 minutes. After some time, a wash in tap water to turn the color and 
the samples are stained with eosin for 5 minutes. 
 
3.8.5  Histologic analysis of joint cartilage in Zmpste24 mice 
Mice knee joints from the three groups were harvested. The joints were fixed in 
formalin for 24 hours, decalcified solution (Decalc™, HistoLab, 00601) for 6 hours, and 
then embedded in paraffin. Serial sagittal sections (4μm) were cut, stained with Safranin 
O-fast green, and examined for histopathological changes using the OARSI 
semiquantitative scoring system (Glasson et al, 2010). In this system the scores are 
defined as follows: 0=normal cartilage, 0.5=loss of proteoglycan with a intact surface, 
1=superficial fibrillation without loss of cartilage, 2=vertical clefts and loss surface 
lamina (any % or joint surface area), 3=vertical clefts/ erosion to the calcified layer 
lesion for 1–25% of the quadrant width, 4=lesion reaches the calcified cartilage for 25–
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50% of the quadrant width, 5=lesion reaches the calcified cartilage for 50–75% of the 
quadrant width, 6=lesion reaches the calcified cartilage for >75% of the quadrant width. 
 
3.8.5.1 Histologic analysis of bone changes in Zmpste24 mice 
Subchondral bone in mouse knee joints was examined and scored using a grading 
system (17) that measures 3 parameters: subchondral bone thickening, number of 
trabeculae, and osteophyte formation, which were graded as normal (grade 0), mild 
(grade 1), moderate (grade 2), or severe (grade 3). 
 
3.8.5.2 Histologic analysis of spine changes in Zmpste24 mice 
Human and mouse samples were washed in phosphate buffered saline (PBS) and 
fixed using zinc buffered formalin (ZFix, Anatech) for 48 hours. After fixing, samples 
were decalcified in a Shandon TBD-2 decalcifier (Thermo Scientific) for 24 hours on a 
shaker, thoroughly washed with PBS and embedded in paraffin. 4-μm-thick sections 
were cut and stained with Safranin O-fast green. In mouse spines, histological analysis 
of C3/C4 and L4/L5 IVD was performed as follows. Degenerative changes in NP and 
AF were graded following Masuda et al (146) whereas changes in EP were scored 
according to the grading system described by Boos et al (147). 
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3.9 Statistical analysis 
To compare means we will use Student's t or Mann Whitney test as appropriate 
after checking the normality of the quantitative variable with the Kolgomorov-Smirnov 
test. In general, the data sets follow a normal distribution. In the cases where the 
number of samples was too small to be tested accurately, we assumed the data follow a 
normal distribution. Statistically significant differences between 2 groups were 
determined by Student´s unpaired t-test. Statistically significant differences between 
multiple groups were determined analyzing variance (ANOVA) in conjunction with 
Tukey´s multiple comparison. Data are presented as the mean (lower level, upper level) 
(ll, ul) 95% confidence interval (CI). The data analysis and statistical interference was 
performed using Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). 
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CHAPTER 4.1 : TO STUDY THE EFFECTS OF DEFECTIVE 
AUTOPHAGY TO MITOCHONDRIAL FUNCTION USING 
PHARMACOLOGICAL AND GENETIC APPROACHES 
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4.1.1 Specific background 
A common feature of aging-related diseases, such as osteoarthritis (OA), is the 
progressive accumulation of damaged macromolecules leading to cell dysfunction and 
death. Cellular homeostasis is dependent of intracellular mechanisms that maintain 
functional organelles and macromolecules required for cell survival and normal 
biosynthetic function (40). In tissues with a high rate of cell turnover, cellular 
constituents are continuously renewed. However, cartilage is a post-mitotic tissue with 
very low, barely detectable rate of cell replication. In fact, chondrocytes, the only cell 
type of adult articular cartilage, are capable of responding to structural changes in the 
surrounding cartilage matrix but the capacity of the adult articular chondrocyte to 
regenerate the normal cartilage matrix architecture is limited and declines with aging 
(19). Because cartilage homeostasis is disturbed in OA, leading to progressive 
extracellular matrix (ECM) destruction, identification of mechanisms of chondrocyte 
aging may create opportunities for preserving normal homeostasis and to prevent or 
delay chondrocytes death and cartilage structural damage.  
Autophagy is a lysosome degradation pathway that is essential for cell survival, 
differentiation, development, and homeostasis. Autophagy serves as an adaptive role to 
protect organisms against diverse pathologies, including infections, cancer, 
neurodegeneration, and aging (21). Autophagy occurs at low basal levels in mammalian 
cells to perform homeostatic functions such as protein and organelle turnover. It is 
rapidly upregulated when intracellular nutrients or energy are required. Also, autophagy 
is activated when cells are undergoing structural remodeling such as during 
developmental transitions or to protect against oxidative stress or protein aggregate 
accumulation (80). Furthermore, genetic studies in mice support the importance of 
autophagy in many physiological and pathological events. In fact, loss of autophagy 
genes leads to neurodegeneration, cardiomyopathies, abnormalities in skeletal 
development and death (86, 87). Therefore, a better understanding of the autophagy 
mechanisms may lead to the discovery of new potential therapeutic targets for cell 
homeostasis regulation. In articular cartilage, which is characterized by a very low rate 
of cell turnover  (19) autophagy would appear to be essential to maintain cellular 
integrity, function and survival, particularly during aging (148). Recent studies 
demonstrated that autophagy is a constitutively active and apparently protective process 
for the maintenance of articular cartilage homeostasis. By contrast, human OA and 
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aging-related and surgically induced OA in mice are associated with a reduction of 
autophagy regulators expression in articular cartilage. Furthermore, the reduction of 
these key regulators of autophagy is accompanied by increased apoptosis (37). These 
observations in cartilage are consistent with the notion that basal autophagic activity 
decreases with age, thus contributing to the accumulation of damaged macromolecules 
and susceptibility to aging-related cellular damage (94). Abnormal protein aggregation 
and formation of characteristic pathological structures are central features of such 
diseases (95, 96). 
The role of mitochondria in OA is an area of research interest, and recent 
investigations have yielded novel and exciting discoveries. Indeed, mitochondrial 
dysfunction has been demonstrated in OA and is associated with an excessive reactive 
oxygen species (ROS) production (20). Furthermore, recent studies showed that 
mitochondrial dysfunction mediates several pathways involved in cartilage degradation 
(104). These include oxidative stress, deficiency of chondrocytes biosynthesis, up-
regulated inflammation and increased chondrocyte death. In fact, OA chondrocytes 
show decreased activity in MRC complexes I, II, and III, which results in a reduction in 
the mitochondrial membrane potential and in ATP synthesis (149). Other reports 
indicate that decreased mitochondrial bioenergy reserve is a pathogenic factor in 
degenerative cartilage pathology (150, 151). Recently, a large body of evidence has 
shown that mitophagy, the selective autophagy degradation of mitochondria, is a critical 
quality control mechanism (152). Thus, this bulk, nonselective recycling system also 
has a vital role in mitochondrial homeostasis. Notably, defects in autophagy associated 
with human diseases are also linked to mitochondrial dysfunction (111, 114). 
Understanding the functional relationship between mitochondria and autophagy is 
critical for understanding the molecular mechanisms underlying aging-related diseases.  
A current working model is that impaired autophagy results in a cell-damaging 
accumulation of dysfunctional mitochondria over time. These data indicate an 
interdependence of mitochondrial function and autophagy and raise the possibility that 
negative regulation of autophagy by dysfunctional mitochondria is a critical 
contributing factor in many aging-related diseases, such as OA. Here, we determine 
whether pharmacological activation of autophagy protects from induced mitochondrial 
dysfunction in normal human chondrocytes.  
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4.1.2 Material and methods 
In this chapter, the following material and methods were used to study the 
influence of mitochondrial dysfunction in the Autophagy in human chondrocytes, as we 
described in the Material and Methods Section. 
 Cell Culture: Immortal juvenile human chondrocytes (T/C-28A2) and Primary 
human chondrocytes were obtained and employed in this objective. 
 Reactives: Oligomycin (Oligo, 10μg/ml) was employed to induce mitochondrial 
dysfunction. Rapamycin (10μM) and Torin 1 (50nM) were used to activate 
autophagy. Antimycin A (40μg/ml), Valinomycin (1μM), H2O2, (100μM) and 
TNFα+ActD (1μg/ml) were employed as positive controls for Mitochondrial 
dysfunction, ROS production and Cell Death by apoptosis, respectively. 
 Mitochondrial studies:  
a. Mitochondrial Membrane Potential (Δψm): JC-1 and DILC1 were used to 
quantified the Mitochondrial Membrane Potential. 
b. Reactive Oxygen Species Production: DCFH-DA and MitoSox were 
employed to evaluate and quantified the intracellular ROS, respectively.  
c. Cell Death Studies: To show the percentage of apoptosis or necrotic cells, 
Annexin-V and propidium iodide (PI) were used. 
 Autophagy Studies: Autophagy was monitorized by determination of LC3 by  
Inmunofluorescence and WB). The influence of the mTOR pathway was 
investigated by WB.  
 Functional studies: To study the importance of homeostasis maintenance to 
mitochondrial function, human chondrocytes were transfected with siRNA for 
Atg5, a key autophagy regulator, to knockdown  the autophagy pathway. 
 Statistical analisys:  Statistically significant differences between 2 groups were 
determined by Student's t-test, while differences between multiple groups were 
determined analyzing ANOVA with Tukey's multiple comparison. The results 
are reported as the mean ± SEM. P values less than 0.05 were considered 
significant. 
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4.1.3 Results 
4.1.3.1 Induction of mitochondrial dysfunction and cell death in human 
chondrocytes by inhibition of mitochondrial respiratory chain 
Mitochondrial dysfunction has a negative influence on cell homeostasis by uncoupling 
the mitochondrial respiratory chain (MRC), increasing reactive oxygen species (ROS) 
production, and inducing cell death by apoptosis (153). Immortalized human chondrocytes 
T/C28a2 were treated with mitochondrial respiratory chain complex V inhibitor, Oligomycin 
(Oligo; 10 μg/ml), according previous studies (99, 154). The results indicated that mitochondrial 
dysfunction was induced by treatment with MRC inhibitor (Figure 4.1A), which significantly 
decreased Δψm (Oligo: 41.74 ± 7.59, expressed as % vs. control; *p < 0.01 compared to control 
condition) (Figure 4.1B). These results are consistent with increased intracellular ROS 
production (25.7 % vs. control; *p < 0.001 compared to control condition) (Figure 4.1C), and 
mitochondrial superoxide generation (29.61 % vs. control; *p < 0.001 compared to control 
condition) (Figure 4.1D) at 5 minutes of treatment.  
Moreover, increased cell death was observed at 14 hours, as shown by FACS 
analysis of Annexin-V (Control: 11.35 ± 1.735; Oligo: 25.37 ± 6.767, *p<0.05 vs. 
control) and Propidium iodide (Control: 15.34 ± 1.791; Oligo: 31.53 ± 2.61, *p<0.05 vs. 
control) (Figure 4.2A-C).  
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Figure 4.1: Inhibition of mitochondrial respiratory chain induces mitochondrial dysfunction  in 
human chondrocytes. T/C-28a2 human chondrocytes were untreated (DMEM 2% FCS) or treated with 
Oligo 10 μg/ml for the indicated times. A, Mitochondrial membrane potential (Δψm) was analyzed by 
flow cytometry using JC-1 dye. A representative density plot for each condition at 6 hours is shown. B, 
Bar graph shows the Δψm expressed as Red/Green fluorescence ratio and DilC1 fluorescence and 
represented as % vs. Ctrl at 6 hours post-treatment. Values are mean ± SEM of 7 individual experiments. 
*p < 0.01 versus for JC-1 dye and values are mean ± SEM of 3 individual experiments. *p < 0.01 versus 
Ctrl for DilC1 dye. C, Quantitative analysis of intracellular ROS production by flow cytometry employing 
DCFH-DA dye at 5 minutes post-treatment. Values were expressed as percentage versus control 
condition at 5 minutes post-treatment. Values are mean ± SEM of 4 individual experiments. *p < 0.01 
versus control. D, Quantitative analysis of mitochondrial superoxide by flow cytometry using MitoSox™ 
Red mitochondrial superoxide indicator. Values are mean ± SEM of 4 individual experiments. p < 0.01 
versus control. Antimycin A (AA, 40 μg/ml), Valinomycin 1 μM and H2O2 100 μM were employed as 
positive controls for Mitochondrial dysfunction, Δψm and ROS production, respectively (*p < 0.01 
versus control). 
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Figure 4.2: Inhibition of mitochondrial respiratory chain induces cell death by apoptosis in human 
chondrocytes. TC28a2 human chondrocytes were untreated (DMEM 2% CS) or treated with Oligo 10 
μg/ml for 14 hours. Cell Death by apoptosis was analyzed by flow cytometry using annexin-V/propidium 
iodide dyes. A, A representative density plot for each condition at 14 hour is shown. B, Quantitative 
analysis of cell death induced by Oligo at 14 hours was performed by annexin-V and propidium iodide 
(PI) staining. Values were expressed as percentage versus control condition. Values are mean ± SEM of 5 
individual experiments. *p < 0.01 versus control. Antimycin A (AA, 40 μg/ml) and TNFα (10 ng/ml) + 
ActD (1 μg/ml) were employed as positive control for Mitochondrial dysfunction and Cell Death by 
apoptosis, respectively (*p < 0.01 versus control; **p < 0.001 versus control). 
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4.1.3.2 Defective Autophagy in human chondrocytes with mitochondrial 
dysfunction 
A common characteristic of aging-related pathologies is the accumulation of 
damaged macromolecules and organelles, such as mitochondria. As a consequence, the 
ability of cells to function normally and survive against stress stimuli is compromised. 
Autophagy is an essential homeostatic mechanism that regulates the elimination of 
damage macromolecules and promotes protection and cell survival. 
To determine the activation and function of autophagy under mitochondrial 
dysfunction conditions, fluorescence-based detection of LC3 isoforms in TC28a2 cells 
was performed. Oligo treatment resulted in a significant reduction in the LC3 puncta, 
indicative of reduced autophagosome formation, compared to control condition at 14 
hours (Figure 4.3A, B). Western blot analysis enables to detect LC3-I lipidation and 
conversion to LC3-II as a marker of autophagy activation and autophagosome formation 
(79). In response to Oligo treatment of normal human chondrocytes, the expression of 
LC3-II was increased at 24 hours after treatment, likely as an early response to stress, 
and then, decreased at 48 hours (Figure 4.3C).  
These results demonstrate a decrease in autophagy activation as a response to 
mitochondrial dysfunction. 
 
Figure 4.3: Autophagy is defective in human chondrocytes subjected to mitochondrial dysfunction. 
A, Fluorescence-based detection of LC3 in TC28a2 cells treated with Oligo 10 μg/ml for 14 hours reveals 
either diffuse cytoplasmic protein or puncta formation (vesicles), which reflects protein associated with 
autophagosomes. The number of punctate LC3 is associated with autophagosomes. Magnification 20x. B, 
Quantification of LC3 vesicles per cell in response to Oligo 10 μg/ml after 14 hours treatment. Values are 
mean ± SEM of 3 individual experiments. * = P < 0.05 vs. control. C, WB analysis was performed to 
detect autophagosome formation by lipidation of LC3-I to LC3-II, as a marker of autophagy activation, in 
normal human chondrocytes treated with Oligo 10 μg/ml at 24 and 48 hours.  
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4.1.3.3 Autophagy activation protects from mitochondrial dysfunction in human 
chondrocytes 
To determine whether autophagy protects from mitochondrial dysfunction, 
autophagy was pharmacologically induced by using the mTORC1 selective inhibitor, 
Rapamycin (Rapa; 5, 10 μM) and the dual mTORC1 and mTORC2 inhibitor, Torin 1 
(20, 50 nM). These inhibitors led to a significant concentration-dependent increase in 
the amount of LC3-II represented by LC3 puncta formation in the cytoplasm (*p < 
0.001) (Figure 4.4 A,B). These data suggest that there are no differences in terms of 
autophagy activation when mTORC1 or mTORC2 isoforms are selectively inhibited. 
Next, T/C28a2 human chondrocytes were pre-treated with Rapa (10 μM) or 
Torin 1 (50 nM) for 4 hours, followed by addition of Oligo (10μg/ml) for the indicated 
times. Rapa treatment induced an increase in the Δψm (Figure 4.3C) and a significant 
decrease in the level of apoptosis induced by Oligo treatment (* p < 0.05) (Figure 4.4 
E,F). However, we did not find any effect on ROS production (Figure 4D). By contrast, 
Torin 1 pre-treatment also significantly increased the Δψm (* p < 0.01). This was 
accompanied by a significant decrease in ROS production and apoptosis (*p < 0.05). 
These results indicate a protective role of autophagy activation on mitochondrial 
dysfunction and a differential role of mTOR complex isoforms on ROS levels 
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Figure 4.4: Autophagy activation protects from mitochondrial dysfunction in human chondrocytes. 
A, Fluorescence-based detection of LC3 in T/C28a2 human chondrocytes treated with Rapa 10 μM or 
Torin 1 50 nM during 14 hours. Magnification 40x. B, Quantification of LC3 vesicles per cell in response 
to Rapa or Torin 1 (20, 50 nM). Values are mean ± SEM of 3 individual experiments. * = P < 0.01 vs. 
control. T/C28a2 chondrocytes were pre-treated with Rapa 10 μM or Torin1 50 nM for four hours and 
then treated with Oligo 10 μg/ml. C, Statistical analysis of Δψm expressed as Red/Green fluorescence 
ratio and represented as percentage versus control condition at 6 hours. Values are mean ± SEM of 4 
individual experiments. * = P < 0.01 vs. control. D, Quantitative analysis of mitochondrial superoxide. 
Values were expressed as percentage versus control condition at 5 minutes post-treatment. Values are 
mean ± SEM of 3 individual experiments. * = P < 0.01 vs. control. E, Quantitative analysis of early 
apoptosis induced by Oligo at 14 hours. F, Quantitative analysis of late apoptosis induced by Oligo at 14 
hours. Values were expressed as percentage versus control condition. Both values are mean ± SEM of 5 
individual experiments. * = P < 0.01 vs. control. 
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4.1.3.4 Oligomycin-mediated mitochondrial dysfunction is dependent on 
Akt/mTOR pathway activation in human chondrocytes 
To investigate the molecular components of oligomycin effect on autophagy, we 
studied Akt, mTOR and LC3, in normal human chondrocytes and in TC28a2 human 
chondrocytes. The results indicated that Oligo treatment induced phosphorylation of the 
serine/threonine kinase Akt, an upstream positive regulator of the mammalian target of 
rapamycin (mTOR), and the ribosomal protein S6 (rbS6), a direct and downstream 
target of mTOR (Figure 4.5A).  
However, a differential role of Rapa and Torin 1 on Akt and rbS6 
phosphorylation status was found. Torin 1 inhibited phosphorylation of Akt and rbS6 
more potently than Rapa. These differences might be due to dual mTORC1 and 
mTORC2 Torin 1 inhibition and could explain the differential effects of Rapa and Torin 
1 on mitochondrial dysfunction induced by Oligo. Moreover, analysis of LC3 
expression indicated that Rapa and Torin 1 highly enhanced the LC3 puncta in response 
to Oligo treatment (Figure 4.5B).  
These results suggest that Oligo is associated with an activation of Akt and 
mTOR signaling pathway in human chondrocytes that consequently reduces autophagy 
by blocking LC3-II formation. 
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Figure 4.5: Oligomycin-mediated mitochondrial dysfunction is dependent on Akt/mTOR pathway 
activation in human chondrocytes. A, Normal human chondrocytes were untreated (DMEM 2% CS) or 
pretreated with Rapa 10 μM or Torin1 50 nM for four hours or treated with Oligo 10 μg/ml for 24 hours. 
Phosphorylation of Akt and ribosomal protein S6 (rbS6) was determined by Western blotting. B, 
Fluorescence-based detection of LC3 in T/C28a2 human chondrocytes untreated (DMEM 2% CS) or 
pretreated with Rapa 10 μM or Torin 1 50 nM for four hours or treated with Oligo 10 μg/ml for 14 hours. 
Magnification 20x. 
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4.1.3.5 Defective autophagy increases mitochondrial dysfunction in human 
chondrocytes 
To determine the role of basal constitutive autophagy on mitochondrial function 
in human chondrocytes, we inhibited autophagy with siRNA for Atg5, which is 
essential for autophagosome formation and autophagy activation (155). Decreased Atg5 
expression following siRNA treatment (Figure 4.6A) significantly induced 
mitochondrial dysfunction in human chondrocytes by decreasing the Δψm and 
increasing ROS production (p < 0.05) (Figure 4.6B). These data indicate an 
interdependence between mitochondrial function and autophagy. 
 
 
Figure 4.6: Defective autophagy induced by ATG5 siRNA increases mitochondrial dysfunction in 
human chondrocytes. Normal human chondrocytes were transfected with siCtrl or siAtg5 for 72 hours. 
A, The levels of Atg5 were determined by Western blotting. B, Bar graph show the statistical analysis of 
Δψm expressed as Red/Green fluorescence ratio and represented as percentage versus control condition at 
72 hours posttransfection. Values are mean ± SEM of 3 individual experiments. * = P < 0.05 vs. control. 
C, Quantitative analysis of intracellular ROS production by Flow cytometry employing DCFH-DA dye at 
72 hours post-transfection. Values are expressed as percentage versus control condition. Values are mean 
± SEM of 3 independent experiments. * = P < 0.05 vs. control. 
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Overall, these results support the notion that identification of mechanisms of 
chondrocyte degeneration may create opportunities for preserving normal homeostasis 
and to prevent or delay chondrocytes death and cartilage structural damage (Figure 
4.7). 
 
Figure 4.7: Flow chart for autophagy protective effect against mitochondrial dysfunction on human 
chondrocytes. 
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CHAPTER 4.2: TO IDENTIFY POTENTIAL TARGETS OF DEFECTIVE 
AUTOPHAGY ASSOCIATED WITH THE PATHOLOGY OF THE  
MUSCULOSKELETAL SYSTEMSpecific Background  
We previously demonstrated that decreased autophagy is an early event that 
precedes joint damage in the pathogenesis of Osteoarthritis (OA)(156). A failure of 
cellular homeostasis mechanisms, such as autophagy, can cause extracellular matrix 
destruction, chondrocyte senescence, mitochondrial dysfunction and death, main 
features of cartilage pathogenesis. (62, 124, 157, 158)However, the specific targets that 
contribute to cartilage degeneration have not been completely identified. 
Chondrocyte senescence has been highlighted as one of the major factor 
contributing to age-related changes in cartilage. (157). Since cartilage is a post-mitotic 
tissue with very low rate of cell turnover, (159) protecting chondrocyte function and 
viability is essential. In this sense, we previously shown that pharmacological activation 
of autophagy protects from chondrocyte loss and cartilage damage in cultured human 
chondrocytes, cartilage explants and in mice with experimental OA (40, 158, 160, 161). 
To better delineate the role of autophagy in aging and OA, we examined the 
impact of compromised autophagy in the proteome of human chondrocytes with 
silenced Atg5, critical for autophagosome formation and autophagy activation. (144) 
Mice lacking Atg5 die whithin a day of birth, (162) whereas deletion of Atg5 in selected 
tissues promotes age-related abnormalities, such as neurodegeneration and OA (86, 
163) To identify potential targets affecting autophagy regulation, we employed 
proteomics to perform a broad analysis of human chondrocytes. We found differential 
expression of proteins involved in the structural organization of the extracellular matrix 
and nucleus. Prelamin A/C, a nuclear protein implicated in premature cellular 
senescence, was upregulated under defective autophagy in human chondrocytes.  
Nuclear lamins are intermediate filament proteins that are essential to maintain 
the structural properties of the nucleus. Lamins are involved in several nuclear 
processes including DNA replication, transcription and chromatin organization (164). In 
mammals, two major LMNA (A and C) and two major LMNB (B1 and B2) isoforms 
have been characterized (165). LMNA has been received a remarkable amount of 
attention because mutations on LMNA are associated with a variety of human diseases 
called laminophaties. These disorders are associated with cardiomyophaty, neuropathy 
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and premature aging (166).  Hutchinson Gilford Progeria Syndrome (HPGS) is perhaps 
the most severe, and is characterized by defects in Lamin A maturation, resulting in 
acumulation of Prelamin A/C that leads to accelerated aging (167). Interestingly, Lamin 
A/C was found upregulated in OA cartilage, although the mechanism that regulates this 
alteration is still unknown (132).  
The enzyme that mediates this process is Zn
2+ 
membrane metalloprotease 
(Zmpste24). Zmpste24 plays a dual role in the maturation of Lamin A by participating 
in the elimination of the endoproteoytic AAX, and in the carboxymethylacion of the 
cysteine (130). Importantly, disruption in Zmpste24 cause failure in lamin A 
maturation, and in accumulation of prelamin A. This leads to the generation of 
abnormalities in nuclear architecture, that eventually lead to accelerated aging. In this 
sense, disruption of Z24 caused severe growth retardation and premature death.  
Therefore, Z24 deficient mice provide an ideal mouse model to study the impact of 
aging in the musculoskeletal system. 
Since age is a risk factor strongly correlated with OA (168) and decreased basal 
autophagy activity, (156) efforts to identify and establish the role of the targets 
regulating these processes are necessary to find ways to prevent cartilage aging and 
degeneration.  
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4.2.2 Specific Material and methods 
In this chapter, the following experimental procedures, were employed to identify 
and validate potential targets of autophagy related with aging and OA, as we described 
in the Material and Methods Section. 
 Cell Culture: OA human cartilage was obtained from patients undergoing knee 
replacement (mean  SD; 76,75 ± 3,30 years, n=2). OA human chondrocytes 
were transiently transfected with small interference RNA (siRNA) for Atg5 100 
nM using Lipofectamine™ 2000. The sense strand sequence of the siRNA was 
5’-GCUAUAUCAGGAUGAGAUATT-3’. The transfected chondrocytes were 
then collected and used for iTRAQ analysis. Immortal juvenile human 
chondrocytes (T/C-28A2) were employed for validation studies. 
 Human Cartilage Samples: Articular cartilage sections from healthy donors 
(mean ± SD, 28,5 ± 3,53, n=2), aged cartilage (mean ± SD, 75,33 ± 10,34, n=6), 
OA cartilage grade II-III (mean ± SD, 54,75 ± 6,29, n=4) and OA cartilage grade 
III-IV (mean ± SD, 65,33 ± 14,15, n=4) were employed for 
inmunohistochemical studies. 
 Proteomic Studies: Proteomic screening was performd by isobaric tags for 
relative and absolute quantification (iTRAQ) labeling to identify targets 
regulating autophagy in human chondrocytes with defective autophagy. 
 Validation Studies: Upregulation of Lamin A/C, the identified target by 
proteomic screening under defective autophagy conditions, was validated in 
human chondrocytes and healthy, aging and OA human cartilage by 
Inmunofluorescence, Western Blotting and Immunohistochemistry, respectively. 
 Functional studies:  
In vitro:  
a. Clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) 
technology: The Genetic deletion of Zmpste24 was performed in T/C28a2 
human chondrocytes by CRISPR-Cas9 knockdown to evaluate the role of Lamin 
A/C up-regulation on chondrocyte homeostasis. 
b. Quantification of cell death by apoptosis, determination of mitochondrial 
membrane potential (Δψm) and quantification of ROS production: To 
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investigate the role of Lamin A/C accumulation on OA phenotype in human 
chondrocytes. 
c. In Vivo: 
a. Mutant Mice: Zmpste24 KO mice were employed to evaluate the 
consequences of aging in the musculoskeletal system. 
b. Phenotypic studies: Body weight, cartilage changes, bone changes and 
spine degeneration were evaluated to investigate the role of Lamin A/C 
accumulation on Musculoskeletal system.  
Statistical analysis: Statistically significant differences between 2 groups were 
determined by Student's t-test, while differences between multiple groups were 
determined analyzing ANOVA with Tukey's multiple comparison. The results 
are reported as the mean ± SEM. P values less than 0.05 were considered 
significant.  
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4.2.3 Results 
4.2.3.1 Identification of differentially regulated proteins in autophagy deficient 
human chondrocytes 
Autophagy is reduced in articular cartilage of elderly and OA patients (37, 156). 
To identify the key proteins regulated when autophagy is compromised, we silenced 
Atg5 in primary human chondrocytes. Atg5 is essential for autophagosome formation 
and represents a critical checkpoint (144). We hypothesize that proteins exhibiting 
altered expression in Atg5-knockdown chondrocytes might be potential regulators of 
cartilage homeostasis. Lysates from siCtrl and siAtg5 chondrocytes were subjected to 
iTRAQ labeling and on-line 2D LC/MS/MS analysis as described in the Materials and 
Methods section.  
 
Figure 4.8: Defective autophagy induced by ATG5 siRNA in human chondrocytes. OA human  
chondrocytes were transfected with siCtrl or siAtg5 for 72 hours. A, The levels of Atg5 and LC3 were  
determined by Western blotting.  
 
We identified 487 proteins in human chondrocytes (Appendix 3: Table 3). 
Interestingly, 24 proteins were significantly modulated (p<0.05) in siAtg5 chondrocytes 
compared to siCtrl (Table 1). Proteins involved in cytoskeleton organization, collagen 
catabolism, oxidative stress, and aging pathways were differentially regulated. From 
this set, 11 proteins were significantly down-regulated and 13 were significantly up-
regulated. For follow up studies, we decided to focus on Prelamin A/C, a nuclear 
protein implicated in cell senescence, significantly upregulated. Alterations in Lamin A 
and C cause cellular senescence, and mutations in the LMNA gene have been correlated 
with degenerative disorders and accelerated aging in humans (166).  
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4.2.3.2 Defective autophagy increases Lamin A/C accumulation in human 
chondrocytes  
 Genetic knockdown of Atg5 in TC28a2 human chondrocytes  reduced the 
expression of LC3, the main marker for autophagosome formation and autophagy 
activation. This reduction was correlated with an increase in Lamin A/C expression 
(Figure 4.9 A and B). Immunofluorescence detected increased Lamin A/C localization 
in the nuclear membrane of chondrocytes in response to defective autophagy (Figure 
4.9C). We reasoned that nuclear lamina component Lamin A/C might play a role in 
articular cartilage aging due to abnormal accumulation. 
 
Figure 4.9: Defective autophagy increases Lamin A/C accumulation in human chondrocytes. A, 
Western blot analysis to detect Atg5, autophagosome formation by lipidation of LC3 I to LC3 II and 
Lamin A/C expression in TC28a2 human chondrocytes under defective autophagy conditions (siCtrl 
versus siAtg5). B, Densitometric analysis of ratio of LC3II/LC3I, and Lamin A/C. GAPDH was 
employed as a loading control. Values are mean ± SEM of three repeated observations. LC3 II/LC3I: *p < 
0.01 versus siCtrl; Lamin A/C: *p < 0.05 versus siCtrl.  C, Fluorescence-based detection of Lamin A/C in 
TC28a2 chondrocytes under defective autophagy (siAtg5 versus siCtrl). Scale bar 10μm. Lamin A/C 
expression was localize in the nuclear membrane: white arrows. 
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4.2.3.3 Increased of expression of nuclear Lamin A/C in human aging cartilage 
 Alterations in Lamin A/C cause cellular senescence in humans, and mutations in 
LMNA gene are correlated with degenerative disorders, referred to as laminopathies 
(169). We evaluated the expression of Lamin A/C in human aged cartilage and found 
increased expression in aged cartilage compared to healthy cartilage. We observed a 
strong expression of Lamin A/C in the nuclear membrane of the chondrocytes. 
However, the expression in the healthy cartilage was diffuse and only few cells show 
positive immunoreactivity (Figure 4.10 A and B). These results indicate that aging 
chondrocytes highly express markers of cellular senescence from the nuclear lamina, 
and support further investigations of the role of Lamin A/C in cartilage. 
 
Figure: 4.10: Increased Lamin A/C expression in aging cartilage. A, Human cartilage from healthy 
and aged patients were employed. Lamin A/C expression was evaluated and quantified by 
immunohistochemistry. Magnification: 40x. Scale bar 100μm. B, Quantitative analysis of Lamin A/C-
positive cells. Total cell number in three fields and Lamin A/C-positive cells were counted. Values are the 
means ± SEM of 6 independent human cartilage donors sections. *p<0.0001 versus healthy cartilage.  
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4.2.3.4  Lamin A/C accumulation in osteoarthritic cartilage   
To investigate the association between chondrocyte senescence by Lamin A/C 
accumulation and OA, we evaluated the expression in OA human cartilage by 
immunohistochemistry. The results showed increased Lamin A/C expression in OA 
cartilage compared to healthy cartilage. Indeed, cartilage with different grades of OA 
severity expressed differential abundance of Lamin A/C. We found a significant 
increase in Lamin A/C-positive cells in mild and severe cartilage pathology, even in 
grade IV OA cartilage where the superficial zone is particularly compromised. 
Consistent with abnormalities often observed in laminopathies, chondrocytes positive 
for Lamin A/C in severe OA samples showed irregular nuclear architecture which may 
cause cellular fragility (Figure 4.11 A and B). 
 These results suggest a direct relationship between Lamin A/C regulation and 
cartilage degeneration that occurs in OA progression.  
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Figure: 4.11. Lamin A/C expression is increased in OA cartilage. Cartilage sections from healthy 
(n=2), OA grade II-III cartilage (n=4) and OA grade III-IV cartilage (n=4) were analysed by 
immunohistochemistry for Lamin A/C. Magnification: 40x. Scale bar 100μm. B, Quantitative analysis of 
Lamin A/C-positive cells. Total cell number in three fields and Lamin A/C-positive cells were counted. 
Values are mean ± SEM. *p<0.01 versus healthy cartilage. 
 
  
  Chapter 4: Results 
93 
 
4.2.3.5 Lamin A/C disrupts chondrocyte homeostasis in human chondrocytes 
 To determine the role of Lamin A/C on the autophagy pathway, we performed 
an in vitro premature aging model by genetic deletion of Zinc Metalloproteinase STE24 
(Zmpste24) via CRISPR-Cas9 technology in TC28a2 chondrocytes. Zmpste24 (Z24) 
plays a critical role in Lamin maturation. Genetic deletion of Z24 accelerates the ageing 
process due to accumulation of Prelamin A, which leads to nuclear abnormalities and 
Lamin A/C alterations (170).  
 In this sense, the genetic reduction of Z24 in human chondrocytes significantly 
reduced the expression levels of Lamin A and LC3 (Figure 4.12A). Importantly, protein 
studies confirmed that genetic deletion of Z24, increased Prelamin A/C expression and 
reduced autophagy by decreasing the ratio between LC3II and LC3I (Figure 4.12B). 
Moreover, this reduction in autophagy was correlated with an increase in chondrocyte 
death by apoptosis in Z24
-/- 
chondrocytes compared to wild type (WT) chondrocytes 
(Figure 4C and D).  
These results suggest that deficient autophagy is associated with increased 
senescence and disruption of homeostasis in human articular cartilage. 
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Figure 4.12: Upregulation of Lamin A/C expression reduced autophagy in human chondrocytes. A, 
Relative expression of Zmpste24 (Z24), Lamin A and LC3 in wild type (WT)  and Z24
-/-
 TC28a2 human 
chondrocytes. Values are mean ± SEM of two repeated observations for duplicate. Z24: *p < 0.01 versus 
WT; Lamin A: p = 0.0523; LC3: *p < 0.001 versus WT. B, Western Blot analysis to detect Prelamin A/C 
and lipidation of LC3 I to LC3 II in WT and Z24
-/- 
TC28a2 human chondrocytes. C, Flow cytometry 
determination of early apoptosis by Annexin-V staining, and late apoptosis by propidium iodide (PI) 
staining in WT and Z24
-/-
 TC28a2 human chondrocytes. D, Quantitative analysis of chondrocyte death by 
Annexin-V and PI staining. Values are mean ± SEM of three repeated observations. Annexin-V: *p < 
0.001 versus WT; PI: * p < 0.0001 versus WT. 
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4.2.3.6 Increased mitochondrial dysfunction in accelerated ageing chondrocytes 
 Mitochondria plays a key role in aging-related diseases, such as OA(20). To 
establish the connection between aging, chondrocyte homeostasis and mitochondrial 
function, we employed Z24
-/- 
human chondrocytes. Our results showed a significant 
increase in the mitochondrial superoxide production (Figure 4.13A) and a significant 
decrease in the mitochondrial membrane potential in Z24
-/- 
chondrocytes compared to 
WT chondrocytes (Figure 4.13B). Taking together, these results demonstrated that 
accelerated ageing is associated to defective autophagy, chondrocyte death by apoptosis, 
and mitochondrial dysfunction, all main features of OA disease. 
 
Figure: 4.13. Increased mitochondrial dysfunction in accelerated ageing chondrocytes. A, 
Quantitative analysis of mitochondrial superoxide using MitoSox red dye in wild type (WT)  and Z24
-/-
 
TC28a2 human chondrocytes. Values are mean ± SEM of three repeated observations. *p < 0.0001 versus 
WT. B, Analysis of mitochondrial membrane potential (Δψm) using DILC1 dye in wild type (WT) and 
Z24
-/-
 TC28a2 human chondrocytes. Expression of Δψm as DILC1 fluorescence (percentage of Ctrl). 
Values are mean ± SEM of three repeated observations. *p < 0.0001 versus WT. 
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4.2.3.7 Zmpste24 deficient mice as a model of accelerated aging in 
musculoskeletal system 
The Zmpste24 deficient mice (Zmpste24
-/-
) show phenotypic changes that 
accelerate the aging process in most tissues (17). At birth, Zmpste24
-/-
 mice are similar 
to the heterozygous siblings (Zmpste24
+/-
) and seemed healthy, until four weeks of age, 
approximately. Successively, the Zmpste24
-/-
 mice might be distinguished from 
Zmpste24
+/-
  in size and body weight. After 4 weeks of age, the growth rate was reduced 
and the mice stopped to grow. As shown in Figure 4.14 A, the size of Zmpste24
-/-
 mice 
is smaller than Zmpste24
+/-
 ( Zmpste24
+/-
: 26.29 ± 0.8841 g, N=21; Zmpste24
-/-
: 13.77 ± 
0.8098 g, N=13), indicating that the body weight of Zmpste24
-/-
 mice is aproximately 
50% less than the Zmpste24
+/-
: mice (Figure 4.14B). Body weight of males and females 
was also evaluated with no significance differences found within sex (Figure 4.14C). 
  Chapter 4: Results 
97 
 
 
Figure: 4.14. Phenotypic changes of Zmpste24 deficient mice. A, Image of two littermates of 
Zmpste24
+/-
 and Zmpste24
-/-
 mice at 20 weeks of age. B, Statistical analysis of body weight of Zmpste24
+/-
 
and Zmpste24
-/-
  mice, *p < 0.0001 versus Zmpste24
+/-
. C, Statistical analysis of body weight of 
Zmpste24
+/-
 and Zmpste24
-/-
 mice distributed by sex; *p < 0.0001 versus female Zmpste24
-/+
 and *p < 
0.0001 versus male Zmpste24
-/+
. 
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4.2.3.8 Aging-associated histopathological changes in Zmpste 24 deficient mice 
joint tissues 
Aging represents the major risk factor for OA and progress has been made in 
characterizing the phenotype of aging-related changes in cartilage extracellular matrix 
and in cartilage cells. However, this analysis remains incomplete, and the mechanisms 
and pathways responsible for such changes are poorly defined.  
Here, we investigated the role of lamin A/C on joint damage by employing an 
accelerated aging model, the Zmpste24
-/-
 mice. Surprisingly, we did not found any 
histological changes in joint cartilage (Figure 4.15 A and B), although cartilage is the 
tissue with the highest prevalence of aging-related pathological changes, probably 
because this accelerated aging model is too short to develop evident changes in the joint 
cartilage. Because OA is a whole-joint disorder, synovium and bone were also 
evaluated. The analysis of synovial inflammation indicated that there is no synovitis 
associated with lamin A/C accumulation (Data not shown). Interestingly, we found 
significant differences in bone integrity after evaluation. The results showed a 
significant reduction in the subchondral bone thickening and in the trabeculae bone. 
Furthermore, we found that the bone was very osteoporotic and fragil (Figure 4.15C). 
 Our histological analysis of joint indicates evidence of pathological damage in 
the bone of Zmpste24
-/-
 mice, without any defect in joint cartilage or synovium. 
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Figure 4.15: Aging-associated histopathologic changes in Zmpste24 deficient mice joint tissues. A, 
Knee joints obtained from Zmpste24+/- and Zmpste24-/- mice at 18 weeks of age were analyzed. 
Representative images of knee joints stained with Safranin O. Original magnification 40x. B, Scoring of 
cartilage changes (Zmpste24+/-, n=17; Zmpste24-/-, n=12). C, Quantification of bone changes 
(Zmpste24+/-, n=14; Zmpste24-/-, n=12). Values are the mean ± SEM, *p < 0.001 versus Zmpste24+/- 
mice. 
                                                 
B 
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4.2.3.9 Accelerated aging induces intervertebral disc degeneration in Zmpste24 
mice 
Because intervertebral disc degeneration (IVD) is also an important feature in 
aging-related diseases, we evaluated the spine. We collected the spines at 20 weeks for 
histological analysis to compare Zmpste24
-/-
 mice and Zmpste24
+/-
. To determine the 
aging-related pattern of cervical and lumbar spines, sections were stained with Safranin-
O/Fast green and Hematoxylin-Eosin, respectively. The results indicated that Zmpste24 
-/-
 mice exhibited histological changes that are characteristic of IVD degeneration in 
cervical and lumbar spine compared to Zmpste24
+/-
. These changes included a 
disruption of the Nucleus Pulposus (NP) and Annulus Fibrosus (AF) borders, associated 
with a reduction in NP size. Furthermore, we found ruptured fibers and a 
disorganization of AF and an apparent loss of proteoglycan staining and some 
ossification in the EP. In addition, these changes were more severe in male mice than in 
female mice (Figure 4.16). In addition, these changes included decreased cellularity in 
the NP, AF and EP in Zmpste24
-/-
 mice compared to Zmpste24
+/-
 mice. These 
differences in cellularity were also higher in male mice than in females (Figure 4.17). 
These results indicate that the abnormal accumulation of Lamin A/C is 
associated with age-related degeneration in the IVD, and this phenotype was more 
severe in male mice. 
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Figure 4.16: Accelerated aging induces intervertebral disc degeneration (IVD) in Zmpste24 mice. A, Spines obtained fromZmpste24+/- and Zmpste24-/- mice at 18 weeks 
of age were analyzed. Representative images of spine (cervical and lumbar) stained with Safranin O. Magnification 40x. B, Quantification of IVD changes in cervical and 
lumbar spine (Zmpste24
+/-
, n=6; Zmpste24
-/-
, n=6). Values are the mean ± SEM; Cervical spine: *p < 0.05 versus Zmpste24
+/-;
; Lumbar spine: *p < 0.01 versus Zmpste24
+/-
 mice. Lumbar: *p < 0.05 versus Zmpste24
+/-
; Cervical: *p < 0.01 versus Zmpste24
+/-
. 
A 
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Figure 4.17: Loss of cellularity in Intervertebral disc in accelerated aging mice. Representative 
pictures of loss of cellularity in spine from males and females Zmpste24
-/-
 and Zmpste2
+/-
 mice by 
Hematoxilin- Eosin staining. Magnification 20x. 
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5.1 To study the effects of defective autophagy to mitochondrial function using 
pharmacological and genetic approachesDefective autophagy and 
mitochondrial dysfunction are features of aging-related cartilage degeneration (20, 37). 
However, the interdependence of these critical cellular homeostasis mechanisms in the 
pathogenesis of cartilage degeneration has not been directly investigated. 
The data from the present study indicate that autophagy activation protects 
against mitochondrial dysfunction in human chondrocytes. Autophagy is an essential 
cellular homeostasis mechanism that functions not only by adjusting to variations in 
nutrient supply, but also by removing dysfunctional organelles and macromolecules, 
such as mitochondria (155), which have been observed in OA cartilage (104). The 
critical role of autophagy in chondrocytes and cartilage function is illustrated by the 
presence of deficient autophagy activity in experimental and spontaneous aging-
associated OA models. In this regard, manifestations of autophagy defects are often 
linked to cell dysfunction and cell death (63). Cellular dysfunction leads to tissue and 
organ failure and can manifest as aging-associated degenerative disease (171, 172). 
Conversely, pharmacologic augmentation of autophagy protects against cell dysfunction 
and disease and, in model organisms, extends lifespan (172) and health (173, 174). We 
previously demonstrated that autophagy activation protects against mechanical damage 
in cultured cartilage explants and in mice with experimental OA (62, 160). These 
findings support the notion that mechanisms that can induce repair of cellular damage 
are critical for chondrocyte homeostasis. 
The mitochondrial respiratory chain oxidizes nutrients to generate the energy 
molecule ATP. An abnormal production of ROS during the oxidative phosphorylation 
process can cause harm and may eventually cause cell death (175). In human 
chondrocytes, the oxygen supply is gradually reduced across the different zones of 
articular tissue (20), which most likely result in a tight regulation of the number and 
function of mitochondria to maintain cellular energy homeostasis. Nevertheless, data on 
adaptation of chondrocytes to oxygen needs by regulating mitochondrial density and 
function are limited. 
In the present study, we investigated autophagy as a critical mechanism for 
maintaining mitochondrial function in human articular chondrocytes. We used 
oligomycin, a mitochondrial respiratory chain complex V inhibitor, to induce 
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mitochondrial dysfunction in human chondrocytes. The respiratory capacity of 
chondrocytesis compromised in OA articular cartilage due to defects in mitochondrial 
coupling efficiency (149). Oligomycin reduces electron flow through the electron 
transport chain, although not completely, due to mitochondrial uncoupling (176). 
Because of this defect in the respiratory capacity of chondrocytes in OA, we tried to 
mimic the mitochondrial dysfunction by using oligomycin, an inhibitor of the ATP 
synthase that blocks the inducible proton leak but not the basal uncoupling capacity. On 
the other hand, mitochondrial respiratory chain inhibitors such as antimycin A, a 
complex III inhibitor, have irreversible effects by binding to cytochrome c reductase. 
The subsequent disruption of the proton gradient and ATP synthesis by antimycin A 
results in the formation of high levels of superoxide and a dramatic loss of 
mitochondrial coupling efficiency (176), which likely potently affects the respiratory 
capacity of chondrocytes. 
The effects of oligomycin we observed were consistent with those from previous 
studies  (99, 153). 
Under conditions where oligomycin induced significant mitochondrial 
dysfunction in chondrocytes, the basal level of autophagy was reduced, which indicates 
that partial inhibition of mitochondrial respiratory chain is sufficient to disrupt 
autophagy. Furthermore, we found an early activation of autophagy at 24 hours in 
response to mitochondrial dysfunction, followed by a clear and sustained reduction at 
48 hours. We hypothesize that autophagy activation may protect against cell damage as 
a compensatory mechanism. However, when prolonged stress exceeds cellular 
compensation, autophagy may not be able to maintain the cellular balance, and 
ultimately, the presence of toxic molecules may lead to cell death (177). 
A major regulator of autophagy is mTOR. To determine whether autophagy 
activation protects against mitochondrial dysfunction, autophagy was activated by 
rapamycin, a selective inhibitor of mTORC-1, and by torin 1, a dual inhibitor of 
mTORC-1 and mTORC-2. 
Rapamycin has been shown to induce autophagy in a variety of cell types (178, 
179), including articular chondrocytes and cartilage, which prevents cartilage damage in 
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vivo (62, 160). Our study is the first to demonstrate that torin 1 activates autophagy in 
human chondrocytes in a manner similar to that of rapamycin. 
We evaluated the effects of oligomycin in mTOR signaling. Interestingly, 
oligomycin has stimulatory effects in articular chondrocytes, activating phosphorylation 
at the Ser235/236 residue of the ribosomal protein S6, a downstream target of mTOR 
activated with growth and proliferation (180). We also investigated Akt protein kinase, 
an upstream mTOR regulator activated by growth and survival factors (180). Our data 
indicate that oligomycin induces Akt phosphorylation at residue Ser473, which is an 
indication that mTORC-2 is directly regulated when mitochondrial ATP synthase is 
pharmacologically inhibited. Taken together, our evidence indicates that oligomycin 
decreases autophagy in an Akt/mTOR-dependent manner in human chondrocytes, 
which might result in reduced cell growth and may partly explain the cartilage 
degradation observed in OA. 
In summary, our study is the first to demonstrate that autophagy is a protective 
mechanism in human chondrocytes with mitochondrial dysfunction. Our observations 
suggest that autophagy plays an important role in the protection of chondrocytes from 
oxidative stress and support the idea that pharmacologic interventions that target 
autophagy may prevent cartilage degradation. 
Furthermore, we provide evidence of a direct link between mitochondrial 
function and autophagy regulation in cartilage, which may lead to new therapeutic 
strategies for aging-related musculoskeletal disorders such as OA. 
  
  Chapter 5: Discussion 
 
107 
 
5.2 To identify potencial targets of defective autophagy associated with the 
pathology of the musculoskeletal system 
Autophagy regulation in cells has been recognized as a paradigm-shifting in our 
molecular understanding of disease (181). Alterations in autophagy contribute to the 
progression of various rheumatic diseases, including OA, where chondrocytes within 
articular cartilage show decreased autophagy, leading to cell death and degeneration 
(182). We previously demonstrated that some of the consequences of autophagy 
deficiency in human chondrocytes are associated to oxidative stress and mitochondrial 
dysfunction (158).  However, the potential targets regulating the link between 
autophagy and cartilage homeostasis are still unknown.  
Here, we performed a proteomic analysis to identify the biological processes and 
proteins relevant to the homeostatic state of human chondrocytes. We carried out a 
comparative analysis and protein quantification through incorporation of stable isotopes 
(iTRAQ) in Atg5-deficient primary human chondrocytes. Our list of protein explains 
many biological processes and mechanisms present in articular cartilage, including 
nuclear structure, cytoskeleton organization, collagen catabolism, oxidative stress, and 
aging. Interestingly, upregulation of Prelamin A/C indicated that nuclear structural 
components might be implicated in cell senescence. Increased accumulation of Lamin A 
is observed in OA chondrocytes and cartilage(132, 183). We therefore propose Lamin 
A/C accumulation as a inherent alteration related to chondrocyte senescence and OA 
progression. 
We observed Lamin A/C accumulation in the nuclear membrane and reduced 
LC3 expression in Atg5-deficient human chondrocytes, which indicates that nuclear 
lamina components play a key role in articular cartilage aging. Lamin A/C accumulation 
is primarily observed not only in human aged cartilage but in OA cartilage. Indeed, 
Lamin A/C-positive cells are apparent in mild and severe cartilage, even in grade IV 
OA cartilage where the superficial zone is particularly compromised. These results 
suggest a direct relationship between Lamin A/C regulation and OA progression.  
 To explore the molecular mechanism of this association, we deleted Zmpste24, 
that accelerates the ageing process due to accumulation of Prelamin A in tissues and 
leads to nuclear abnormalities and Lamin A/C alterations m (170). Zmpste24, a 
metalloprotease, is required for the proteolytic clevages during Lamin A maturation. 
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[33] Mutations in Zmpste24 gene cause nuclear abnormalities that lead to accelerated-
aging human syndromes, such as Hutchinson-Gilford Progeria Syndrome (HGPS) (116, 
170, 184). Interestingly, Prelamin A accumulation enhance aging phenotype in hMSCs 
(185). However, the role of Prelamin A/C in premature aging chondrocytes has not been 
established yet. Deletion of Zmpste24 by CRISPR-Cas9 in human chondrocytes 
significantly reduced the expression of Prelamin A/C and decreased LC3II/LC3I ratio. 
The presence of accumulated Prelamin A/C under autophagy defects could ultimately 
lead to senescence of chondrocytes. Pathways otherwise intact in cartilage might be 
altered, for example in the premature aging phenotype of chondrocytes, such as the 
dysregulation of autophagy under starvation conditions that occurs in joint aging.  
 Because mitochondria plays a key role in the aging process, we explored 
whether premature aging in chondrocytes influence mitochondrial function. Indeed, 
accumulation of Prelamin A in human chondrocytes is associated with increased 
oxidative damage and mitochondrial dysfunction. These results are consistent with 
previous studies where deletion of Zmpste24 elevates ROS production and induces 
depolarization of mitochondrial membrane potential in human fibroblasts (186).  
Similarly, Zmpste24 deficient mice are associated with mitochondrial dysfunction, but 
more importantly, fibroblasts from HGPS patients showed alterations in the 
mitochondrial function (187, 188). These results highlight the notion that mitochondrial 
function is altered during aging in articular cartilage.  
Our data collectively establish that autophagy is a key factor for the 
accumulation of Prelamin A in chondrocytes, inducing a premature aging phenotype 
which ultimately results in a clear decrease in cartilage functional capacity in vivo. In 
this human experimental model of premature aging, the aged phenotype is clearly 
exacerbated when autophagy is impaired. Our results are similar to those observed in 
both mice and patients where the presence of progerin induce aging,(189, 190) 
indicating the value of our model to the study of late onset of cartilage aging.  
Ultimately, the identification of a relevant role of nuclear lamins in the aging of 
human chondrocytes and cartilage might provide the basis to explore the therapeutic 
potential of manipulating this pathway in OA. 
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1. To study the effects of defective autophagy to mitochondrial function using 
pharmacological and genetic approaches:  
1.1. Mitochondrial dysfunction and cell death by apoptosis in human chondroytes 
were induced by inhibition of mitochondrial respiratory chain complex V by 
Oligomycin. 
1.2. Autophagy is defective in human chondrocytes with mitochondrial dysfunction.  
1.3. Pharmacological activation of autophagy by Rapamycin and Torin1 protects 
from mitocondrial dysfunction in human chondrocytes. 
1.4. AKT/mTOR pathway is critical for mitochondrial dysfunction of human 
chondrocytes. 
1.5. Defective autophagy by genetic deletion of Atg5, a key autophagy regulator, 
increases mitochondrial dysfunction in human chondrocytes. 
 
2. To identify potencial targets of defective autophagy associated with the 
pathology of the musculoskeletal system 
2.1. Among the proteins detected, a number of 24 differentially regulated proteins 
were found in autophagy deficient primary human chondrocytes.  
2.2. Proteins differentially regulated in defective autophagy human chondrocytes 
are implicated in key cellular processes, such as, structural organization, 
protein transport, stress response, and calcium metabolism of chondrocytes.      
2.3. Defective autophagy increases Lamin A/C expression, a nuclear protein 
implicated in the structural organization and involved in the aging process, in 
human chondrocytes.  
2.4. Accumulation of Lamin A/C is observed in human aging cartilage and is 
directly correlated with OA severity. 
2.5. Accumulation of Lamin A/C, by genetic deletion of Zmpste24 in human 
chondrocytes, disrupts chondrocyte homeostasis in conditions of accelerated 
aging associated to cell death by apoptosis and mitochondrial dysfunction. 
2.6. In mice with accelerated aging as a result of Lamin A/C accumulation, bone 
changes in mice joint were observed. Intervertebral disc degeneration (IVD) in 
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cervical and lumbar spine is also affected, and together might contribute to the 
pathology of the musculoskeletal system in mice. 
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Appendix 1: Resumen en lengua castellana 
La osteoartrosis (OA) es la enfermedad articular más común, y el 
envejecimiento representa uno de sus principales factores de riesgo. La relación entre el 
envejecimiento y el desarrollo de la OA no se conoce en detalle, pero es evidente que 
los cambios relacionados con el envejecimiento en el sistema músculo-esquelético 
contribuyen a la progresión, y se acompañan por otros factores de riesgo como los 
factores mecánicos, genéticos o la mala alineación de la articulación. Recientemente se 
ha avanzado en la caracterización de las vías patogénicas más relevantes, Sin embargo, 
estas investigaciones no han permitido definir los mecanismos y vías responsables de 
tales cambios en relación con los mecanismos implicados en el envejecimiento del 
cartílago articular. Una posible estrategia sería dirigir las intervenciones terapéuticas 
hacia las etapas iniciales de la patología artrósica, sin embargo, los mecanismos que 
conducen a estos cambios tempranos no están bien caracterizados. 
Una característica común en las patologías relacionadas con el envejecimiento, 
como la osteoartritis (OA), es la progresiva acumulación de macromoléculas dañadas 
que provocan daño celular y finalmente el deterioro de los tejidos. 
 La autofagía es un proceso de degradación lisosomal esencial para la 
supervivencia celular, la diferenciación, el desarrollo y la homeostasis. La autofagía 
desempeña un mecanismo fundamental para proteger a los organismos frente a  diversas 
patologías, como las infecciones, el cáncer, la neurodegeneración, las enfermedades del 
corazón, y el envejecimiento, mediante la eliminación de moléculas dañadas. La 
característica morfológica más importante de este proceso es la formación de vesículas 
con doble membrana, denominadas autofagosomas. Los componentes moleculares del 
proceso de autofagía, son los genes ATG, que fueron identificados por primera vez en 
levaduras, sin embargo la mayoría de las proteínas implicadas en este proceso tienen sus 
homólogos en eucariotas superiores. En este sentido Atg1, Atg6, Atg8 (ULK1, Beclin1 
y LC3 en mamíferos, respectivamente) y Atg5 son cuatro de los principales reguladores 
de la vía de la autofagía. Finalmente, la formación y expansión de los autofagosomas 
requiere dos sistemas de conjugación de proteínas que implican a Atg5 y LC3.  
Además, la autofagía se activa cuando las células están experimentando una 
remodelación estructural, como en las transiciones de desarrollo o para proteger a las 
células contra los efectos del estrés oxidativo, las infecciones o la acumulación de 
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agregados proteicos mutados. De hecho, la pérdida de genes autofagía da lugar a 
procesos de neurodegeneración, cardiomiopatías, anormalidades en el desarrollo y la 
muerte. Por lo tanto, un mejor entendimiento de los mecanismos de la autofagía puede 
ayudar al descubrimiento de nuevas dianas terapéuticas para la regulación de la 
homeostasis celular. 
El cartílago articular está caracterizado por una  baja tasa de renovación celular, 
la autofagía parece ser esencial para mantener la integridad celular, la función y la 
supervivencia. Además, mientras que la autofagía esta alterada en diversos modelos y 
tejidos con el envejecimiento, esto no ha sido investigado en el cartílago articular. 
Hemos demostrado que existe una disminución de autofagía en cartílago y condrocitos 
de pacientes de edad avanzada y con OA. Estas observaciones en el cartílago son 
consistentes con otros tejidos donde la actividad de autofagía basal disminuye con la 
edad, lo que contribuye a la acumulación de macromoléculas y a un daño celular 
relacionado con el envejecimiento. 
Por otro lado, otros estudios han descrito alteraciones en la respuesta de este 
proceso a los cambios hormonales en el envejecimiento. En particular, los efectos del 
estrés oxidativo sobre la vía del receptor de señalización de la insulina parecen jugar un 
papel crítico en la disminución de la autofagía en los organismos envejecidos. La red de 
señalización que implica a los factores de longevidad como SIRT1, mTOR, FoxO3, NF-
kB y p53 regulan la autofagía y podrían tener un papel en el proceso de envejecimiento. 
En concreto, mTOR y NF-kB son represores de la vía de la autofagía en virtud de las 
señales de entrada de estrés y de inflamación, mientras que SIRT1, es un factor de 
resistencia al estrés y de longevidad; y FoxO3, un importante regulador del 
metabolismo celular, la proliferación y la resistencia al estrés, mejoran la autofagía. 
Durante la última década, la importancia de la mitocondria en la biología celular 
ha sido enfatizada por la evidencia de que alteraciones en proteínas mitocondriales 
pueden causar algunas enfermedades humanas. Estas modificaciones pueden conducir a 
importantes disfunciones celulares que contribuyen a fallos neurológicos, como las 
enfermedades de Alzheimer, Parkinson y Huntington, diabetes tipo 2, enfermedades 
cardiovasculares, o diversos síndromes neuromusculares y algunos procesos de 
envejecimiento. 
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La comprensión de la relación funcional entre las mitocondrias y la autofagía es 
fundamental para el entendimiento de los mecanismos moleculares que subyacen a las 
enfermedades relacionadas con el envejecimiento. En este sentido, existen evidencias 
que apuntan a una interdependencia entre la función mitocondrial y la autofagía y 
plantean la posibilidad de que la regulación negativa de la autofagía por las 
mitocondrias disfuncionales es un factor que contribuye en el desarrollo de muchas 
enfermedades relacionadas con el envejecimiento, como la OA. 
 Las intervenciones farmacológicas actuales son insuficientes, puesto que sólo 
abordan el dolor crónico y no existe ninguna terapia modificadora de la enfermedad. La 
prevalencia de OA aumenta directamente con la edad y es la causa más común de 
discapacidad crónica en los adultos mayores. A día de hoy, no existe ninguna 
aproximación terapéutica para el tratamiento del envejecimiento del cartílago. Una 
posible estrategia sería dirigir las intervenciones terapéuticas hacia las etapas iniciales 
de la patología artrósica, sin embargo, los mecanismos que conducen a estos cambios 
tempranos no están bien caracterizados.  
Nuestra hipótesis se centra en la búsqueda de dianas que nos indiquen los fallos 
en la homeostasis celular, aquellos defectos en la autofagía que conducen a la 
disfunción celular y en consecuencia a la muerte, iniciando así, el proceso de 
degradación del cartílago característico de la OA.  
“Una reducción en la autofagía durante el proceso de envejecimiento, 
contribuye a la acumulación de orgánulos y proteínas dañadas, produciendo un fallo en 
el mecanismo de homeostasis en el cartílago, contribuyendo al desarrollo de OA” 
Nuestra propuesta se basa en resultados previos donde demostramos la pérdida 
de función del proceso de autofagía en el cartílago y condrocitos humanos de pacientes 
con OA y de edad avanzada. Creemos que estos hallazgos proporcionan una 
oportunidad única para estudiar el envejecimiento del cartílago a través de la regulación 
del proceso de autofagía como mecanismo fundamental del envejecimiento del cartílago 
articular, y al mismo tiempo explorar el potencial terapéutico para prevenir 
farmacológicamente la senescencia y activar la autofagía. 
Nuestro objetivo principal ha sido investigar el papel de la autofagía en la 
disfunción mitocondrial en el cartílago articular, e identificar dianas para el futuro 
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desarrollo de terapias farmacológicas para prevenir, retrasar o incluso revertir la 
artrosis. 
Para ello hemos dividido el trabajo en dos objetivos principales: 
1. Estudiar los efectos de la pérdida de la función de autofagía sobre la función 
mitocondrial en condrocitos normales. 
2. Identificar potenciales dianas en el contexto de una disminución de autofagía en 
el proteína de condrocitos humanos y validar el efecto de la autofagía sobre el 
envejecimiento en un modelo murino.  
 
Para la realización del primer objetivo empleamos condrocitos humanos 
inmortalizados procedentes de la línea celular TC28a2 y condrocitos humanos 
procedentes de cultivo primario de donantes sanos donde se realizaron dos abordajes 
experimentales diferentes: En el primero se indujo una disfunción mitocondrial 
farmacológica, empleando Oligomicina (Oligo, 10 g/ml), un inhibidor del complejo V 
de la cadena respiratoria mitocondrial (CRM) y posteriormente analizamos su efecto 
sobre el mecanismo celular de autofagía. Los resultados obtenidos indicaron que la 
Oligo provocó una disfunción mitocondrial en los condrocitos humanos, representado 
por una disminución significativa del potencial de membrana mitocondrial  (Δψm). 
Estos resultados fueron consistentes con un incremento significativo en la producción 
de especies reactivas del oxígeno (ROS) y en la muerte celular por apoptosis a las 12 h. 
El siguiente paso fue evaluar cuál es el efecto de la disfunción mitocondrial sobre la 
autofagía. Para ello se evaluó la expresión de LC3, el marcador más importante de 
activación de autofagía que indica la formación de autofagosomas y la activación del 
proceso de autofagía. Lo resultados indicaron la reducción significativa de la expresión 
de LC3 en respuesta a Oligomicina a las 12 horas. Para evaluar si la autofagía regula la 
disfunción mitocondrial, los condrocitos fueron pre-tratados durante 4 horas con dos 
activadores farmacológicos de autofagía, Rapamicina 10 M y Torin 1 50 nM. 
Finalizado el tiempo de preincubación las células fueron tratadas con Oligomicina solo 
o en combinación con los activadores de autofagía durante 12 horas. Los resultados 
obtenidos indicaron que la activación farmacológica de autofagía tuvo un efecto 
protector frente a la disfunción mitocondrial provocada por la oligomicina. El 
tratamiento con los inductores de autofagía Rapamicina y Torin1 incrementaron el  
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Δψm, disminuyeron la producción de ROS  y redujeron la muerte celular. Estos 
resultados sugieren un efecto protector de la activación de autofagía sobre la disfunción 
mitocondrial inducida por la inhibición de la CRM. El segundo abordaje planteó 
estudiar cómo una disminución de autofagía puede afectar a la función mitocondrial de 
los condrocitos. Para disminuir la autofagía, empleamos la tecnología siARN dirigida a 
Atg5, un gen indispensable para la translocación y activación de LC3-I a LC3-II, 
presente en la doble membrana de los autofagosomas. Los resultados obtenidos 
mediante estudios de expresión de proteínas, indicaron una disminución en la expresión 
de Atg5 y de LC3-II. Los resultados han indicado que la disminución de autofagía 
provocó una mayor predisposición a un daño mitocondrial traducido por una 
disminución significativa del potencial de membrana y un incremento en la producción 
de ROS.  
Para llevar a cabo la identificación de dianas potenciales en caso de una 
disminución de autofagía en condrocitos humanos, hemos empleado la misma 
tecnología que en nuestro primer objetivo, el silenciamiento génico mediante tecnología 
siRNA para Atg5. Una vez bloqueado el proceso de autofagía, se aisló la proteína total 
de cada condición (siCTRL y siAtg5) y se realizó la técnica proteómica iTRAQ 
(isobaric tags for relative and absolute quantification) acoplada con 2D LC/MS/MS. La 
identificación y la cuantificación de proteínas se realizó mediante la utilización del 
software Protein Pilot v4.0. Cada espectro obtenido en el MS/MS es procesado en la 
base de datos Uniprot/Swissprot para la especie Homo Sapiens.  
Mediante el empleo de dicha técnica se identificaron un total de 487 proteínas, 
de las cuales 24 están moduladas o alteradas.  La prelamina-A/C, precursora de la 
lamina A/C esta significativamente sobreexpresada en los tres donantes con respecto al 
control. Esta proteína es de gran interés, ya que la lamina A/C está implicada en la 
senescencia prematura de la célula, por lo que resulta de gran interés para el estudio del 
envejecimiento del condrocito en OA. 
Estos resultados indican que cuando el proceso de autofagía esta disminuído o 
bloqueado, hay un incremento en la expresión de proteínas relacionadas con el 
envejecimiento y la muerte celular, indicando que la autofagía juega un papel 
importante en la regulación de los procesos de supervivencia celular.  
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Para la validación de estos resultados, se utilizará la línea de condrocitos 
inmortalizada Tc28a2 transfectada para el bloqueo del gen Atg5. Mediante la técnica de 
Western blot se evaluarán los niveles de nuestras proteínas de interés para la autofagía 
(atg5 y LC3) y envejecimiento (Lamina A/C). La expresión de lamina A/C será también 
evaluada mediante Inmunofluorescencia. Paralelamente, se empleó cartílago procedente 
de pacientes humanos y se evaluó mediante técnicas histológicas la expresión de estos 
marcadores (LC3, Lamina A/C) en cartílago humano procedentes de cartílago 
procedente de donantes sin patología (normal) vs. Cartílago envejecido vs. Cartílago 
OA. 
Posteriormente, para observar el efecto sobre la autofagía en condrocitos con 
envejecimiento prematuro, hemos utilizado la tecnología de edición genética 
CRIPSPR/Cas9 para el gen de la metaloproteasa STE24 (Zmpste24), un gen importante 
para el proceso de maduración correcta de la lamina A/C. Estos estudios confirmaron 
que una delección de Zmpste 24 produce un incremento de acumulación de prelamin 
A/C, así como una reducción de la autofagía mediante western-Blot. Además, esta 
reducción de autofagía fue correlacionada con un incremento de muerte celular en 
células con envejecimiento prematuro (Zmpste 24
-/-
). 
Para evaluar la importancia de la autofagía en el envejecimiento en el cartílago, 
utilizamos un modelo in vivo de ratones que tienen sobreexpresada la lamina A/C. Para 
ello empleamos un modelo murino que presenta una mutación en el gen Zmpste24 
causando envejecimiento prematuro en ratones homocigóticos. Esto es debido a que 
estos ratones presentan una acumulación de “farnesylated lamin A precursor” producida 
por la mutación en el gen Zmpste24, lo que ocasiona un mal procesado de la lamina 
A/C a progerina, convirtiéndola en una herramienta de gran utilidad para el estudio del 
envejecimiento.  
Se evaluaron los cambios fenotípicos comparando ratones con fenotipo Wild 
tipo (Zmpste24
-/+
) que no tiene alterado el gen frente a ratones Zmpste24
-/-
 que si 
presentan mutación para el gen.  Los ratones fueron sacrificados a los 4 meses de edad y 
se obtuvieron las rodillas de los ratones para evaluar el daño en el cartílago.  
 Estos ratones nos han permitido iniciar los estudios articulares para el estudio 
de la autofagía durante el envejecimiento. Para ello se utilizaron tinciones histológicas 
(Safranina O-Fast Green y hematoxilina-Eosina), que permitieron evaluar la 
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degradación del cartílago mediante la deformación y desgaste del mismo, así como la 
perdida de proteoglicanos. Los resultados han permitido demostrar una diferencia en el 
hueso de articulaciones de rodilla, así como diferencias significativas en columna 
vertebral, donde hemos podido observar una degeneración del disco intervertebral, 
causado por un estrechamiento del nucleus pulposus y desorganización de annulus 
fibrosus. 
En conclusión, hemos podido comprobar que la disfunción mitocondrial juega 
un papel fundamental en el proceso de envejecimiento en el cartílago artrósico, pero que 
una activación farmacológica de la autofagía por rapamicina tiene un efecto 
condroprotector sobre el cartílago articular humano.  Por otro lado, la inhibición de 
autofaxía incrementa la expresión de lamina A/C, implicada en el proceso de 
envejecimiento. Por lo que, una acumulación de lamina por mutación del gen zmpste24, 
altera la homeostasis celular acelerando el envejecimiento asociado con la muerte 
celular. En el caso de ratones con un envejecimiento prematuro, hemos podido observar 
un aumento de la patología musculoesquelética causado por cambios en el hueso 
articular y cambios en el cartílago a nivel intervertebral. 
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Appendix 2:  Total proteins identified in defect autophagy in chondrocytes. 
Table 8.1: Identification of 487 regulated proteins in autophagy deficient human chondrocytes by iTRAQ analysis (siAtg5 vs. siCtrl) 
                    
Total % Cov 
(95) 
Accession Name Peptides 
(95%) 
DONOR 
1 115:114 
PVal 
115:114 
DONOR 
2 117:116 
PVal 
117:116 
141,25 48,9 P21333 Filamin-A  90 0,302 0 0,6368 0,0298 
21,23 47,6 P09601 Heme oxygenase 1 OS 16 2,2284 0 1,3305 0,042 
96,2 33,3 P35579 Myosin-9 OS 68 0,4529 0 0,7516 0,0412 
215,09 43,8 Q09666 Neuroblast differentiation-associated protein AHNAK OS 140 0,5445 0 1,3183 0,0018 
39,44 75,3 P08758 Annexin A5 35 2,8054 0,0001 1,5276 0,0011 
229,01 31,3 Q15149 Plectin OS 130 0,3945 0 0,6545 0,0217 
60,19 20,4 Q00610 Clathrin heavy chain 1 OS 36 0,3981 0,0001 0,6546 0,005 
22,67 51,1 O43852 Calumenin OS 15 2,8576 0,001 2,1677 0,0026 
27,01 46,2 P36222 Chitinase-3-like protein 1 OS 24 1,7219 0,0017 1,2246 0,0273 
42,29 36,1 P07900 Heat shock protein HSP 90-alpha OS 27 0,6855 0,0019 0,871 0,0496 
14,1 30,8 Q96D15 Reticulocalbin-3 OS 10 2,421 0,0032 1,7219 0,0449 
55,2 68 P06733 Alpha-enolase OS 56 0,597 0,0037 1,0471 0,4455 
61,66 45,3 P12814 Alpha-actinin-1 OS 44 0,6081 0,0046 0,6607 0,0367 
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38,46 34,6 Q14764 Major vault protein OS 25 0,6081 0,0061 0,7516 0,0491 
30,92 44,6 P06576 ATP synthase subunit beta, mitochondrial OS 23 1,803 0,0064 1,4588 0,0234 
24,09 45,6 P67936 Tropomyosin alpha-4 chain OS 14 1,556 0,0091 1,6596 0,01 
28,74 41,1 O60701 UDP-glucose 6-dehydrogenase OS 21 0,521 0,0113 0,7178 0,0416 
26,54 10,1 P02751 Fibronectin OS 16 0,6138 0,0125 1,0186 0,7646 
14,28 22,7 Q15084 Protein disulfide-isomerase A6 OS 12 1,4322 0,0156 1,0864 0,891 
64,73 66,5 P14618 Pyruvate kinase isozymes M1/M2 OS 58 0,6138 0,0159 0,7244 0,0413 
13,96 52,4 P62805 Histone H4 OS 13 1,556 0,027 1,3305 0,0668 
46,17 36,4 P11216 Glycogen phosphorylase, brain form OS 30 0,6194 0,0285 0,787 0,28 
41,29 32,5 P12109 Collagen alpha-1(VI) chain OS 32 1,4997 0,0315 0,3873 0 
8,19 11,9 Q02818 Nucleobindin-1 OS 4 2,421 0,0318 1,3062 0,6913 
17,7 2,2 Q14204 Cytoplasmic dynein 1 heavy chain 1 OS 7 0,4831 0,0379 0,5754 0,1018 
21,45 52,3 P04179 Superoxide dismutase [Mn], mitochondrial OS 25 1,888 0,0379 2,0137 0,0346 
17,57 41,6 P05388 60S acidic ribosomal protein P0 OS 10 0,7516 0,0394 0,9376 0,5738 
48,23 47,3 P02545 Lamin-A/C OS 44 1,4588 0,0413 1,4859 0,044 
46,89 42,8 P08133 Annexin A6 OS 27 0,6427 0,0435 0,8166 0,2732 
11,12 37,6 P04792 Heat shock protein beta-1 OS 10 1,4723 0,0435 1,0666 0,7161 
36,88 11,9 Q9NZM1 Myoferlin OS 19 0,6918 0,0448 0,6982 0,0435 
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40,97 64,8 P00558 Phosphoglycerate kinase 1 OS 36 0,6427 0,0448 0,879 0,8106 
38,86 51,1 P30101 Protein disulfide-isomerase A3 OS 34 1,6749 0,0449 1,2589 0,231 
10,04 24,7 P50914 60S ribosomal protein L14 OS 6 1,3183 0,0457 0,9817 0,755 
32,18 35,1 Q07065 Cytoskeleton-associated protein 4 OS 21 1,3932 0,0475 1,1169 0,6495 
24,01 50 P10915 Hyaluronan and proteoglycan link protein 1 OS 17 1,9231 0,048 0,4966 0,005 
13,16 14,5 O60506 Heterogeneous nuclear ribonucleoprotein Q OS 8 0,7047 0,0481 0,955 0,7378 
145,01 31,7 P12111 Collagen alpha-3(VI) chain OS 122 0,6194 0,0487 0,3373 0 
16,33 49,8 P37802 Transgelin-2 OS 14 1,7539 0,0487 2,0701 0,0314 
9,27 6,6 P16070 CD44 antigen OS 6 1,2474 0,0595 1,5136 0,0268 
20,09 16,7 Q7KZF4 Staphylococcal nuclease domain-containing protein 1 OS 12 0,7727 0,0679 0,9727 0,9665 
55,02 46,6 P11021 78 kDa glucose-regulated protein OS 50 1,1695 0,0689 1,0666 0,2321 
7,16 12,6 P52209 6-phosphogluconate dehydrogenase, decarboxylating OS 4 0,7112 0,0703 0,863 0,4981 
11,97 51,5 P19105 Myosin regulatory light chain 12A OS 8 1,7061 0,0731 2,1677 0,0144 
15,83 16,3 P52272 Heterogeneous nuclear ribonucleoprotein M OS 9 0,6427 0,0732 1,2706 0,3011 
18,33 28 Q6NZI2 Polymerase I and transcript release factor OS 14 1,7865 0,0752 1,4859 0,2672 
9,85 39,4 P02511 Alpha-crystallin B chain OS 5 1,5136 0,079 0,8872 0,2035 
19,65 19,2 P19338 Nucleolin OS 14 1,556 0,0805 1,3428 0,2667 
8,12 33,7 Q99584 Protein S100-A13 OS 5 1,8707 0,0813 1,4997 0,216 
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30,82 15,3 Q9P2E9 Ribosome-binding protein 1 OS 17 0,9036 0,0821 0,9817 0,7784 
16 45,1 P08865 40S ribosomal protein SA OS 9 2,0137 0,0833 1,0375 0,7219 
12,02 35,3 Q01995 Transgelin OS 9 1,5276 0,0872 1,3428 0,1741 
14,01 20,6 Q13838 Spliceosome RNA helicase BAT1 OS 9 0,5546 0,0884 0,9204 0,776 
38,74 30 P13639 Elongation factor 2 OS 21 0,7178 0,0891 0,7447 0,1828 
15,02 22,7 Q16658 Fascin OS 8 0,597 0,0906 0,7586 0,3041 
8 3,6 P07814 Bifunctional aminoacyl-tRNA synthetase OS 4 0,7586 0,0946 0,9727 0,8022 
10 64,4 P07108 Acyl-CoA-binding protein OS 7 1,5704 0,0955 1,556 0,1374 
14,7 22,5 P61158 Actin-related protein 3 OS 8 0,912 0,0971 0,929 0,2983 
6,25 18,5 P52907 F-actin-capping protein subunit alpha-1 OS 5 0,7586 0,0973 1,0765 0,5069 
6,11 7,8 P07602 Proactivator polypeptide OS 4 2,2491 0,0978 2,0701 0,0569 
9,07 7,1 Q05682 Caldesmon OS 5 1,2474 0,0989 1,1588 0,2237 
4,33 2,8 O94925 Glutaminase kidney isoform, mitochondrial OS 2 0,8472 0,1056 0,9727 0,6636 
11,32 15,5 P36578 60S ribosomal protein L4 OS 6 0,6918 0,1227 0,7586 0,2342 
28,02 46,2 P50454 Serpin H1 OS 20 1,3305 0,1297 0,6546 0,3148 
85,13 29,8 P24821 Tenascin OS 56 0,8241 0,1317 0,7447 0,3361 
5,11 7,2 Q10471 Polypeptide N-acetylgalactosaminyltransferase 2 OS 3 0,8241 0,132 0,8872 0,5144 
7,3 29,1 P62277 40S ribosomal protein S13 OS 4 1,556 0,1363 1,0568 0,5625 
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10,73 29,9 P29692 Elongation factor 1-delta OS 7 1,2023 0,1385 0,9727 0,7896 
8,84 19,4 Q15019 Septin-2 OS 6 1,6293 0,1416 1,2706 0,5134 
8,05 14,3 Q12907 Vesicular integral-membrane protein VIP36 OS 4 0,871 0,1443 1,0186 0,7604 
75,24 53,5 O43707 Alpha-actinin-4 OS 56 0,6486 0,1454 0,955 0,8077 
6,08 5,1 P35606 Coatomer subunit beta' OS 3 0,7311 0,1498 0,8472 0,4093 
10,04 3 Q13813 Spectrin alpha chain, brain OS 5 0,8872 0,1519 1,0765 0,1294 
9,01 22,8 P78417 Glutathione S-transferase omega-1 OS 6 0,5649 0,1533 1,1912 0,6023 
24,89 48,2 P23284 Peptidyl-prolyl cis-trans isomerase B OS 21 1,3932 0,1538 1,1803 0,4481 
5,27 7,7 Q96QK1 Vacuolar protein sorting-associated protein 35 OS 5 0,6194 0,156 0,955 0,6938 
4,65 15,3 O15173 Membrane-associated progesterone receptor component 2 OS 3 1,0864 0,1619 1 0,8031 
32,95 46,4 P00338 L-lactate dehydrogenase A chain OS 20 0,8091 0,1629 0,8551 0,2656 
18,05 18,5 P07686 Beta-hexosaminidase subunit beta OS 9 1,4859 0,1641 1,0471 0,2642 
9,79 13,5 Q9UHD8 Septin-9 OS 6 0,8551 0,1649 0,9727 0,7742 
11,89 28,1 P40926 Malate dehydrogenase, mitochondrial OS 8 0,52 0,1658 0,9638 0,7814 
20,01 20,8 P13797 Plastin-3 OS 11 0,7047 0,1684 0,9817 0,9388 
5 17,2 P61313 60S ribosomal protein L15 OS 4 0,7244 0,1739 0,631 0,1135 
19,01 18,4 P40939 Trifunctional enzyme subunit alpha, mitochondrial OS 10 0,7516 0,1793 0,8395 0,5471 
29,08 20,2 P22314 Ubiquitin-like modifier-activating enzyme 1 OS 21 0,7244 0,182 0,929 0,5697 
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6,97 47,9 P69905 Hemoglobin subunit alpha OS 10 1,556 0,1859 1,1169 0,6807 
11,88 57 P09382 Galectin-1 OS 16 0,8017 0,187 1,1272 0,3819 
15,3 16,2 Q06210 Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1 OS 
8 0,4786 0,188 0,9462 0,4656 
9,77 6,7 P63010 AP-2 complex subunit beta OS 5 0,6252 0,1906 0,6427 0,1439 
7,09 24,3 P62701 40S ribosomal protein S4, X isoform OS 7 0,52 0,1958 0,871 0,7758 
7,83 35,2 P39019 40S ribosomal protein S19 OS 5 1,5417 0,2002 1,1066 0,747 
5,05 2,8 Q04637 Eukaryotic translation initiation factor 4 gamma 1 OS 4 0,8091 0,2081 1,0186 0,8358 
14,02 30,5 P23396 40S ribosomal protein S3 OS 8 0,8472 0,2119 0,8472 0,1774 
45,62 20,9 P46940 Ras GTPase-activating-like protein IQGAP1 OS 28 0,8318 0,2136 0,9638 0,9256 
6,31 5,8 P53618 Coatomer subunit beta OS 4 0,8017 0,2165 1 0,9724 
8,23 10,8 Q13228 Selenium-binding protein 1 OS 4 0,8395 0,2165 0,9376 0,6705 
0,94 10,3 Q71DI3 Histone H3.2 OS 2 1,2134 0,2179 1,1482 0,511 
4,69 15,6 P00441 Superoxide dismutase [Cu-Zn] OS 2 1,8365 0,2193 1,7219 0,2291 
8,85 23,3 P30443 HLA class I histocompatibility antigen, A-1 alpha chain OS 5 1 0,2205 0,9727 0,6131 
12,96 23 Q07960 Rho GTPase-activating protein 1 OS 7 1,5276 0,2212 0,9462 0,9856 
2,96 12,6 P02792 Ferritin light chain OS 2 1,3062 0,2218 0,9462 0,7494 
6,65 11,4 P14550 Alcohol dehydrogenase [NADP+] OS 3 0,912 0,2231 1,0471 0,4331 
6,15 16,5 Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 OS 3 1,2942 0,2263 1,0864 0,6364 
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26,62 34 P21589 5'-nucleotidase OS 18 0,929 0,2267 0,9638 0,5234 
12,87 18 P36871 Phosphoglucomutase-1 OS 8 0,787 0,2281 1,0765 0,6279 
8 40 P30050 60S ribosomal protein L12 OS 6 0,9376 0,2294 0,9817 0,5038 
8,57 22,9 P51858 Hepatoma-derived growth factor OS 5 1,5136 0,2342 1,6904 0,2235 
7,57 8 P11940 Polyadenylate-binding protein 1 OS 4 0,8241 0,2343 0,879 0,4706 
12,53 23,6 P15880 40S ribosomal protein S2 OS 7 0,9376 0,2349 0,9727 0,5394 
25,14 33,6 Q5VTE0 Putative elongation factor 1-alpha-like 3 OS 25 0,6855 0,2359 0,6792 0,0962 
15,25 27,8 P60842 Eukaryotic initiation factor 4A-I OS 9 0,9036 0,2397 0,9817 0,893 
22,96 28,1 P02768 Serum albumin OS 30 1,1066 0,2432 3,3419 0,0342 
6,54 5,2 Q15436 Protein transport protein Sec23A OS 3 0,7112 0,2433 0,955 0,8498 
24,66 27,2 P06396 Gelsolin OS 19 0,6194 0,2452 0,9204 0,7591 
6,07 27,3 P16104 Histone H2A.x OS 6 1,8197 0,2466 1,2023 0,4914 
20,21 32,6 P50395 Rab GDP dissociation inhibitor beta OS 11 0,929 0,2529 0,9462 0,3452 
8,33 14,4 P11766 Alcohol dehydrogenase class-3 OS 4 0,8395 0,2541 0,9204 0,673 
14,82 51 P60660 Myosin light polypeptide 6 OS 12 1,3932 0,2574 1,2942 0,2049 
25,03 34,8 P27797 Calreticulin OS 24 1,2823 0,2591 1,2023 0,5234 
10,52 17,2 Q15293 Reticulocalbin-1 OS 5 1,5276 0,26 1,7219 0,1243 
6,86 19,7 P62269 40S ribosomal protein S18 OS 5 1,2134 0,2613 1,028 0,7971 
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6,28 3,2 P0C0L5 Complement C4-B OS 5 1,803 0,2644 0,9908 0,97 
4,06 10,9 O95336 6-phosphogluconolactonase OS 2 1,1803 0,2678 1,028 0,7972 
3,15 3,2 Q14974 Importin subunit beta-1 OS 2 0,879 0,2686 0,9462 0,5822 
4,32 10,3 Q14847 LIM and SH3 domain protein 1 OS 3 1,6749 0,2711 1,4454 0,4603 
41,5 68,7 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS 46 0,8472 0,2759 1,028 0,9784 
9,2 36,7 P62987 Ubiquitin-60S ribosomal protein L40 OS 9 1,3677 0,2768 0,9462 0,903 
20,9 35,8 O75874 Isocitrate dehydrogenase [NADP] cytoplasmic OS 12 0,7447 0,278 1,0864 0,6029 
17,55 27,7 P78371 T-complex protein 1 subunit beta OS 10 0,7447 0,2789 0,5808 0,0647 
23,01 50,3 P04075 Fructose-bisphosphate aldolase A OS 23 0,7727 0,2792 0,8017 0,2621 
5,21 17,5 Q9BTV4 Transmembrane protein 43 OS 5 1,0965 0,2795 0,8472 0,1588 
76,65 66,7 P08670 Vimentin OS 126 0,492 0,2804 1,0471 0,5945 
4,2 5,1 P23246 Splicing factor, proline- and glutamine-rich OS 3 1,0375 0,2822 1,028 0,7539 
5,16 25,2 O43399 Tumor protein D54 OS 4 1,1803 0,286 1,1588 0,2596 
10,48 19,8 P40925 Malate dehydrogenase, cytoplasmic OS 6 0,5916 0,2877 0,871 0,7537 
4,97 9,8 P51884 Lumican OS 4 1,0765 0,2891 1,0471 0,4875 
7,4 14,8 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 OS 4 0,879 0,2904 0,9376 0,6258 
4,75 4,5 Q99613 Eukaryotic translation initiation factor 3 subunit C OS 3 0,8551 0,2938 0,863 0,1988 
20,97 22,4 Q15582 Transforming growth factor-beta-induced protein ig-h3 OS 14 0,7798 0,2945 0,5754 0,0247 
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13,71 55,2 P63241 Eukaryotic translation initiation factor 5A-1 OS 9 0,912 0,2956 1 0,7852 
6,4 19,4 P62906 60S ribosomal protein L10a OS 4 0,9376 0,301 0,9036 0,4147 
14,49 3,5 P16112 Aggrecan core protein OS 10 1,2942 0,3091 0,5649 0,0138 
5,46 11,9 P43307 Translocon-associated protein subunit alpha OS 3 1,6144 0,3111 1,0965 0,7615 
5,77 24,2 P04216 Thy-1 membrane glycoprotein OS 6 1,5704 0,3123 1,3428 0,6114 
23,85 35,4 Q9BUF5 Tubulin beta-6 chain OS 19 0,9462 0,3158 1 0,6288 
7,27 7,4 P21980 Protein-glutamine gamma-glutamyltransferase 2 OS 5 0,7311 0,3185 0,7178 0,2233 
5,64 12 P62280 40S ribosomal protein S11 OS 4 0,5754 0,3232 0,7178 0,4548 
9,44 22,2 Q15365 Poly(rC)-binding protein 1 OS 8 0,7798 0,3296 0,8954 0,6301 
20 40,2 Q99536 Synaptic vesicle membrane protein VAT-1 homolog OS 12 0,6668 0,3363 1,0093 0,9324 
31,77 76,7 P60174 Triosephosphate isomerase OS 29 1,1376 0,3396 1,2589 0,077 
5,82 12,5 P61163 Alpha-centractin OS 3 1,1066 0,3457 1,0471 0,4322 
8,39 9,6 Q9Y5X1 Sorting nexin-9 OS 4 0,9908 0,3478 0,9376 0,605 
8 22,2 P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 OS 6 1,1912 0,3483 1 0,9234 
7,98 7,7 O43776 Asparaginyl-tRNA synthetase, cytoplasmic OS 5 0,8241 0,3513 0,879 0,3545 
8,28 24,4 P24534 Elongation factor 1-beta OS 5 1,3062 0,352 1,6444 0,1507 
10,43 76,5 P05387 60S acidic ribosomal protein P2 OS 9 1,2474 0,3523 1,3183 0,1738 
9,82 42,9 P10599 Thioredoxin OS 8 1,4454 0,3531 1,8197 0,1378 
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10 23 P16403 Histone H1.2 OS 6 1,3804 0,3542 1,888 0,1427 
10,41 16,2 P06753 Tropomyosin alpha-3 chain OS 6 1,2706 0,361 1,1912 0,4717 
60,03 37,7 P14625 Endoplasmin OS 37 0,7447 0,3637 1,0965 0,9717 
14,18 10,5 P06737 Glycogen phosphorylase, liver form OS 10 0,863 0,3688 0,9817 0,9066 
15,41 24,2 Q16851 UTP--glucose-1-phosphate uridylyltransferase OS 11 0,9204 0,3715 0,9817 0,971 
21,82 7 P35580 Myosin-10 OS 12 0,871 0,3719 0,929 0,6476 
8,61 45,6 P62158 Calmodulin OS 7 2,1478 0,3722 1,9055 0,1345 
0,81 16,7 P06703 Protein S100-A6 OS 2 1,1695 0,3745 1,1588 0,4362 
4,41 21,6 P61604 10 kDa heat shock protein, mitochondrial OS 2 1,3428 0,3776 1,2589 0,61 
6 28,6 Q9Y3U8 60S ribosomal protein L36 OS 3 1,0864 0,3782 1,028 0,7515 
3,75 34,8 P62888 60S ribosomal protein L30 OS 4 1,1066 0,3813 0,9727 0,8511 
6 12,9 P42765 3-ketoacyl-CoA thiolase, mitochondrial OS 3 0,8091 0,3816 0,8091 0,4022 
18,86 14,2 Q14697 Neutral alpha-glucosidase AB OS 9 0,9376 0,3837 0,9727 0,7061 
7,77 11,9 P40227 T-complex protein 1 subunit zeta OS 5 0,7047 0,3871 1,1169 0,6416 
6,7 8,5 P48643 T-complex protein 1 subunit epsilon OS 4 0,863 0,3885 0,7943 0,3349 
9,68 1,5 Q07954 Prolow-density lipoprotein receptor-related protein 1 OS 5 0,6792 0,3954 0,6081 0,1567 
6 12,8 Q01105 Protein SET OS 5 1,3183 0,3985 1,2359 0,6857 
10,3 32 P84077 ADP-ribosylation factor 1 OS 6 0,9376 0,4006 0,9036 0,1712 
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3,82 10,3 Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein OS 3 1,2246 0,4031 1,0965 0,5156 
5,3 8,4 Q13510 Acid ceramidase OS 3 0,955 0,4065 1 0,8105 
6 15 P02647 Apolipoprotein A-I OS 6 1,8365 0,4066 1,5417 0,7144 
13,64 8,6 P27816 Microtubule-associated protein 4 OS 8 1,0375 0,407 1,0471 0,3414 
5,52 19,1 P09429 High mobility group protein B1 OS 5 1,2023 0,4104 1,4322 0,2356 
4,72 18 P02794 Ferritin heavy chain OS 3 1,1803 0,4181 0,863 0,6203 
4,07 13,2 Q9UIJ7 GTP:AMP phosphotransferase, mitochondrial OS 2 1,1803 0,4197 1,1588 0,4763 
5,73 27,9 Q13404 Ubiquitin-conjugating enzyme E2 variant 1 OS 3 0,871 0,424 1,028 0,7202 
10,8 20,9 Q08431 Lactadherin OS 7 1,3305 0,4242 0,9376 0,9889 
16,73 67,8 P22392 Nucleoside diphosphate kinase B OS 12 1,2134 0,4259 1,1695 0,3059 
5,92 13,3 P21281 V-type proton ATPase subunit B, brain isoform OS 4 0,8318 0,4297 0,955 0,8724 
12 14,4 Q14247 Src substrate cortactin OS 7 1,0666 0,4305 1,0568 0,6266 
6 10,2 P45880 Voltage-dependent anion-selective channel protein 2 OS 3 0,8241 0,4306 0,912 0,7622 
52,13 40,3 P08238 Heat shock protein HSP 90-beta OS 34 0,8551 0,4317 0,8318 0,5476 
58,44 14,6 Q99715 Collagen alpha-1(XII) chain OS 31 0,8017 0,4327 0,4875 0 
8,55 5,6 P02461 Collagen alpha-1(III) chain OS 6 0,9204 0,4336 0,879 0,1909 
7,68 13,3 P21810 Biglycan OS 5 0,8472 0,4351 0,929 0,7391 
3,57 9,6 P09486 SPARC OS 2 0,863 0,4354 1,1066 0,537 
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4 3,1 O60763 General vesicular transport factor p115 OS 3 0,863 0,4366 0,9036 0,6229 
23,16 41,3 P07339 Cathepsin D OS 25 1,1066 0,4378 1,0765 0,758 
15,9 17 P50281 Matrix metalloproteinase-14 OS 8 0,912 0,4397 0,9638 0,9838 
4,18 2,3 O95782 AP-2 complex subunit alpha-1 OS 2 0,8318 0,4424 0,8395 0,4611 
3,02 7,6 P08962 CD63 antigen OS 4 1,406 0,4434 1,0568 0,7404 
20,68 22,4 P38646 Stress-70 protein, mitochondrial OS 13 0,7727 0,4435 0,8872 0,9631 
5,46 2,8 Q86VP6 Cullin-associated NEDD8-dissociated protein 1 OS 4 1,1912 0,4479 1,0765 0,6526 
7,14 6,6 P10253 Lysosomal alpha-glucosidase OS 4 1,028 0,4499 0,9376 0,7197 
14,89 22,8 P07195 L-lactate dehydrogenase B chain OS 7 0,929 0,4535 0,9204 0,3657 
18,04 64,3 P09211 Glutathione S-transferase P OS 17 0,8166 0,4541 0,9727 0,9173 
9,03 49 P04080 Cystatin-B OS 5 1,4191 0,4545 1,6596 0,2812 
5,02 6,2 P49368 T-complex protein 1 subunit gamma OS 3 0,929 0,4558 1,0471 0,5896 
5,84 7,2 P14314 Glucosidase 2 subunit beta OS 4 1,1482 0,4586 1,1803 0,2742 
4,16 2,2 Q08211 ATP-dependent RNA helicase A OS 2 0,8241 0,4636 0,9908 0,9911 
4 17,3 P51571 Translocon-associated protein subunit delta OS 3 1,0375 0,4644 0,9727 0,2598 
16,4 10,4 P05023 Sodium/potassium-transporting ATPase subunit alpha-1 OS 8 0,8017 0,4647 1,0375 0,8642 
5,08 34,5 P59998 Actin-related protein 2/3 complex subunit 4 OS 5 1,1272 0,4663 0,9376 0,7123 
3,62 4,2 O60749 Sorting nexin-2 OS 3 1,2023 0,4696 0,9204 0,7727 
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11,94 16,9 P09493 Tropomyosin alpha-1 chain OS 7 1,3183 0,4718 1,4454 0,4107 
32,91 50,5 P07437 Tubulin beta chain OS 39 0,7178 0,4727 0,8551 0,6498 
35,96 33,8 P26038 Moesin OS 25 0,9462 0,4745 0,9462 0,3069 
3,8 16,4 P62829 60S ribosomal protein L23 OS 2 0,879 0,4792 0,9204 0,6376 
6 34,3 P31949 Protein S100-A11 OS 11 1,2246 0,4821 1,2589 0,5449 
7,95 13,3 Q9UHG3 Prenylcysteine oxidase 1 OS 5 1,0864 0,4826 1,0375 0,8033 
6,36 11,8 P40121 Macrophage-capping protein OS 5 1,2942 0,4829 1,2942 0,4011 
9,27 27 Q99880 Histone H2B type 1-L OS 15 1,406 0,4851 1,1482 0,708 
5,18 19,4 Q15056 Eukaryotic translation initiation factor 4H OS 3 1,0375 0,4859 1,2023 0,1758 
7,64 6,1 P34932 Heat shock 70 kDa protein 4 OS 4 0,9376 0,4871 0,9376 0,4579 
13,58 35,8 P60981 Destrin OS 7 0,879 0,4883 0,9376 0,7769 
2,88 8,5 O75718 Cartilage-associated protein OS 3 1,1272 0,489 1,0568 0,6912 
4 12,8 Q9UKK9 ADP-sugar pyrophosphatase OS 3 0,9376 0,4898 1,0471 0,558 
4,35 10,9 Q9UBS4 DnaJ homolog subfamily B member 11 OS 2 0,955 0,4907 1,0965 0,1803 
6 26,7 Q14011 Cold-inducible RNA-binding protein OS 3 1,2246 0,4908 1,0864 0,9306 
7,13 12,6 P50991 T-complex protein 1 subunit delta OS 5 0,9376 0,4912 1,0666 0,3486 
7,75 15,2 P18463 HLA class I histocompatibility antigen, B-37 alpha chain OS 4 1,1695 0,4941 1,0864 0,7139 
5,94 14,1 P62140 Serine/threonine-protein phosphatase PP1-beta catalytic 
subunit OS 
4 0,8318 0,4959 0,912 0,8138 
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4,98 16,4 O15260 Surfeit locus protein 4 OS 5 1,1066 0,4984 1,0666 0,6313 
13,96 32,6 P40261 Nicotinamide N-methyltransferase OS 8 0,9036 0,5012 1,1912 0,7562 
4,26 3,1 O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 OS 2 0,912 0,5012 0,955 0,7843 
4,53 4 Q96TA1 Niban-like protein 1 OS 3 0,955 0,5028 1,0186 0,78 
4,68 16,2 Q9BVK6 Transmembrane emp24 domain-containing protein 9 OS 4 1,0093 0,5037 0,9817 0,4653 
4,03 14,6 P46783 40S ribosomal protein S10 OS 4 1,1588 0,5124 1,0568 0,7626 
3,12 3,8 Q92499 ATP-dependent RNA helicase DDX1 OS 2 0,8395 0,5126 0,955 0,8628 
20,4 23,9 Q96AY3 Peptidyl-prolyl cis-trans isomerase FKBP10 OS 12 0,929 0,518 0,9908 0,9287 
23,94 41,4 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 OS 19 1,1169 0,5213 1,0375 0,8524 
7,68 10 P12956 X-ray repair cross-complementing protein 6 OS 6 0,9376 0,5391 1,0186 0,9189 
11,81 14,7 P39656 Dolichyl-diphosphooligosaccharideprotein glycosyltransferase 
48 kDa subunit 
6 0,9204 0,5397 0,912 0,526 
8,6 15,4 Q01518 Adenylyl cyclase-associated protein 1 OS 6 0,9204 0,5402 0,912 0,6468 
4,61 9,7 P35998 26S protease regulatory subunit 7 OS 3 0,9036 0,5407 0,9817 0,9627 
4,02 19,5 P30046 D-dopachrome decarboxylase OS 2 1,0864 0,546 1,0568 0,6195 
4,89 7,3 P04062 Glucosylceramidase OS 3 0,6546 0,5484 0,8954 0,8506 
9,27 27 Q8N257 Histone H2B type 3-B OS 15 1,3305 0,5486 1,1376 0,7643 
10,86 7,3 P49588 Alanyl-tRNA synthetase, cytoplasmic OS 5 0,929 0,5495 1,0375 0,6479 
13,88 18,8 Q14108 Lysosome membrane protein 2 OS 7 1,1066 0,5545 1,0375 0,8768 
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25,82 34,7 P25705 ATP synthase subunit alpha, mitochondrial OS 20 1,2023 0,5558 0,8472 0,4144 
24,09 28,9 P08107 Heat shock 70 kDa protein 1A/1B OS 18 1,028 0,5564 1,028 0,7778 
14,08 45,2 O00299 Chloride intracellular channel protein 1 OS 10 0,7112 0,5572 0,9462 0,7566 
11,38 15,9 P05455 Lupus La protein OS 6 1,0375 0,558 1,0093 0,9753 
13,74 31,4 Q13162 Peroxiredoxin-4 OS 11 1,0965 0,5606 0,871 0,093 
3,04 20,4 P68871 Hemoglobin subunit beta OS 6 1,1912 0,5651 0,9817 0,9497 
2,24 5 P28838 Cytosol aminopeptidase OS 2 0,8872 0,5699 0,9727 0,8569 
15 18,8 P26641 Elongation factor 1-gamma OS 9 0,9462 0,5744 0,929 0,4427 
12,01 24,5 P30040 Endoplasmic reticulum resident protein 29 OS 6 1,028 0,5753 1,028 0,6252 
6,56 20,7 P62241 40S ribosomal protein S8 OS 5 0,929 0,5761 0,912 0,4754 
10 21,4 Q99439 Calponin-2 OS 5 1,0568 0,5857 1,0568 0,5571 
3,49 5,1 P20073 Annexin A7 OS 3 0,9462 0,5865 1,0375 0,5036 
26,63 38,6 P10809 60 kDa heat shock protein, mitochondrial OS 20 1,1169 0,5887 1,1169 0,7607 
17,7 23,2 P13674 Prolyl 4-hydroxylase subunit alpha-1 OS 11 1,0864 0,5894 1,2134 0,5517 
10,59 14,8 Q13557 Calcium/calmodulin-dependent protein kinase type II subunit 
delta OS 
7 0,9727 0,5935 0,955 0,9306 
4,97 12,3 P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit 
OS 
3 1,0864 0,5961 0,9376 0,5937 
2,6 8,6 P63208 S-phase kinase-associated protein 1 OS 2 0,7943 0,5961 1,0666 0,8535 
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3,27 4,9 P20810 Calpastatin OS 2 1,2589 0,5977 1,1376 0,7286 
6 61,4 P62328 Thymosin beta-4 OS 6 1,2823 0,5982 1,3305 0,594 
9,65 8,6 Q9Y678 Coatomer subunit gamma OS 5 0,9376 0,5989 0,8954 0,5909 
10,02 13,8 Q04446 1,4-alpha-glucan-branching enzyme OS 7 0,9204 0,5993 0,9376 0,7397 
3,07 12 P62834 Ras-related protein Rap-1A OS 3 1,0093 0,601 0,8954 0,4461 
7,15 8,2 P50990 T-complex protein 1 subunit theta OS 4 0,955 0,603 0,955 0,725 
21,93 25,2 P50995 Annexin A11 OS 11 0,6982 0,6043 1,0093 0,4945 
6,93 24 P27105 Erythrocyte band 7 integral membrane protein OS 6 0,9204 0,6046 0,9376 0,7339 
4,94 25,3 Q03135 Caveolin-1 OS 4 1,1066 0,609 0,955 0,8969 
11,89 15,4 P55084 Trifunctional enzyme subunit beta, mitochondrial OS 6 0,9638 0,6095 1 0,871 
38,17 25,9 P12110 Collagen alpha-2(VI) chain OS 42 1 0,6103 0,4656 0,0001 
4 5,9 P22234 Multifunctional protein ADE2 OS 2 0,863 0,6143 0,9638 0,9921 
4 20,4 Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3 OS 5 1,1912 0,6148 1,1169 0,7985 
12,76 20,4 P43490 Nicotinamide phosphoribosyltransferase OS 7 0,9817 0,6152 1,0666 0,2484 
4 9,2 P09012 U1 small nuclear ribonucleoprotein A OS 2 1,3552 0,617 1,1272 0,8349 
7,33 6,8 P17844 Probable ATP-dependent RNA helicase DDX5 OS 4 0,9036 0,6178 0,912 0,6476 
22,29 38,4 Q04828 Aldo-keto reductase family 1 member C1 OS 17 0,8241 0,6193 0,8472 0,7736 
6 9,7 P55209 Nucleosome assembly protein 1-like 1 OS 4 1,1272 0,6196 1,0864 0,6715 
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6,92 8,3 P06865 Beta-hexosaminidase subunit alpha OS 4 0,9462 0,621 1,0765 0,4737 
16,47 19,7 P06744 Glucose-6-phosphate isomerase OS 13 1,0471 0,6235 1,0186 0,7291 
8,13 24 P17931 Galectin-3 OS 7 1,1169 0,6245 1,2023 0,5432 
12,61 34,8 P51149 Ras-related protein Rab-7a OS 8 1,0375 0,625 0,912 0,6307 
1,41 8,7 Q15907 Ras-related protein Rab-11B OS 2 1,1066 0,6313 0,955 0,9241 
47,86 46,7 P07237 Protein disulfide-isomerase OS 44 0,8166 0,6335 1,1803 0,2025 
4,26 11,2 P27635 60S ribosomal protein L10 OS 5 0,863 0,6351 1,0568 0,726 
20,36 59,1 P18669 Phosphoglycerate mutase 1 OS 17 1,0765 0,6352 1,7865 0,0704 
9,61 13 Q8NBS9 Thioredoxin domain-containing protein 5 OS 5 1,0765 0,6354 1,0568 0,6582 
25,93 11,9 P01023 Alpha-2-macroglobulin OS 26 0,8872 0,6369 0,955 0,9161 
13,78 11,8 P15311 Ezrin OS 8 0,9376 0,6375 0,9817 0,6848 
5,95 8,6 P11279 Lysosome-associated membrane glycoprotein 1 OS 4 1,1169 0,6378 1,1803 0,5313 
13,92 22,3 Q14103 Heterogeneous nuclear ribonucleoprotein D0 OS 7 0,912 0,6437 1,0666 0,4999 
4,78 22,9 Q9Y696 Chloride intracellular channel protein 4 OS 3 0,8872 0,6449 1,1695 0,3659 
11,11 41,8 Q99497 Protein DJ-1 OS 7 1,0186 0,6466 1,028 0,5711 
3,75 4,5 Q02809 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 OS 2 0,8166 0,65 0,8395 0,7366 
16,49 35,7 Q06830 Peroxiredoxin-1 OS 12 0,9376 0,652 1,028 0,6989 
5,63 17,4 P54727 UV excision repair protein RAD23 homolog B OS 5 1 0,6525 1,1272 0,1949 
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4 17,4 P14174 Macrophage migration inhibitory factor OS 7 1,2589 0,6539 1,2359 0,717 
6 24,4 P62750 60S ribosomal protein L23a OS 4 1,0965 0,6548 1,0186 0,8396 
5,82 12,9 P19623 Spermidine synthase OS 4 0,879 0,6556 0,787 0,5353 
10,65 8,5 P05556 Integrin beta-1 OS 6 1,0765 0,6611 1,1066 0,6166 
2,26 13,5 O75531 Barrier-to-autointegration factor OS 2 1,1482 0,6613 1,2474 0,581 
8 30,1 P08134 Rho-related GTP-binding protein RhoC OS 7 0,9727 0,6614 0,879 0,4175 
5,08 12,5 P00367 Glutamate dehydrogenase 1, mitochondrial OS 6 0,929 0,6628 0,8954 0,5412 
25,45 39,3 P68366 Tubulin alpha-4A chain OS 25 0,8551 0,6637 0,8318 0,5732 
5,41 10,4 P49411 Elongation factor Tu, mitochondrial OS 3 0,9036 0,6639 0,7943 0,3648 
10,84 30,4 P00568 Adenylate kinase isoenzyme 1 OS 6 1,0375 0,6645 1 0,9998 
6,59 22,4 P49755 Transmembrane emp24 domain-containing protein 10 OS 3 0,929 0,665 0,9036 0,6309 
5,92 9,3 P15289 Arylsulfatase A OS 3 0,9376 0,6684 0,955 0,8851 
7,36 22,7 P61247 40S ribosomal protein S3a OS 7 1,028 0,6713 1,0864 0,5815 
13,99 16,6 Q96HC4 PDZ and LIM domain protein 5 OS 9 0,9638 0,6727 1,0186 0,7987 
2,52 3,4 Q16891 Mitochondrial inner membrane protein OS 2 0,955 0,6772 1 0,6882 
5,51 6,2 P15586 N-acetylglucosamine-6-sulfatase OS 3 1,0666 0,6778 1,0093 0,8892 
4 15,2 P62263 40S ribosomal protein S14 OS 3 0,912 0,68 0,9817 0,8883 
9,87 10,1 O43390 Heterogeneous nuclear ribonucleoprotein R OS 5 1,0864 0,6807 0,9817 0,964 
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6 11,9 Q92597 Protein NDRG1 OS 3 0,8954 0,6823 0,9817 0,9636 
10 18 P61160 Actin-related protein 2 OS 6 1,0568 0,6857 0,9817 0,8537 
9,12 25,6 P16152 Carbonyl reductase [NADPH] 1 OS 6 0,9638 0,6858 1,0568 0,6018 
6,33 6,2 O15460 Prolyl 4-hydroxylase subunit alpha-2 OS 3 0,9376 0,6859 0,9727 0,9686 
2,95 5,7 P63000 Ras-related C3 botulinum toxin substrate 1 OS 2 1,1588 0,6886 1,028 0,9111 
8,46 4,8 P41252 Isoleucyl-tRNA synthetase, cytoplasmic OS 4 1,0186 0,6901 0,9638 0,6492 
4,37 3,6 Q9BSJ8 Extended synaptotagmin-1 OS 3 1,0568 0,6902 1,0864 0,6161 
4,31 16 P62851 40S ribosomal protein S25 OS 2 1,0965 0,6912 1,0093 0,9491 
6,19 21,2 P62249 40S ribosomal protein S16 OS 3 0,9462 0,6956 0,912 0,493 
4 6 Q8IWE2 Protein NOXP20 OS 2 1,1482 0,6966 1,406 0,448 
2,95 2,3 P46977 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A OS 
2 0,9204 0,7005 0,9036 0,6834 
8,17 45,4 P60903 Protein S100-A10 OS 12 1,0186 0,7016 1,0765 0,4036 
8,54 17,3 P18124 60S ribosomal protein L7 OS 4 0,929 0,7051 0,863 0,2914 
16 54 P30086 Phosphatidylethanolamine-binding protein 1 OS 10 0,9817 0,7061 1,0666 0,2505 
4,11 10,2 P30048 Thioredoxin-dependent peroxide reductase, mitochondrial OS 2 1 0,7073 0,9638 0,6741 
10,75 6 P01024 Complement C3 OS 9 1,0568 0,7116 2,0324 0,4225 
26,68 23,5 P02458 Collagen alpha-1(II) chain OS 32 1,028 0,7131 0,7727 0,3594 
0,32 3,2 P02790 Hemopexin OS 2 0,8551 0,7131 1,0375 0,8838 
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4,05 11,4 P21964 Catechol O-methyltransferase OS 2 1,028 0,7135 0,9817 0,9349 
2 12,1 Q01629 Interferon-induced transmembrane protein 2 OS 2 1,1912 0,7153 1,1169 0,9044 
4,64 12,7 P61019 Ras-related protein Rab-2A OS 3 1,0568 0,7211 1,0471 0,7835 
1,69 7 Q15233 Non-POU domain-containing octamer-binding protein OS 2 1 0,7271 1,0568 0,6902 
6 29,1 O15511 Actin-related protein 2/3 complex subunit 5 OS 3 1,1169 0,7278 1,0666 0,6291 
7,56 6,2 Q9Y4L1 Hypoxia up-regulated protein 1 OS 4 0,929 0,7369 0,8318 0,0793 
9,45 2,8 P49327 Fatty acid synthase OS 5 1,028 0,7385 0,879 0,3086 
4,88 5,9 P23381 Tryptophanyl-tRNA synthetase, cytoplasmic OS 2 0,9204 0,7405 0,8318 0,3354 
2,18 6,9 P35237 Serpin B6 OS 2 1,0568 0,7423 1,0186 0,8944 
15,88 33,9 P00387 NADH-cytochrome b5 reductase 3 OS 10 0,9727 0,7425 0,9376 0,5017 
6,87 6,3 P38606 V-type proton ATPase catalytic subunit A OS 3 0,9727 0,7452 0,9908 0,9801 
4 25 P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A OS 2 1,0864 0,7455 1,028 0,8596 
27,97 37,9 Q16555 Dihydropyrimidinase-related protein 2 OS 18 0,7656 0,7466 0,787 0,6266 
7 5,6 P17655 Calpain-2 catalytic subunit OS 3 1 0,7471 1 0,9248 
31,74 44,3 Q13885 Tubulin beta-2A chain OS 34 1,0471 0,7475 0,9462 0,8039 
2,77 2,8 Q86W92 Liprin-beta-1 OS 2 0,912 0,7528 0,8472 0,5721 
3,86 6,9 Q9Y6N5 Sulfide:quinone oxidoreductase, mitochondrial OS 3 0,955 0,7545 1 0,9649 
8,92 13,1 O43854 EGF-like repeat and discoidin I-like domain-containing protein 
3 OS 
5 1,2134 0,7563 1,1482 0,5873 
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9,64 23,4 Q9BS26 Endoplasmic reticulum resident protein 44 OS 8 0,9817 0,7568 1 0,753 
3,73 2,5 P55786 Puromycin-sensitive aminopeptidase OS 2 0,9727 0,7602 0,9638 0,7305 
6 15,4 P20618 Proteasome subunit beta type-1 OS 3 0,9638 0,762 0,9638 0,8773 
1,61 4,7 O95302 Peptidyl-prolyl cis-trans isomerase FKBP9 OS 2 0,9462 0,7625 0,9638 0,8412 
4 33 Q15836 Vesicle-associated membrane protein 3 OS 3 1,0186 0,7655 1,0471 0,6713 
4,01 5 P10619 Lysosomal protective protein OS 3 1,1169 0,7692 0,8241 0,6589 
7,17 16,4 P17980 26S protease regulatory subunit 6A OS 4 1,0186 0,773 0,8551 0,3144 
4 18,8 Q15185 Prostaglandin E synthase 3 OS 2 0,8551 0,7743 1,0666 0,8708 
6,55 10,7 Q8N8S7 Protein enabled homolog OS 6 1,0666 0,7747 1,0765 0,8081 
11,25 15,9 P49748 Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial OS 
7 0,929 0,7755 0,5649 0,1255 
5,25 15,9 P54920 Alpha-soluble NSF attachment protein OS 5 1,0093 0,7778 1 0,4231 
39,31 61,9 P04083 Annexin A1 OS 29 1 0,7786 1 0,3006 
4 5,4 P31939 Bifunctional purine biosynthesis protein PURH OS 2 0,871 0,7809 0,9376 0,9028 
7,82 10 P29401 Transketolase OS 6 0,955 0,7852 1 0,9688 
4 10,8 P62753 40S ribosomal protein S6 OS 3 0,871 0,7869 0,9462 0,873 
10,59 33,3 P32119 Peroxiredoxin-2 OS 8 1 0,7869 1,0093 0,7597 
15,55 17 P04843 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 OS 
9 0,9908 0,7875 0,9638 0,7682 
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42,64 13,5 Q9Y490 Talin-1 OS 25 1 0,7879 1,028 0,1224 
4,61 2,5 Q12906 Interleukin enhancer-binding factor 3 OS 2 1,0186 0,7925 1,0186 0,7621 
20,74 7,1 Q6UVK1 Chondroitin sulfate proteoglycan 4 OS 10 0,9908 0,7928 1,0375 0,501 
8,32 27,2 P18621 60S ribosomal protein L17 OS 4 0,9817 0,7936 0,9817 0,8973 
3,47 11,1 P07711 Cathepsin L1 OS 2 0,9204 0,7937 0,871 0,6395 
6,99 25,5 P30085 UMP-CMP kinase OS 4 1,0375 0,7941 1,0666 0,6918 
1,25 5,6 P04632 Calpain small subunit 1 OS 3 0,9462 0,7956 1,0965 0,7396 
4,52 4,8 P55884 Eukaryotic translation initiation factor 3 subunit B OS 3 0,929 0,798 0,912 0,7372 
25,64 30 Q9NZN4 EH domain-containing protein 2 OS 14 1 0,7995 1,028 0,4835 
8,28 16,4 P52597 Heterogeneous nuclear ribonucleoprotein F OS 6 1,0765 0,7996 0,9727 0,961 
6,37 5,2 Q00839 Heterogeneous nuclear ribonucleoprotein U OS 3 0,9727 0,801 0,9376 0,6344 
0,76 7,1 P02741 C-reactive protein OS 3 0,871 0,8038 0,9727 0,8231 
18,17 36,1 P62258 14-3-3 protein epsilon OS 11 1,028 0,8042 1,0666 0,5569 
6,16 15,6 Q96AG4 Leucine-rich repeat-containing protein 59 OS 5 1,0375 0,8064 1,1588 0,5581 
5,58 12 P04844 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 OS 
5 0,9462 0,8097 0,9204 0,6452 
7,32 24,7 O75396 Vesicle-trafficking protein SEC22b OS 6 1,0375 0,8112 1,0093 0,7545 
3,17 10,9 P26373 60S ribosomal protein L13 OS 2 1,0765 0,817 0,9638 0,8341 
4 4,7 Q14956 Transmembrane glycoprotein NMB OS 3 1,1376 0,8178 1,0666 0,9004 
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30,86 44,3 P68371 Tubulin beta-2C chain OS 34 0,929 0,8189 1,0186 0,9306 
13,1 17,1 P11413 Glucose-6-phosphate 1-dehydrogenase OS 9 0,9638 0,82 0,9727 0,6496 
4,45 11,3 P15559 NAD(P)H dehydrogenase [quinone] 1 OS 3 0,955 0,8201 0,9638 0,6388 
4,11 7,3 O75367 Core histone macro-H2A.1 OS 2 1 0,8203 0,9727 0,9841 
6,63 5,1 O94832 Myosin-Id OS 4 0,9817 0,8211 0,9817 0,9756 
6,32 33,1 P62244 40S ribosomal protein S15a OS 4 1,028 0,8219 0,9727 0,8055 
11,72 16,7 O75083 WD repeat-containing protein 1 OS 7 0,9817 0,8222 0,9727 0,9692 
6,31 14,5 Q9UK22 F-box only protein 2 OS 3 1,0093 0,832 0,8954 0,2497 
8,31 22,6 P52565 Rho GDP-dissociation inhibitor 1 OS 7 1,0471 0,8328 0,9727 0,8672 
4 7,1 Q9NTK5 Obg-like ATPase 1 OS 2 1,1169 0,8344 1,1169 0,7986 
4 9,6 Q07021 Complement component 1 Q subcomponent-binding protein, 
mitochondrial  
2 1,0666 0,8376 1,1695 0,7216 
19,1 21,7 P13667 Protein disulfide-isomerase A4 OS 11 0,9908 0,8391 0,955 0,5221 
11,54 30,2 P27348 14-3-3 protein theta OS 9 0,9908 0,8395 1,028 0,8592 
7,45 23,2 P62826 GTP-binding nuclear protein Ran OS 4 1,0093 0,8409 0,9638 0,7501 
2,02 17,4 P62857 40S ribosomal protein S28 OS 2 1,1695 0,841 1,2246 0,5331 
10,76 2,3 O75369 Filamin-B OS 8 0,879 0,8417 0,673 0,4462 
3,67 6,5 P41250 Glycyl-tRNA synthetase OS 3 0,929 0,8428 0,8954 0,434 
6,03 16,5 P62081 40S ribosomal protein S7 OS 3 1,0375 0,8448 0,955 0,5817 
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11,69 8,4 O00159 Myosin-Ic OS 7 0,9817 0,8512 0,929 0,6832 
16,45 65,7 P07737 Profilin-1 OS 15 0,9638 0,8515 0,9817 0,9827 
4,15 6,6 P31948 Stress-induced-phosphoprotein 1 OS 2 0,863 0,8533 1,2246 0,6408 
2,57 4,2 P33176 Kinesin-1 heavy chain OS 3 0,9204 0,8534 0,871 0,578 
5,18 15,2 O15145 Actin-related protein 2/3 complex subunit 3 OS 3 0,9462 0,8538 1 0,8828 
25,88 67,3 P62937 Peptidyl-prolyl cis-trans isomerase A OS 23 0,8395 0,856 1,1695 0,3815 
17,03 36,8 P21796 Voltage-dependent anion-selective channel protein 1 OS 10 1,0186 0,8567 0,9727 0,7813 
4,06 4,5 Q96AE4 Far upstream element-binding protein 1 OS 3 1,028 0,8575 1,0765 0,6078 
7,53 15,8 P55795 Heterogeneous nuclear ribonucleoprotein H2 OS 5 1,0186 0,8578 1 0,9407 
12,52 24,1 P07093 Glia-derived nexin OS 9 1,028 0,8581 1,3677 0,1914 
24,38 43 P09525 Annexin A4 OS 13 0,863 0,869 0,8395 0,393 
4,69 9,3 P62191 26S protease regulatory subunit 4 OS 2 0,9638 0,8696 0,9638 0,8704 
8,04 17,2 P46777 60S ribosomal protein L5 OS 5 0,9727 0,8708 1,0471 0,5384 
4 19,5 Q9BRA2 Thioredoxin domain-containing protein 17 OS 3 1,028 0,8735 1,0765 0,8262 
3,72 9,2 P28482 Mitogen-activated protein kinase 1 OS 3 0,955 0,8748 1,0666 0,8777 
11,92 36,9 P30044 Peroxiredoxin-5, mitochondrial OS 10 1,0864 0,8809 1,2589 0,4188 
9,76 19,8 Q13642 Four and a half LIM domains protein 1 OS 6 1,0375 0,881 1,2474 0,5325 
21,38 69,3 P23528 Cofilin-1 OS 18 1,0568 0,8825 1,2706 0,3638 
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4 18,8 P26447 Protein S100-A4 OS 3 1,0765 0,8881 1,1803 0,7522 
8,1 6,8 Q12884 Seprase OS 4 1,0965 0,8906 1,1588 0,8113 
4,16 6,3 Q8IV08 Phospholipase D3 OS 3 1,0186 0,8918 0,9462 0,8582 
7,54 4 P07996 Thrombospondin-1 OS 4 1 0,8989 0,4875 0,1265 
4 7,6 Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 
OS 
2 0,912 0,9002 0,912 0,8782 
4 12,8 P46776 60S ribosomal protein L27a OS 3 1,1066 0,9011 0,9908 0,9568 
4,45 5,9 Q9Y625 Glypican-6 OS 3 0,9908 0,9012 1,1066 0,6474 
12 23,1 P04899 Guanine nucleotide-binding protein G(i) subunit alpha-2 OS 7 0,9908 0,9074 0,955 0,7784 
3,46 9,6 P35232 Prohibitin OS 2 0,9817 0,9108 0,912 0,6545 
13,6 31,3 P31946 14-3-3 protein beta/alpha OS 13 0,9727 0,9145 1,028 0,7182 
6 18,3 P60953 Cell division control protein 42 homolog OS 3 1 0,9162 1,1066 0,6492 
4,49 5,5 Q6DD88 Atlastin-3 OS 3 0,9817 0,9167 0,9376 0,612 
13,33 27,3 P51991 Heterogeneous nuclear ribonucleoprotein A3 OS 8 0,9036 0,9191 0,9727 0,8815 
2,8 15,3 Q02543 60S ribosomal protein L18a OS 2 1,0093 0,9215 1 0,9811 
4 11 P60900 Proteasome subunit alpha type-6 OS 3 0,9817 0,9234 1,0186 0,9104 
3,8 6,3 P00966 Argininosuccinate synthase OS 2 0,9462 0,9266 0,9817 0,9283 
4,87 1,8 Q01082 Spectrin beta chain, brain 1 OS 3 0,9727 0,9269 0,8318 0,3803 
10,37 23,6 Q02878 60S ribosomal protein L6 OS 6 0,9817 0,927 0,8954 0,4158 
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8,94 21,7 P40429 60S ribosomal protein L13a OS 5 1 0,9271 0,9462 0,8094 
15,46 13,5 P27824 Calnexin OS 9 0,9817 0,9288 0,9908 0,7564 
4,19 25,5 Q04760 Lactoylglutathione lyase OS 3 0,9727 0,9347 0,9727 0,9425 
2 2,1 P02748 Complement component C9 OS 2 0,9376 0,9378 0,9817 0,9328 
14,35 37,5 P07858 Cathepsin B OS 12 0,9727 0,9414 1,2706 0,5584 
6,54 48,5 P25398 40S ribosomal protein S12 OS 6 0,9817 0,9428 1,1066 0,7865 
2 8,5 P60033 CD81 antigen OS 4 0,955 0,9436 1,1482 0,7879 
1,56 2 O94979 Protein transport protein Sec31A OS 2 0,9817 0,9464 1,028 0,2908 
51,11 31,3 P18206 Vinculin OS 32 1,0093 0,9464 1,1272 0,3797 
48,3 43,7 P11142 Heat shock cognate 71 kDa protein OS 46 1 0,9485 0,9908 0,863 
14,23 20,8 P13489 Ribonuclease inhibitor OS 10 1,0186 0,9523 0,9638 0,5114 
4 9,6 Q8IZP2 Putative protein FAM10A4 OS 2 1,028 0,9536 0,9376 0,8936 
6,18 12,3 O15144 Actin-related protein 2/3 complex subunit 2 OS 3 0,9727 0,9537 0,9908 0,9808 
4 15,7 P13693 Translationally-controlled tumor protein OS 2 1,0186 0,9546 1,1376 0,7284 
4,57 7,1 P02765 Alpha-2-HS-glycoprotein OS 3 0,9908 0,9596 2,3988 0,0386 
1,48 3,6 P54136 Arginyl-tRNA synthetase, cytoplasmic OS 2 0,9817 0,9611 0,7943 0,3126 
6,16 16 Q16181 Septin-7 OS 4 0,912 0,9628 0,929 0,27 
2,34 3,4 Q99829 Copine-1 OS 2 0,9462 0,9635 0,9204 0,8332 
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2,26 5,2 P04004 Vitronectin OS 2 0,9817 0,9637 0,863 0,8054 
0,74 10,3 P46781 40S ribosomal protein S9 OS 2 0,9908 0,9657 0,9727 0,7035 
4,09 5,3 P49189 4-trimethylaminobutyraldehyde dehydrogenase OS 2 0,929 0,9662 0,9036 0,8274 
12,99 42,9 P62820 Ras-related protein Rab-1A OS 10 0,9727 0,9696 0,9817 0,8701 
6,17 24,5 O75915 PRA1 family protein 3 OS 5 0,955 0,9697 1,0093 0,7403 
3,6 13,3 Q01469 Fatty acid-binding protein, epidermal OS 2 0,912 0,971 0,9908 0,9875 
6,19 16,1 O14818 Proteasome subunit alpha type-7 OS 4 1,0093 0,9719 0,9908 0,8364 
2,76 12 P36543 V-type proton ATPase subunit E 1 OS 2 1,0471 0,9735 1,0965 0,8205 
5,11 7,4 O94905 Erlin-2 OS 3 0,9908 0,9781 0,8395 0,6046 
4 5,7 P32969 60S ribosomal protein L9 OS 2 0,9462 0,9796 0,871 0,7991 
12,89 31,3 P06748 Nucleophosmin OS 11 0,8017 0,9807 1,7378 0,2327 
5,51 28 P21291 Cysteine and glycine-rich protein 1 OS 3 0,9817 0,9816 1,2359 0,4583 
6,05 10,5 P04181 Ornithine aminotransferase, mitochondrial OS 3 1,0093 0,9817 0,9462 0,848 
8 5,6 Q9NQC3 Reticulon-4 OS 6 0,9908 0,9837 0,9638 0,8991 
5,7 4,9 Q9UHB6 LIM domain and actin-binding protein 1 OS 4 0,9908 0,9886 0,9638 0,9157 
4,31 4,5 Q9UHL4 Dipeptidyl peptidase 2 OS 2 0,9908 0,99 1,0864 0,7291 
2,98 5,5 Q00325 Phosphate carrier protein, mitochondrial OS 2 1,0375 0,9918 0,9727 0,7947 
6 23,4 P13987 CD59 glycoprotein OS 4 0,9908 0,9922 1,3552 0,5773 
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25,11 35,8 P09651 Heterogeneous nuclear ribonucleoprotein A1 OS 15 0,929 0,9931 1,0093 0,8952 
23,59 72,8 P30041 Peroxiredoxin-6 OS 15 0,9817 0,9933 0,9908 0,8458 
3,75 6,6 Q15181 Inorganic pyrophosphatase OS 2 1,0093 0,9944 0,9638 0,9446 
12,82 11,3 P02788 Lactotransferrin OS 12 0,9908 0,9952 1,5417 0,5539 
6,26 3,5 Q00341 Vigilin OS 3 1 0,9961 0,9727 0,5973 
6,1 25,5 P83731 60S ribosomal protein L24 OS 5 0,9908 0,9968 0,929 0,7074 
5,02 12,9 P09496 Clathrin light chain A OS 3 0,9727 0,9987 1,0471 0,7911 
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Appendix 3: Tables to evaluate the state of mouse. 
To evaluate the general state of the mouse, we used a template with criteria of 
severity that includes those clinical signs that are visibly perceived about its 
symptomatology with a score of 0 to 4. 
Mice will be programmed for slaughter at four months of age according to 
current regulations, one month before their life expectancy, to decrease the suffering 
and alterations caused by the mutation in the mice. On the other hand, if, during the 
follow-up, any of the mice has a score greater than or equal to 10 (Table 2), they will be 
sacrificed to avoid suffering the animal. 
Table 8.2: Table of severity criteria 
Observation Symptoms punctuation 
Body weight (% peso) Lose Body weight 0 - 5% 
0 
 
Lose Body weight 5 - 10% 
1 
 
Lose Body weight 11% -15% 
2 
 
Lose Body weight 16% -20% 3 
 
Lose Body weight al 20% 4 
Observation  
Physic Parameters (Appearance) Symptoms of Discomfort  
Skin Normal 
0 
 
General lack of grooming 
 
1 
 
Dry skin and/or nasal and/or ocular 
discharge 
 
2 
Hair Normal 
0 
 
Small changes/piloerection 
1 
 
Coat in poor condition / ocular or nasal 
secretions 
 
2 
Eyes Normal 
0 
 
Sunken or off 
1 
Dehydration 
Dehydration when pinching the skin. 
Stretch marks 
 
3 
 
Dehydration> 48 hours 
 
4 
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Abnormal postures 
Bent Abdomen 
 
1 
 
Body Stretch 
 
2 
Locomotion 
Difficulties in locomotion 
 
4 
 
Weakness or paralysis of the extremities 
4 
Physiological Parameters Síntomas de Malestar  
Breathe 
Normal 0 
 
Accelerated (Tachypnea) 1 
 
Slow Breathing (Dyspnea) 2 
 
Working Breathing (Great Dyspnea) 3 
 
Respiration Labored and accompanied by 
nasal discharge and / or cyanosis 
4 
Tremors 
Normal 0 
 
Transient 1 
 
Blinking 2 
 
Continuous 3 
Spontaneous Behavior 
Normal 0 
 
Moderate change in behavior and / or away 
from your cage mates 
2 
 
Reacts violently / vocalization 3 
 
Repetitive Movements (Stereotypies) 1 
Behavior under manipulation 
Normal 0 
 
Small changes 1 
 
Moderated changes 2 
 
Aggressive or comatose animal 3 
Temperature 
Normal 0 
 
Fever 2 
 
Hypothermia 1 
 
Persistent hypothermia 4 
Skin 
Anemia, as indicated by symptoms such as 
pale paws 
4 
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Cyanosis 4 
Environmental Parameters Symptoms of Discomfort 
 
Food and drink Normal 0 
 
Increase / Decrease 
1 
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Table 8.3: Scoring table for slaughter according to severity criteria. 
Severity score Action to realise 
Severity 
puntuaction 
0 
No Action 
Leve 
1 - 5 
Watch more closely 
Leve 
Up to 5 
Increase the frequency of surveillance, consider liquid 
supplements or monitor the care that should be given to the 
animal. Account must be taken into account the application of 
analgesia. Notify to Investigator Principal (IP). 
Moderate 
6-10 
Probable Significant Suffering: Provide some mode of self-
relieving, frequent observation, and consideration of a 
humanitarian endpoint (including euthanasia). 
Severe 
> 10 
Maximum severity limit. Severe suffering. Proceed to 
euthanasia. It is not recommended to repeat the project. If the 
project is essential, an exemption must be requested from the 
Competent Authority. 
Severe 
Endpoint 
Criteria 
When a symptom appears with a score of 4 points, euthanasia 
will be performed directly Euthanasia 
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